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This thesis describes the application of 2,4,6 trichlorophenylsulfonate esters in the 
synthesis of sulfonamides. 
The sulfonamide unit is an important structural motif due to its frequent occurrence 
in a range of pharmaceuticals, particularly antibiotics. Sulfonamides can be readily 
synthesised from pentafluorophenyl (PFP) sulfonate esters and as an expansion to 
this 2,4,6 trichlorophenyl (TCP) sulfonates have been developed. These have the 
added  advantage  of  lower  toxicity  and  reduced  cost  of  trichlorophenol.  TCP 
sulfonates  can  be  synthesised  directly  from  sulfonic  acids  via  activation  by 
triphenylphosphine ditriflate in moderate to excellent yields.  
These compounds can then be utilised in the synthesis of sulfonamides and suitable 
conditions  for  reactions  with  both  simple  aliphatic  amines  and  more  challenging 
anilines have been found. 
The differing reactivity’s of the TCP and PFP sulfonate esters have been exploited in 
selective  sulfonamide  formation.  The  greater  stability  of  TCP  sulfonate  in 
comparison to PFP sulfonate also means that a broader range of transformations can 
be achieved in its presence. This has been shown particularly in the application of 
palladium chemistry to synthesise more elaborate TCP sulfonates. Also, the synthesis 
of novel amino acids have been targeted inorder to further demonstrate the stability 
of  the  group  when  performing  more  diverse  reactions  on  remote  sites  in  the 
molecule. 
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Chapter One 
Introduction 
1.1 Sulfonamides as Potent Therapies for Disease 
Since  the  discovery  of  the  first  sulfonamide  antibiotic  prontosil  and  its  active 
metabolite sulphanilamide (1) the importance and diversity of sulfonamide drugs has 
grown placing them at the forefront of drug design.
1 Although initially exploited as 
antibiotics  their  activity  has  since  been  demonstrated  to  encompass  diuretic, 
antitumour, antithyroid, hypoglycaemic and protease inhibitory activity.
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Figure 1 The main classes of therapeutic agents developed from sulfanilamide 
The development of many therapeutic agents has started with sulfanilamide (1) as the 
lead molecule resulting in the discovery of drugs with a varied spectrum of biological 
actions. This is epitomised by the antibacterial agent sulfathiazole (2),
1 the anticancer 5 
sulfonamide indisulam (3),
6 the diuretic furosemide (4),
7 the hypoglycaemic agent 
glibenclamide  (5),
8  the  HIV  protease  inhibitor  amprenavir  (6),
9  the  carbonic 
anhydrase inhibitor acetazolamide (7)
2 or the metalloprotease inhibitors of type 8 
(Figure 1).
10  
1.1.2 Sulfonamides as Anti Bacterial Agents 
Starting with the first recognised sulfonamide antibacterial, sulfanilamide, in 1935 
sulfonamides were initially employed as antibiotics.  
Sulfonamides were shown to act as bacteriostatic agents, disrupting the synthesis of 
folic  acid.
7  By  mimicking  para aminobenzoic  acid  (PABA)  they  inhibit 
dihydropteroate synthetase, an enzyme vital in the eventual synthesis of folic acid 
(Scheme 1). Folic acid is essential for the synthesis of purine nucleotides for DNA 
and  RNA  and  thus,  sulfonamides  act  by  preventing  DNA  replication  and 
transcription and therefore cell growth.
11 Humans are unaffected as their cells do not 
synthesise folic acid but instead they obtain it from the diet, and it is brought through 
the cell membranes by a transport protein not possessed by bacteria. 
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Scheme 1 Inhibition of the synthesis of folic acid 
The development of bacterial resistance to some sulfonamides has seen their use as 
antibacterials restricted in modern therapy. Even so, it is worth highlighting some of 
the sulfonamide antibiotics still in clinical use. Nowadays sulfonamide antibiotics are 
often  used  in  combination  with  other  drugs,  for  example,  sulfamethoxazole  (9, 
Figure  2)  and  trimethoprim  are  used  together  in  the  treatment  of  urinary  tract 
infections,  acting  synergistically  to  block  sequential  steps  in  bacterial  folic  acid 6 
metabolism.
12 Sulfathiazole (2, Figure 2) is used in combination with sulfacetamide 
and sulfabenzamide in the treatment of vaginal bacterial infections.
13 
Another  antibacterial  used  today  is  silver  sulfadiazine  (10,  Figure  2),  which  has 
found  applications  as  a  treatment  of  toxoplasmic  encephalitis  in  HIV infected 
patients  and  as  a  topical  treatment  for  severe  burns,  where  its  anti microbial 
properties aid healing.
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Figure 2 Sulfonamide antibiotics 
1.1.3 Sulfonamides as Carbonic Anhydrase Inhibitors 
Carbonic  anhydrases  (CA)  are  ubiquitous  metalloenzymes  consisting  of  a  single 
polypeptide chain co ordinated around a zinc centre. In mammals 16 different CA 
isozymes or CA related proteins (CARP) have been identified and these have a broad 
tissue and subcellular distribution.
17 Several of these isozymes are cytosolic (CA I, 
CA II, CA III, CA VII, CA XIII), some are membrane bound (CA IV, CA IX, CA 
XII, CA XIV, CA XV), CA VA and CA VB are located in the mitochondria and CA 
VI is secreted in the saliva and milk.
17, 18 
Carbonic anhydrases catalyse the hydration of carbon dioxide and dehydration of 
bicarbonate (CO2 + H2O   HCO3
  + H
+, Scheme 2). They are involved in many 
important  physiological  processes  as  bicarbonate  is  required  for  carboxylation  in 
several  fundamental  metabolic  pathways  including  lipogenesis,  ureagenesis, 
pyrimidine synthesis, glucogenesis and biosynthesis of amino acids.
19 CAs are also 
implicated in physiological processes associated with respiration and transport of 
CO2/bicarbonate  between  metabolising  tissues  and  lungs,  pH  homeostasis  and 
electrolyte secretion in a range of tissues/organs.
2 Their broad distribution and vital 
roles in many important physiological processes make CAs attractive targets in drug 
discovery. 7 
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Scheme 2 Representation of catalytic mechanism for the CA catalysed CO2 hydration
 
X ray  crystallographic  structures  have  been  elucidated  for  many  sulfonamide 
inhibitors  bound  to  isozymes  CA  I,  II  and  IV.
20 22  These  demonstrate  that  the 
sulfonamides bind, in deprotonated form, to the Zn(II) ion of the enzyme through the 
nitrogen atom of the sulfonamide moiety in a tetrahedral geometry (Figure 3). The 
NH  moiety  is  also  hydrogen  bonded  to  Thr  199,  which  in  turn  participates  in  a 
hydrogen bond with the carboxylate group of Glu 106.
20 22 The backbone NH moiety 
of  Thr  199  is  involved  in  a  hydrogen  bond  with  one  of  the  oxygens  of  the 
sulfonamide group. These interactions result in the sulfonamides having a strong 
affinity for the CA active site.  
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Figure 3 Sulfonamide bound to carbonic anhydrase  
The ability of sulfonamides to act as carbonic anhydrase inhibitors has lead to their 
application  in  the  treatment  or  prevention  of  a  variety  of  diseases  including 
glaucoma, epilepsy, edema, diabetes and potentially cancer.
1, 3, 7 8 
1.1.3.1 Sulfonamides as Antiglaucoma agents 
Elevated intraocular pressure (IOP) associated with this disease can be reduced by 
the inhibition of the CA isozymes (CA II and CA VI) present within the ciliary 
processes of the eye, which results in a diminished rate of bicarbonate and aqueous 
humor secretion.  
1.1.3.1.1 Systemic drugs 
Sulfonamides  such  as  acetazolamide  (AZA,  7),  methazolamide  (MZA,  11), 
ethoxzolamide (EZA, 12) and dichlorophenamide (DCP, 13) have been employed in 
the systemic treatment of glaucoma for over 45 years (Figure 4).
2, 23 These inhibitors 
indiscriminately inhibit all CA’s and consequently they have many associated side 
effects, such as fatigue, depression, weight loss, gastrointestinal irritation, metabolic 
acidosis, renal calculi and transient myopia.
24 These side effects led to investigations 
into topical treatments for glaucoma. 
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Figure 4 Systemic anti glaucoma drugs 
1.1.3.1.2 Topically acting drugs 
Initial  issues  in  developing  a  topically  acting  drug  arose  due  to  the  undesirable 
physicochemical  properties  of  the  existing  CAIs,  which  proved  ineffective  when 
administered topically.
7, 25, 26 In 1995 dorzolamide (DZA, 14) was the first drug to be 
clinically used as a topical treatment for ocular hypertension and glaucoma followed 
in 1998 by brinzolamide (BRZ, 15) (Figure 5).
27, 28  
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Figure 5 Topical anti glaucoma drugs 9 
They show fewer side effects compared to the systemic drugs with the main observed  
side effects being stinging, burning or reddening of the eye, blurred vision and a 
bitter  taste.
28  They  both  contain  chiral  centres  making  then  more  expensive  to 
produce and there are on going investigations into alternative inhibitors.  
One  approach  to  this  search  is  that  taken  by  Supuran  et  al.,  whereby  they  take 
aromatic/heterocyclic sulfonamide cores, which are well established inhibitiors of 
CA, and attach water solubilising tails to improve their physiocochemical properties. 
29 35 For example, benzolamide (BZA, 16) is a very potent CA inhibitor but as a 
consequence of its polar nature and hence poor physiocochemical properties it does 
not show systemic efficacy against glaucoma.
36 BZA was seen as an ideal candidate 
for the ‘tail’ approach
29 35 and several ester and amide derivatives were synthesised 
and tested for CA inhibition and then investigated for topical efficacy. All derivatives 
showed low nanomolar activity against CAs I, II and IV and some were topically 
effective  in  lowering  IOP  in  normotensive  rabbits.  In  fact,  in  comparison  to 
dorzolamide and brinzolamide, compounds 17 20 showed improved efficacy with 
prolonged duration of action (Figure 6).
37 Also solutions of these new CAI’s had 
neutral pH compared to the acidic solutions of dorzolamide and brinzolamide (pH 
5.5), which cause eye irritation. 
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Figure 6 CA inhibitors with potential topical anti glaucoma properties  10 
1.1.3.2 Sulfonamides as Potential Anti Obesity Drugs 
CA isozymes VA and VB are located in the mitochondria and are implicated in many 
physiological processes including fatty acid biosynthesis.
38 Bicarbonate, rather than 
carbon  dioxide,  has  been  established  to  be  the  substrate  for  the  carboxylating 
enzymes pyruvate carboxylase (PC), acetyl CoA carboxylase (ACC) and carbamoyl 
phosphate synthetases I and II. These enzymes are involved in many biosynthetic 
processes such as lipogenesis. The bicarbonate is mostly supplied by the catalytic 
action of the mitochondrial isozymes CA VA and VB (probably assisted by the high 
activity of isozyme CA II).
39 This has led to speculation about the potential of CA II, 
VA and VB inhibitors as therapeutic agents involved in the prevention and treatment 
of obesity. 
This has been substantiated by evidence of weight loss in obese patients who have 
been  administered  the  antiepileptic  drugs  zonisamide  and  topiramate.  X ray 
structures of both topiramate and zonisamide bound to CA II have been reported. 
These  show  their  high  affinity  for  this  CA  isozyme  and  further  studies  have 
demonstrated that they both inhibit CA isozymes II, VA and VB.
40, 41 Hence, it is 
believed that the antiobesity properties of these drugs may be due to the CA II/CA V 
inhibition.  This  has  led  to  the  synthesis  of  CA  VA  and  VB  inhibitors  with  the 
purpose of investigating their potential as antiobesity drugs with a novel mechanism 
of action.
39 
Supuran  et  al.  synthesised  a  range  of  triazole  sulfonamides,  via  the  facile  ‘click 
chemistry’, to evaluate their activity against CAs II, VA and VB and their potential 
as therapeutics against obesity.
42 A library of ten benzenesulfonamides containing 
triazole tethered phenyl tail groups was synthesised (examples shown in Figure 7). 
They  all  showed  low  to  mid  nanomolar  inhibition  of  the  relevant  isozymes,  as 
exemplified by compounds 21 23. 
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Figure 7 Novel CA inhibitors as potential anti obesity therapeutics 11 
1.1.3.3 Sulfonamides as Anticancer Agents 
With  the  American  Cancer  Society  estimating  the  number  of  cancer  deaths  at 
7.6 million people worldwide during 2007 cancer is a major health problem.
43 New 
therapeutic approaches are needed to augment the existing treatments available for 
the prevention and treatment of cancer. 
Chegwidden and Spencer reported the inhibition of growth of human lymphoma cells 
by CA inhibitors acetazolamide (7), methazolamide (11) and ethoxzolamide (12).
44 
When  nucleotide  precursors  were  added  the  inhibition  was  modulated,  which 
inferred that it was due to the lack of bicarbonate available for nucleotide synthesis.
44 
Pastorek  et  al.  have  shown  that  in  vitro  acetazolamide  strongly  reduces  the 
evasiveness of some renal cancer cell lines.
45 These observations have catalysed a 
proliferation  of  research  into  the  connection  between  CAs  and  cancer,  and  the 
application of CA inhibitors in the prevention of tumour growth.  
CA IX, CA XII and CA XIV have been strongly implicated in tumour growth of 
various cancer types with CA XII and CA XIV being appreciably overexpressed in 
renal carcinoma.
46 CA IX is of particular interest as a target as in healthy human it is 
only present in tissues of gastrointestinal tracts but is significantly overexpressed in 
cancer cells of various organs including oesophagus,
47 lungs,
48 kidney,
49 breast,
50 
cervix,
51 head and neck,
52 and bladder.
53 
Hypoxia is a key feature of many tumours and is strongly associated with tumour 
propagation,  malignant  progression  and  resistance  to  chemotherapy  and 
radiotherapy.
54,  55  The  expression  of  CA  IX  is  regulated  through  the  hypoxia 
inducible factor 1 (HIF1) cascade. Hypoxic tumours have an acidic pH of 6 (normal 
tissue  pH  is  7.4),  which  contributes  to  the  resistance  to  weakly  basic  anticancer 
drugs. On deletion of the CA IX active site and on inhibition of the isozyme by CA 
IX selective sulfonamides this acidification is reduced, thus implicating CA IX in 
this process.
56  
Indisulam (3, Figure 8) is a potent anticancer sulfonamide which is currently in phase 
II clinical trials in Europe and the United States. It acts as a strong CA II and CA IX 
inhibitor with a Ki of 24 nM.
6, 57 12 
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Figure 8 Anticancer sulfonamide Indisulam 
CA IX is a membrane bound isozyme which has an extracellularly exposed active 
site. By the synthesis of membrane impermeant inhibitors selective inhibition of the 
membrane bound (CA IV, IX, XII and XIV) over cystolic CA’s can be achieved. 
This approach has been taken by Supuran et al. with membrane impermeability being 
achieved through the synthesis of highly polar salt like compounds. Compounds of 
type  24  and  25  (Figure  9)  were  shown  to  discriminate  for  the  membrane bound 
versus cytosolic isozymes, selectively inhibiting only CA IV in ex vivo and in vivo 
studies in two model systems (human redblood cells and perfusion experiments in 
rats respectively).
58 They also possess good activity against isozyme CA IX and thus 
compounds of this type may constitute the basis for new anticancer therapies and 
useful probes to further investigate these targets.
59 Indeed, compound 26 was used by 
Svastova  et  al.  to  investigate  the  role  of  CA  IX  in  the  acidification  of  hypoxic 
tumours.
56 
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Figure 9 Selective CA inhibitors 
In  an  effort  to  find  potent  and  selective  CA  IX  inhibitors  a  series  of 
indanesulfonamides were synthesised and assessed for activity against CAI, CA II 
and  CA  IX.
60  All  compounds  in  this  series  showed  weak  inhibition  of  CA  I. 
Compounds 27, 28 and 29 were the most potent inhibitors of CA IX with Ki values 
between 3.4 3.7 nM and they showed good selectivity for CA IX (Figure 10). 13 
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Figure 10 CA IX inhibitors 
1.1.4 Sulfonamides and Protease Inhibition 
1.1.4.1 Cysteine proteases 
Cysteine  proteases  comprise  a  large  of  group  of  enzymes  which  are  involved  in 
numerous physiological processes including osteoporosis, Alzheimer’s disease and 
arthritis.
61, 62 They are connected with a range of pathological conditions and thus, 
their inhibition could potentially be an effective chemotherapy in these cases.
61 63  
Cathepsin K is selectively expressed in bone osteoclasts and has been shown to play 
a role in bone resorption.
64 As such inhibitiors of cathepsin K could be potential 
therapeutic treatments for diseases such as osteoporosis which involves excessive 
bone  loss.  Sulfonamide  30  was  developed  as  a  subnanomolar  peptidomimetic 
inhibitor with the sulfonamide moiety being incorporated in order to remove the 
structural liabilities associated with an amide (Figure 11).
65 Veber et al. synthesised a 
series of azepanone based inhibitors of cathepsin K. They identified sulfonamide 31 
as a potent and selective reversible inhibitor of both human and rat cathepsin K (Ki 
=0.16 nM) which displays good oral biovailability in the rat (Figure 11).
66 14 
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Figure 11 Cathepsin K inhibitors 
Interleukin 1β (IL 1β) is a protein which plays a key role in inflammation, brain 
damage  and  stroke.  Caspase 1  (IL 1β  converting  enzyme,  ICE)  is  the  cysteinyl 
protease which catalyses the synthesis of IL 1β and as such is an attractive target in 
the  search  for  new  therapeutic  agents  for  inflammatory  diseases.
67,  68  Using  the 
crystal structure of caspase 1 Sharipour et al. designed and synthesised a range of 
low molecular weight, non peptidic, sulfonamide inhibitors of ICE.
69 Compound 35 
is the most potent inhibitor of this class with a Ki of 1.6  M (Figure 12). 
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Figure 12 ICE inhibitors 
Caspase 3 and  7 are involved in apoptosis (programmed cell death), which is seen in 
a  variety  of  pathological  conditions  such  as  stroke  and  myocardial  infarction, 
cardiomyopathy, Alzheimer’s disease, sepsis, diabetes and Huntington’s disease.
70 
Mach et al. developed a series of isatin Michael acceptor caspase 3 and  7 inhibitors 
of the type 36, which possessed high potency and selectivity against caspase 1,  6 
and  8 (Figure 13).
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Figure 13  Caspase 3 and  7 inhibitors 15 
1.1.4.2 Human immunodeficiency virus (HIV) proteases 
HIV protease cleaves the viral Pr55gag and Pr160gag pol precursor polyproteins 
releasing structural proteins and enzymes required for viral maturation. Its inhibition 
therefore  renders  the  viral  particles  unable  to  reproduce  or  infect.
72  Protease 
inhibitors have been used clinically since 1996, usually in combination with other 
antiviral compounds, in the treatment of HIV infected patients.
9 
Amprenavir (6) is a clinically used sulfonamide HIV 1 protease inhibitor with a Ki of 
6  nM  (Figure  14).  The  sulfonamide  unit  plays  a  key  part  in  the  activity  of 
amprenivir: by increasing its water solubility, by the interaction of one of the oxygen 
atoms  with  a  molecule  of  water  present  in  all  HIV  protease  complexes  and  by 
positioning  the  aromatic  group  so  that  it  interacts  with  the  S2’  sub  site  of  the 
enzyme.
72, 73 Due to its water solubility and its good lipophilicity it has a high oral 
bioavailability. It has a half life of 7 10 h which enables it to be taken less frequently 
than  other  HIV  protease  inhibitors  and  hence,  has  less  potential  for  side  effects. 
Fosamperenvir (37) is a prodrug of amprenevir which is a slow release version of 
this drug allowing for single daily dosing (Figure 14).
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Figure 14 HIV protease inhibitors 
Mutations of the protease active site can lead to resistance to protease inhibitors, and 
so second generation inhibitors have been developed. These are used to treat patients 
who  have  failed  in  more  than  one  anti retrovirus  treatment.  Dunavir  (38)  and 
tipranavir (39) are two such drugs (Figure 15).
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Figure 15 Second generation HIV protease inhibitors 
Dunavir (38) is an analogue of amprenavir (6) whereby the tetrahydrofuranyl group 
has been substituted by a bicyclic acetal.
75 The bicyclic acetal moiety not only results 
in  increased  hydrogen  bonding  but  also  results  in  binding  orientation  changes 
allowing dunavir to inhibit amprenivir resistant proteases.  
Tipranavir (39) is structurally different to other protease inhibitors resulting in it 
having activity against protease inhibitor resistant viruses. The sulfonamide moiety 
hydrogen bonds to several active site residues and, along with other interactions, 
result in high potency with tipranavir possessing a Ki<1 nM against wild type and 
mutant proteases.
76 
1.1.5 Other applications for sulfonamides 
Sulfonamides furosemide (4) and torsemide (40) are effective loop diuretics and as 
such are an essential part of the management of chronic systolic heart failure (Figure 
16).
77, 78 Diuretics relieve hypertension in chronic heart failure patients by initiating 
the loss of water, minerals and electrolytes from the body via urination.  
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Figure 16 Sulfonamide diuretics 
Glibenclamide (5) is used in the treatment of type II diabetes mellitus. It a potent and 
selective ATP sensitive potassium ion channel blocker, which brings about a calcium 
influx and then subsequent stimulation of insulin production in the β cells of the 
pancreas.
8  17 
Sildenafil  (41)  was  launched  in  1998  to  treat  erectile  dysfunction  and  works  by 
inhibiting the enzyme phosphodiesterase 5, which is responsible for the metabolism 
of cyclic guanosine monophosphate (cGMP). cGMP is responsible for the regulation 
of blood in the penis and therefore its inhibition results in the prolongation of penile 
erection.
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Figure 17 Other sulfonamide drugs 
In  conclusion, it has been shown that sulfonamides have a number of  biological 
applications in the treatment of a wide range of ailments. The sulfonamide moiety 
can be used as bioisosteric replacements for various groups, including amides, 
65  
acids  and  alcohols,  often  helping  to  improve  the  metabolic  stability  and 
pharmacokinetic properties of a compound.
80 Their key importance as motifs in an 
array of therapeutic agents seems certain to continue. 
1.2 Sulfonamide Synthesis 
Due to the abundance and value of sulfonamides in pharmaceuticals it is vital that 
there are efficient and diverse ways of synthesising them. 
Until  recently,  sulfonamides  have  almost  exclusively  been  synthesised  from  the 
highly  reactive  sulfonyl  chlorides.  Sulfonyl  chlorides  in  turn  are  commonly 
synthesised from the appropriate sulfonic acid by treatment with thionyl chloride, 
chlorosulfonic  acid,  phosphorus  oxychloride  or  phosphorus  pentachloride,  or  by 
oxidation of thiols/sulfides with chlorine gas.
81  
Syntheses  of  sulfonamides  utilising  simple  alkyl  sulfonyl  chlorides  have  been 
reported from around 1903. Koburger et al. showed that it was possible to obtain 
reactions  with  the  normally  non nucleophilic  anilines,  whereas  Forster  et  al. 
provided an interesting example in the synthesis of a camphor derived sulfonamide 
(42) (Scheme 3).
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Scheme 3 Synthesis of sulfonamides from sulfonyl chlorides 
In the application of chlorine gas to effect the oxidation of thiols/sulfides to sulfonyl 
chlorides  the  use  of  excess  oxidant  and/or  aqueous  acid  can  be  potentially 
unfavourable in the case of sensitive substrates. Bonk et al. developed a one pot 
synthesis of sulfonamides in which an ice cooled solution of thiol (43), H2O and 
BnMe3NCl  was  treated  with  trichloroisocyanuric  acid  (TCCA)  followed  by  the 
amine (Scheme 4).
84 Key to this method is the generation of chlorine gas by mixing 
benzyltrimethylammonium chloride with TCCA and thus the in situ preparation of 
the sulfonyl chloride (44). This is a mild protocol that minimises both the amount of 
oxidant required and the aqueous component. A selection of alkyl and aryl thiols 
were subjected to these conditions and provided sulfonamides (45) in good yields.  
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Scheme 4 Synthesis of sulfonamides from thiols using TCCA 
De  Luca  et  al.  have  developed  a  microwave  assisted  synthesis  to  generate 
sulfonamides directly from the sulfonic acid (46) or its sodium salt.
85 They form an 
acid chloride (47) in situ under microwave conditions using the mild chlorinating 
agent  2,4,6 trichloro [1,3,5] triazine  (TCT)  in  acetone  with  triethylamine.  After 
filtration NaOH and the amine were added and the reaction mixture was exposed to 
further microwave irradiation (Figure 18). This methodology worked well for alkyl, 
aryl and heteroaromatic sulfonic acids giving the sulfonamides (48) in good yields. 19 
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Figure 18 Microwave assisted synthesis of sulfonamides directly from sulfonic acids  
Although commonly used in the synthesis of sulfonamides sulfonyl chlorides can be 
difficult to prepare and handle and often are not amenable to long term storage. 
These issues have led to the development of alternative methods for sulfonamide 
synthesis.  
In  the  preparation  of  Adenosine  A  receptor  antagonists  Müller  et  al.  were 
unsuccessful in the synthesis of xanthin 8 yl benzene sulfonamides (50) from the 
corresponding sulfonic acids via the sulfonyl chloride. To overcome this issue the p 
nitrobenzene sulfonates (49) were prepared and the sulfonamides (50) synthesised by 
displacement of the p nitrophenol (Figure 19).
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Figure 19 Synthesis of sulfonamides from p nitrophenol sulfonates 
Katritzky et al. have utilised the sulfonylbenzotriazoyl moiety as a replacement to 
sulfonyl chlorides in the synthesis of sulfonamides.
87, 88 They initially synthesised the 
sulfonylbenzotriazoles  (54)  from  the  corresponding  sulfonyl  chlorides,  but  have 
since reported their synthesis from aryl/alkyl lithiums or Grignard reagents (51) by 
treatment with SO2 and N chlorobentriazole. This is believed to proceed through an 
intermediate sulfonyl chloride (52) and benzotriazoyl anion (53) (Scheme 5). 20 
R M
SO2, THF
 78 25 °C
S
O MO
R
BtCl
NEt3 R
S
Cl
O O
N
N
N
M
+ R
S
N
O O
N
N
M = Li, MgBr
51 52 53
54
 
Scheme 5 Synthesis of sulfonylbenzotrazoles 
A  variety  of  alkyl  and  aryl  sulfonyl  benzotriazoles  were  synthesised  via  this 
approach  in  good  yields  (41 93%)  and  these  were  used  to  synthesise  a  range  of  
sulfonamides in good yields (Figure 20).
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Figure 20 Sulfnamides synthesised from sulfonylbenzotriazoles 
Alkyl/aryl  sulfonyl  imidazoles  (55)  have  also  been  employed  in  the  synthesis  of 
sulfonamides; here the imidazole needs to be activated for it to become an effective 
leaving  group.
89  This  is  achieved  by  alkylation  using  methyl  triflate  to  give  the 
imidazolium  triflate  (56).  When  amines  were  added  to  these  salts  the  desired 
sulfonamides (57) were obtained in good yield (Scheme 6). 
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Scheme 6 Synthesis of sulfonamides via sulfonyl imidazolium triflates 
There  are  few  methods  available  for  the  synthesis  of  sulfonamides  from  the 
corresponding sulfonic acid. One such route has been developed by Shaabani et al. 
whereby  the  sulfonamides  are  formed  via  the  reaction  of  sulfonic  acids  (58), 
isocyanides  (59)  and  water  in  dichloromethane  at  ambient  temperature.
90  The 
sulfonamides (60) were isolated in good yield (Figure 21). 21 
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Figure 21 Synthesis of sulfonamides from sulfonic acids and isocyanides 
This  reaction  doesn’t  occur  in  the  absence  of  water  and  they  have  proposed  the 
following mechanism. It is believed that protonation of the isocyanide (59) by the 
sulfonic acid occurs to generate intermediate 61, which on quenching with water 
produces intermediate 62 and thus, elimination of formic acid gives the sulfonamide 
(60) (Scheme 7). 
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Scheme 7 Proposed reaction mechanism between sulfonic acids and isocyanides 
Sulfonamides can also be synthesised from sulfinates. Baskin et al. have developed a 
one  pot  process  utilising  sodium  3 methoxy 3 oxopropane 1 sulfinate  (62)  as  a 
sulfinate transfer reagent.
91 Initial alkylation of sodium 3 methoxy 3 oxopropane 1 
sulfinate  (62)  with  the  alkyl  halide  is  followed  by  β elimination  and  then 
sulfonamide formation (Scheme 8). It is possible to isolate the intermediate sulfones 
(63) and sodium sulfinates (64). This procedure can be applied to aryl halides but at a 
higher temperature (110 °C); the presence of CuI is required for the initial step and 
the sulfone needs to be isolated due to the excess of reagents used. 22 
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Scheme 8 Synthesis of sulfonamides from alkyl and aryl halides 
The sulfonamides 65 are isolated in reasonable yields. This method is a convenient 
procedure which is compatible with many functional groups (Figure 22). 
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Figure 22 Sulfonamides synthesis from alkyl and aryl halides 
An alternative method for synthesising sulfonamide from sulfinates utilises bis(2,2,2 
trichloroethyl)azodicarboxylate (BTCEAD, 67) as an electrophilic nitrogen source.
92 
Treatment of the appropriate sulfinic acid sodium salt (66) with BTCEAD (67) and 
TFA gives the corresponding hydrazide (68), which on treatment with zinc dust and 
then acetone yields the desired sulfonamide (69) (Scheme 9). This is a mild two step 
process which has been successful for both aromatic and aliphatic sulfinates. 
R
S
N
O O H
N
Troc
Troc R
S
ONa
O
+ N N
O
O
CCl3
O
O Cl3C
TFA (1.1eq)
THF, 0 °C
i) Zn dust, AcOH
   25 °C
ii) Acetone, 25 °C
R
S
NH2
O O
66 67 68 69  
Scheme 9 Synthesis of sulfonamides from sulfinates using BTCEAD 
1.2.1 PFP sulfonate esters 
Caddick  et  al.  have  developed  pentafluorophenyl  (PFP)  sulfonate  esters  (70)  as 
alternatives to sulfonyl chlorides in the synthesis of sulfonamides (Scheme 10).
93 95 
The sulfur centre is susceptible to nucleophilic attack, especially by amines, to make 
sulfonamides (71) (Scheme 10). 23 
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Scheme 10 Sulfonamides from PFP sulfonate esters 
PFP sulfonate esters are generally crystalline solids making them amenable to long 
term storage and providing ease of handling. They have also proven to be stable to 
acid and base work ups and column chromatography.  
Extensive  investigations  have  been  carried  out  into  the  nature  of  this  class  of 
compounds demonstrating their versatility in the synthesis of sulfonamides.  
1.2.1.1 Synthesis of Pentafluorophenyl Sulfonate Esters 
Despite  the  plethora  of  coupling  reagents  used  in  the  synthesis  of  amides  until 
recently  there  existed  no  analogous  route  to  the  synthesis  of  sulfonamides  or 
sulfonate esters from sulfonic acids. Hence, initially the PFP sulfonate esters needed 
to be synthesised from the appropriate sulfonyl chloride. This was impractical and 
limited the range of esters that could be produced. A successful route to the desired 
sulfonate  esters  was  found  by  activation  of  sulfonic  acid  salts  (73)  using 
triphenylphosphine ditriflate (72) (Scheme 11). The intermediate 74 is sufficiently 
activated  to  undergo  reaction  with  nucleophiles  such  as  the  PFP  anion,  with  the 
formation of the P=O π bond believed to be the driving force for the reaction.
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Scheme 11 Activation of Sulfonic Acids by Triphenylphosphine Ditriflate 
This methodology has been proven to be robust displaying high functional group 
tolerance and giving excellent yields and can also be applied in the direct synthesis 
of sulfonamides from sulfonic acid salts (Figure 23).
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Figure 23 Synthesis of Sulfonate esters and Sulfonamides directly from sulfonic acids 
By using a solid supported phosphine oxide the need  for purification by  column 
chromatography  can  be  avoided  and  thus  renders  this  reaction  amenable  to  high 
throughput chemistry. 
1.2.1.2 Reactivity of Pentafluorophenyl Sulfonate Esters 
The reactivity of the PFP sulfonate esters falls into two main categories: i) Alkyl 
PFP esters  and  ii)  Aryl PFP esters.  Alkyl PFP esters  are  believed  to  react  via  a 
sulfene intermediate which is formed by deprotonation of the α C H (Scheme 12). 
This mechanism was supported by incorporation of deuterium into the product (76) 
from the reaction of PFP sulfonate 75 with 4 methylbenzylamine in the presence of 
D2O (Scheme 13).
94  
PFPO
S
O O
R
N
H
S
O O
R
H
B
PFPO
S
O O
R S
O
O
R
R'
R'
NH2
R' NH2
 
Scheme 12 Proposed mechanism of reaction for alkyl PFP sulfonate esters 
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Scheme 13 Reaction supporting the mechanism of reaction for alkyl PFP sulfonate esters 
The alkyl PFP sulfonates also generally require milder conditions than the aryl PFP 
sulfonates, for which the reaction proceeds via the direct displacement of the PFP 
alcohol (Scheme 14).  25 
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Scheme 14 Mechanism of reaction for aryl PFP sulfonate esters 
PFP sulfonates are less reactive than sulfonyl chlorides and therefore require higher 
temperatures and stronger bases (typically at 65 °C with DBU).
97 This observation 
was  further  supported  by  the  preferential  nucleophilic  attack  by  an  amine  on  a 
sulfonyl chloride in the presence of a PFP sulfonate. Scheme 15 shows the reaction 
of  one  equivalent  of  4 methylbenzylamine  with  a  mixture  of  benzenesulfonyl 
chloride (78) and PFP tosylate (77) which gave solely 80, the product derived from 
reaction with the sulfonyl chloride (79). 
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Scheme 15 Comparison of reactivities of PFP sulfonate esters and TCP sulfonate esters 
A major advantage PFP sulfonate esters have over sulfonyl chlorides is their ability 
to react under aqueous conditions to give the desired sulfonamide in good yields. 
This was demonstrated when a 1:1 mixture of benzenesulfonyl chloride (78) and PFP 
tosylate  (77)  in  an  aqueous  medium  (1:1  methanol/water)  were  treated  with  one 
equivalent of amine (Scheme 16). This reaction yielded only sulfonamide 84 which 
was derived from the PFP tosylate and the amine.
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Scheme 16  Reaction under aqueous conditions 
The aryl PFP sulfonates bearing electron donating groups and sterically hindered 
amines react more slowly and often require increased temperatures. Wilden et al. 
envisaged that a nucleophilic catalyst would increase the rate and efficacy of these 
reactions.  Indeed  when  the  aminolysis  reaction  is  performed  in  the  presence  of 
tetrabutylammonium chloride an acceleration of the rate is observed (Table 1).
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1.5 h  25 min  77  75 
N
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Table 1 Reaction of amines with PFP p methoxybenzenesulfonate in the absence and presence of 
TBAC 
It has been postulated that this is the result of the formation of a transient sulfonyl 
chloride and it is this reactive species that reacts with the nucleophile (Scheme 17).
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It is of particular note that this reaction still occurs in the presence of water.   
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Scheme 17 
Overall, the PFP sulfonate ester methodology has been shown to be robust and broad 
in its application with alkyl, benzylic, heterocyclic and aromatic PFP sulfonate esters 
reacting with primary, secondary and sterically hindered amines in moderate to good 
yields (Figure 24).
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Figure 24 
1.2.1.4 Elaboration of Pentafluorophenyl Sulfonate Esters 
One PFP sulfonamide that has been of particular interest is PFP vinylsulfonate (82). 
This surprisingly stable compound is easily prepared from 2 chloroethane 1 sulfonyl 
chloride and pentafluorophenol. It is a bifunctional acceptor that reacts with both 
radical  and  nucleophilic  species  allowing  facile  access  to  a  diverse  range  of 
sulfonamide products (Scheme 18).
97  
O
F
F
F
F
F
S
O O
radical addition
amine displacement
functionalised
sulfonamide
82  
Scheme 18 PFP vinylsulfonate 
By using the PFP sulfonate moiety the radical chemistry can be optimised before the 
addition of functionality from the amine and thus the potential for side reactions is 
reduced. 
The  electron  deficient  vinyl  section  of  PFP  vinylsulfonate  (82)  can  undergo 
cycloaddition with the 1,3 dipoles nitrones (83) to give isoxazolidine products 84 
and 85.
98 The 4C substituted regioisomer (84) is seen as the major product and a 
variety  of  nitrones  can  be  reacted  to  give  access  to  a  diverse  set  of  highly 
functionalised isoxazolidines (Scheme 19). 28 
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Scheme 19 Isoxazolidine formation via 1,3 dipolar cycloaddition 
The  resultant  PFP substituted  isoxazolidines  can  then  be  subjected  to  aminolysis 
conditions to successfully give the expected sulfonamides (Scheme 20). 
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Scheme 20 Sulfonamide formation from PFP substituted isoxazolidines 
These isoxazolidines also offer an alternative route to the synthesis of β sultams. 
When treated with Mo(CO)6 the N O bond is cleaved and subsequent displacement 
of  the  pentafluorophenol  with  the  nitrogen  gives  access  to  the  β sultams  (87) 
(Scheme 21).
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Scheme 21 Mo(CO)6 reductive cleavage of isoxazolidines to their corresponding β sultams 
Palladium chemistry is widely used in organic synthesis particularly in the synthesis 
of  compounds  in  drug  discovery.  Avitabile  et  al.  have  demonstrated  that  Suzuki 
reactions can be performed in the presence of a PFP sulfonate ester. By using the 
catalyst PdCl2(PPh3)2 and the base Na2B4O7 in a refluxing mixture of dioxane and 
ethanol the Suzuki reactions proceeded in good yields (Scheme 22).
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Scheme 22 Suzuki chemistry in the presence of PFP sulfonates 
In conclusion, the sulfonamides are used in the treatment of a range of diseases and 
they continue to be of key importance in the search for new therapeutic agents. The 
traditional  route  for  their  synthesis  can  be  problematic  due  to  the  difficultly  in 
synthesising some sulfonyl chlorides, in particular heterocyclic examples, and also 
problems with their long term storage. Although a range of alternative methods have 
been developed there is still need for a straightforward and general protocol. 
Caddick et al. have demonstrated the versatility of the PFP sulfonates but there are 
issues  with  the  cost  and  toxicity  of  these  compounds.  With  this  in  mind  2,4,6 
trichlorophenyl  (TCP)  sulfonates  have  been  put  forward  as  less  toxic  and  less 
expensive alternatives.  30 
Chapter Two 
Synthesis and Aminolysis of 2,4,6 
Trichlorophenyl (TCP) Sulfonate Esters 
2.1 Introduction 
There is a degree of resistance to the use of PFP sulfonate esters on a large and 
general  scale  due  to  their  cost  and  perceived  toxicity.  In  order  to  address  these 
limitations an alternative sulfonamide precursor was desired. This would require a 
leaving group for the aminolysis reactions, which would ideally be more stable than 
the PFP sulfonates. This would allow more chemistry to be carried out with the 
sulfonate in place, thus making them more compatible with library synthesis.  
2,4,6 Trichlorophenyl sulfonates presented themselves as an ideal candidate with the 
parent  phenol  possessing  a  lower  toxicity  (currently  marketed  as  a  household 
antiseptic agent in the UK) and having a reduced cost. In order to establish proof of 
principle initial investigations were carried out within the Caddick group by C.C. 
Lee.
101 Three TCP sulfonate esters (88 90) were synthesised and then subjected to 
aminolysis under both thermal and microwave conditions (Scheme 23). The reactions 
were  carried  out  in  DMF  with  1.5  eq  of  both  4 methylbenzylamine  and 
triethylamine. All the desired sulfonamides (81, 91, 92) were obtained in good yield 
after  purification  by  column  chromatography  (Table  2).  These  successful  results 
showed  that  TCP  sulfonate  esters  were  a  promising  alternative  to  PFP  sulfonate 
esters and that they warranted further investigations. 31 
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Entry  R  Heating  Temperature 
(°C) 
Time 
(h) 
Yield 
(%) 
1  Me  Thermal  85  4.5  51 
2  OMe  Thermal  85  6  66 
3  NO2  Thermal  65  1.5  83 
4  Me  Microwave  85  1  68 
5  OMe  Microwave  85  1  66 
Table 2 Previous sulfonamide synthesis from TCP sulfonates 
2.2 Synthesis of 2,4,6 Trichlorophenyl Sulfonate Esters 
Traditionally sulfonamides and sulfonate esters are synthesised by the reaction of the 
appropriate amine or alcohol with a sulfonyl chloride.
102 This route was employed in 
the synthesis of a selection of TCP sulfonate esters required in order to explore the 
optimal conditions for aminolysis (Scheme 24). 
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Scheme 24 Synthesis of TCP sulfonates from sulfonyl chlorides 
It  is  counterintuitive  to  use  sulfonyl  chlorides  in  order  to  synthesise  alternative 
sulfonamide precursors and so another route was required. The direct synthesis of 
PFP sulfonate esters from sulfonic acids via their activation by triphenylphosphine 32 
ditriflate  is  now  well  established,  and  so  it  follows  that  this  route  should  be 
practicable  for  the  synthesis  of  TCP  sulfonyl  esters.
96  This  procedure  was 
successfully used in the synthesis of TCP tosylate (88) from the pyridinium tolyl 
sulfonate in a 69% yield. In order to test the generality of this route it was used to 
synthesise a range of sulfonate esters, and all were obtained in moderate to good 
yields (Scheme 25, Table 3).   
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Scheme 25 
Entry  Sulfonic acid salt  Product  Yield (%) 
1 
SO3
HN  
S
OTCP
O O
88  
69 
2 
SO3
HN O2N
 
S
OTCP
O O
O2N
99  
72 
3 
Me SO3
HN  
S
OTCP
O O
100  
44 
4 
SO3 Cl
HN
 
S
OTCP
O O
Cl
101  
80 
Table 3 Synthesis of TCP sulfonate esters from sulfonic acids 
2.3 Aminolysis of Trichlorophenyl Sulfonate Esters 
2.3.1 Microwave Conditions 
With the concept verified and a selection of TCP sulfonate esters synthesised the 
optimum conditions for the aminolysis reaction could be investigated. The reaction 
between TCP tosylate (88) and allylamine under microwave irradiation was selected 
for initial studies (Scheme 26). At first the reaction was carried out in DMF but 
under the microwave conditions dimethylamine was liberated and this reacted with 
the TCP tosylate (88). This resulted in a reduced yield of the desired sulfonamide 
102 and N dimethyl 4 methylbenzenesulfonamide was generated as a side product. It 
has been shown for the PFP sulfonate esters that the reaction is more efficient with 
increasing solvent polarity and therefore NMP was chosen as an alternative to DMF, 33 
thus eliminating the liberation of dimethylamine but retaining a similar polarity.
93 In 
NMP  the  reaction  failed  to  proceed  to  completion  after  60  min  at  85  °C  and 
consequently the temperature was raised to 140 °C. At this temperature the reaction 
time could be reduced to 10 min and the sulfonamide 102 was obtained in the best 
yield (Table 4).  
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Entry 
 
Temperature (°C)  Solvent  Time (min)  Yield (%) 
1  85  DMF  60  56 
2  85  NMP  60  50 
3  140  NMP  60  83 
4  140  NMP  20  91 
5  140  NMP  10  83 
Table 4 Optimisation of microwave conditions for aminolysis  
With these optimised conditions the reaction of 4 methylbenzylamine with the TCP 
tosylate was carried out to furnish the desired sulfonamide (81) in a 78% yield. 
The reactions were worked up by diluting with dichloromethane and washing with 
2M sodium carbonate solution, 2M hydrochloric acid and water. Unfortunately, these 
reagents were not effective for complete removal of the trichlorophenol and NMP, 
and  consequently  column  chromatography  was  required  to  purify  the  final 
compounds.  However,  by  changing  the  solvent  from  dichloromethane  to  diethyl 
ether and using 10% aqueous lithium chloride solution instead of water the products 
only  needed  to  be  passed  through  a  plug  of  silica.  The  reaction  of  4 
methylbenzylamine with TCP tosylate (88) was repeated and worked up using this 
improved method and gave the product (81) in a 94% yield (Scheme 26). 
In order to test the scope of the optimised procedure the range of substrates was 
extended and most of the desired sulfonamides were obtained in excellent yields 
(Scheme 25). Unfortunately, when the less nucleophilic aniline was used no reaction 
occurred under these conditions. 34 
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Scheme 25 Aminolysis of TCP sulfonates 
2.3.2 Investigation of Bases 
It has so far been demonstrated that when triethylamine is used under microwave 
conditions the aminolysis proceeds in good yields for most amines but the reactions 
of  the  less  nucleophilic  amines  (e.g.  aniline)  have  been  problematic.  When  the 
reaction times were increased the reaction failed to go to completion after ~4 h in the 
microwave, and upon increasing the temperature poor yields were obtained due to 
decomposition. This indicated that other bases and/or solvents should be explored. 
The reaction between morpholine and 4 bromobenzene TCP sulfonate ester (96) was 
chosen to examine the use of alternative bases (Scheme 27). Morpholine is a very 
good nucleophile and so it was hypothesised that the reaction should proceed to 
completion  at  a  reasonable  rate  for  comparison  of  the  various  bases.  The  bases 
selected  were  1,8 diazabicyclo[5.4.0]undec 7 ene  (DBU),  lithium 
hexamethyldisilazide  (LiHMDS)  and  also  DBU  with  the  catalyst  tetra butyl 
ammonium  chloride  (TBAC),  as  used  previously  with  PFP  sulfonate  esters  (see 
section 1.2.3.2).  35 
The  reactions  were  carried  out  at  room  temperature  in  THF  using  1.1  eq  of 
morpholine and 1.5 eq of base (Scheme 27). All reactions proceeded to completion at 
different rates and each gave excellent yields (Table 5).  
HN O
THF, base, rt.
S
N
O O
Br
O
S
OTCP
O O
Br
110 96  
Scheme 27 
Entry  Base  Catalyst  Time  Yield (%) 
1  Et3N  N/A  64 h  90 
2  DBU  N/A  18 h  85 
3  DBU  TBAC  1 h  91 
4  LiHMDS  N/A  15 min  97 
Table 5 
The choice of base had a marked impact on the rate of reaction, which followed the 
trend: Et3N < DBU < DBU + TBAC <LiHMDS. LiHMDS gave the fastest rate and 
the best yield. 
2.3.2.1 Studies with Lithium Hexamethyldisilazide 
Having demonstrated the reactivity of LiHMDS in the synthesis of sulfonamide 110 
its  general  applicability  and  scope  in  the  aminolysis  conditions  needed  to  be 
explored.  Morpholine  is  a  very  good  nucleophile  and  thus  the  conditions  were 
modified so that they were appropriate for less nucleophilic amines. In order to get 
the reactions to proceed at a reasonable rate they were carried out at 50 ºC with 2 eq 
of amine and 2 eq of LiHMDS (Scheme 28). At lower temperatures and/or with 
reduced base the reactions did not reach completion even after 3 days. 
The sulfonamides were obtained in good yield (Table 6), of particular note were the 
reaction rates and yields from the reactions with aniline, N methylaniline and tert 
butylamine  (Table  6,  Entries  4 6).    Aniline  had  previously  proven  particularly 
problematic  when  reacting  with  TCP  sulfonates  using  triethylamine  under 
microwave  conditions.  In  addition,  anilines  and  the  sterically  hindered  tert 
butylamine  were  known  to  react  slower  and  less  efficiently  with  PFP  sulfonate 
esters.
95, 103 For aniline the best yield achieved with triethylamine was 61% and high 36 
temperatures  (200  ºC)  were  required  whilst  with  LiHMDS  the  reaction  goes  to 
completion at 50 ºC with a 78% yield (Table 6, Entry 5). 
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Entry  Amine  Time (h)  Product  Yield (%) 
1  H2N   4 
S
N
H
O O
102
 
69 
2 
H2N
 
4 
S
N
H
O O
91
 
72 
3  N
H   4 
S
N
O O
111
 
51 
4 
H2N   18 
S
N
H
O O
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75 
5  H2N   4  S
N
H
O O
113
 
78 
6  HN   6  S
N
O O
114
 
92 
Table 6 
These initial results were promising but before expanding the range of substrates the 
different  counterions  of  HMDS  were  compared  to  see  if  any  improvement  on 
reactivity  could  be  obtained.  The  reaction  between  4 methoxybenzene  2,4,6 
trichlorophenylsulfonate  ester  (89)  and  4 nitroaniline  was  used  to  compare  the 
reactivity of lithium hexamethyldisilazide (LiHMDS), sodium hexamethyldisilazide 
(NaHMDS)  and  potassium  hexamethyldisilazide    (KHMDS)  (Scheme  29).  When 
LiHMDS was used a homogenous solution was formed and the reaction proceeded to 
completion after 4 h, whilst with NaHMDS the reaction mixture was a suspension 
and completion was achieved after 24 h. A viscous suspension was formed with 
KHMDS as the base, which caused problems with stirring and the reaction remained 
incomplete after 28 h. The difference in the consistency of the reaction mixtures is 
believed to have had an influence on reactivity.  37 
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LiHMDS had been shown to be the give the fastest rate and had the added advantage 
of producing a homogenous solution, which is easier to handle than a suspension.  
As previously mentioned anilines have so far proven to be difficult substrates not 
only in the reaction with TCP sulfonate esters but also with the more reactive PFP 
analogues.
95 With this in mind it was considered important to fully investigate the 
range of anilines that could be used by synthesising a small array of sulfonamides. In 
order  to  do  this  three  TCP  sulfonate  esters  with  differing  electrophilicities:  4 
nitrobenzene  TCP  sulfonate  ester  (90),  benzene  TCP  sulfonate  ester  (93)  and  4 
methoxybenzene TCP sulfonate ester (89) and a range of anilines were chosen.  
Before synthesising the library the reaction conditions needed to be optimised and so 
with  this  in  mind  the  most  conceptually  difficult  reaction,  between  the  least 
electrophilic sulfonate ester, 4 methoxybenzene TCP sulfonate ester (89), and the 
least  nucleophilic  aniline,  4 nitroaniline,  was  investigated.  There  were  initial 
problems with the work up of this reaction because the basic wash (saturated sodium 
carbonate solution) failed to remove the trichlorophenol and additionally the aniline 
could not be removed by an acidic wash. Unfortunately, the aniline co eluted with 
product 115 in all the TLC systems tried and so column chromatography was futile. 
In order to eliminate the problem of separating the excess aniline from sulfonamide 
115 the number of equivalents used was reduced, initially to 1.1 eq. With 1.1 eq of 
aniline and 2 eq LiHMDS in THF at 50 °C the reaction took 21 h and even using this 
small excess of aniline there was difficulty with its removal. Therefore, microwave 
conditions were investigated which, would allow smaller amounts of aniline to be 
used without resulting in prohibitively long reaction times (Table 7). The optimal 
microwave conditions were found to be 120 °C for 30 min with 0.85 eq aniline and 2 
eq LHMDS in THF (Table 7, Entry 7), and column chromatography was required to 
purify the crude products.  38 
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Scheme 30 
Entry  Aniline 
eq 
Microwave/ 
Thermal 
Temperature 
(°C)  Time  LCMS result  Yield 
(%) 
1  2  Thermal  50  4 h     
2  1.1  Thermal  50  21 h  9% aniline  57 
3  1.1  MW  80  10 min  11% TCP 
sulfonate ester   
4  1.1  MW  100  15 min  6% TCP 
sulfonate ester   
5  1.1  MW  100  30 min  2% aniline   
6  0.9  MW  100  30 min  4% aniline   
7  0.85  MW  120  30 min  1% aniline  47 
Table 7 
With the conditions established the arrays could be synthesised. Most reactions gave 
moderate to excellent yields of the desired product with the whole range of anilines 
reacting with generally a high level of success (Table 8). 
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Table 8 Reactions of anilines with TCP sulfonates 
A number of reactions did not go to completion under the array conditions and for 
these the product was not isolated due to the difficultly in removing the unreacted 40 
aniline. 4 Methoxybenzene TCP sulfonate (89) failed to react to completion with 5 
amino N methylindole, 2 trifluoromethylaniline and 4 trifluoromethylaniline (Table 
8, entries 118b, 118l and 118o). This is thought to be due to the electron rich nature 
of the TCP sulfonate ester 89, and with 2 trifluoromethylaniline there is the added 
problem of possible steric hindrance of the trifluoromethyl group. In the synthesis of 
116p and 117p all the sulfonate ester had been consumed (by LCMS) yet there was 
still some aniline present and this could not be removed by column chromatography 
due  to  co elution  with  the  product.  The  presence  of  the  aniline  indicated  the 
decomposition of the starting TCP ester before the aniline had reacted completely. 
One unusual result was in the reaction between 4 nitrobenzene TCP sulfonate ester 
(90)  and  N methylaniline  (Table  8,  Entry  116c).  Under  the  array  conditions  no 
product  (116c)  or  starting  material  could  be  isolated  and  by  LCMS  the  reaction 
mixture  had  numerous  peaks  present  suggesting  that  side  reactions  and/or 
decomposition  under  the  microwave  conditions  was  occurring.  When  heating 
thermally at 50 °C and even performing the reaction at room temperature the starting 
material was consumed within two hours to give a similar LCMS trace, therefore 
suggesting that unwanted side reactions were occurring.  
2.4 Selectivity 
Having  established  the  reactivity  of  TCP  sulfonate  esters  the  next  step  was  to 
compare the reactivity and selectivity of amines towards a mixture of TCP and PFP 
sulfonate esters. This approach was used to ascertain whether an amine would react 
preferentially with the PFP sulfonate ester in the presence of a TCP sulfonate ester. 
This  was  achieved  by  taking  an  equimolar  mixture  of  these  sulfonate  esters  and 
sequentially treating them to amines under different conditions (Scheme 32). The 
idea was that the first amine would react with the PFP sulfonate ester and the second 
with the TCP sulfonate ester. Thus, with complete selectivity only products 120 and 
122 would be synthesised (Scheme 32). 41 
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  Amine 1  Amine 2  Conditions 
1 
Conditions 
2 
Ratio 
120:121 
Ratio 
122:123 
1 
H2N
 
HN
  50 ºC, 1 h  100 ºC, 3 h  30:1  5:1 
2 
H2N
 
HN   40 ºC, 4 h  100 ºC, 3 h  15:1  15:1 
3 
H2N
 
HN
  rt, 30 h  80 ºC, 18 h  20:1  13:1 
4  HN  
H2N
 
40 ºC, 4 h  80 ºC, 18 h  20:1  11:1 
5  N
H   H2N  
50 ºC, 2 
days  80 ºC, 18 h  9:1  11:1 
6  N
H   H2N  
rt, 1 eq 
TBAC, 4 h 
70 ºC, 18 h 
  10:1  10:1 
Table 9 
A 1:1 mixture of TCP tosylate (88) and PFP benzene sulfonate (119) was initially 
treated with one equivalent of 4 methylbenzylamine and heated to 50 °C for 1 h and 
then one equivalent of piperidine was added and the mixture was heated to 100 °C 
for 3 h (Table 9, Entry 1). The crude 
1H
 NMR spectrum showed that the 4 methyl 
benzylamine had reacted, as expected, preferentially with the benzyl PFP sulfonate to 
give  a  30:1  mixture  of  120  (R  =  4 methylbenzyl,  R
1  =  H,  80):  121  (R  =  4 
methylbenzyl, R
1 = H, 81) and the piperidine had reacted to give a 5:1 mixture of 
122 (R
2 = R
3 = cyclohexyl, 103): 123 (R
2 = R
3 = cyclohexyl, 124). This looked 
promising as it showed that the amine did react preferentially with the PFP sulfonate 
but the poor selectivity of the reaction with piperidine indicated that not all the PFP 
sulfonate ester had been fully consumed in the initial aminolysis reaction and so a 
longer reaction time was required. 42 
In an effort to increase the selectivity the initial temperature was reduced and 40 ºC 
was found to be optimal (Table 9, Entry 2). Reducing the temperature to 20 ºC gave 
minimal advantage in selectivity and increased the reaction time from 4 h to 30 h 
(Table 9, Entry 3). The addition of TBAC as a catalyst allowed the first reaction to 
proceed at room temperature with an increased reaction rate but gave no change to 
the selectivity (Table 9, Entry 6), and so gave no advantage over heating. Adding two 
equivalents  of  the  second  amine  helped  ensure  the  completion  of  the  second 
aminolysis. When the order of amine addition was changed good selectivity was still 
seen (Table 9, Entry 4). With the conditions in place two different amine sequences 
were tried and these also gave the desired products with good selectivity and yields 
(Scheme 33, Scheme 34 and Scheme 35). 
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Scheme 34 43 
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Scheme 35 
Having established the selectivity between the PFP sulfonate ester and TCP sulfonate 
ester it seemed a natural extension of this to also explore the selectivity between a 
sulfonyl chloride, PFP sulfonate ester and TCP sulfonate ester. The approach to this 
was to take an equimolar mixture of 4 fluorobenzenesulfonyl chloride (128), benzene 
PFP  sulfonate  ester  (119)  and  4 methylbenzene  TCP  sulfonate  ester  (88)  and  to 
sequentially expose this to 4 methylbenzylamine at 0°C and then piperidine at room 
temperature (Scheme 36). This was in the expectation that 4 fluoro N (4 methyl 
benzyl) benzenesulfonamide (129) and 1 benzenesulfonylpiperidine (124) would be 
formed and that 4 methylbenzene TCP sulfonate ester (88) would be recovered. The 
4 methylbenzylamine had reacted with a small quantity of the PFP sulfonate ester 
(88) to give a 27:1 mixture of sulfonamides 129:80 and with the piperidine a 30:1 
mixture of the PFP derived sulfonamide (124): TCP derived sulfonamide (103) was 
obtained. 87% of 4 methylbenzene TCP sulfonate ester (88) and 10% of the PFP 
sulfonate ester (119) was recovered. Overall the desired compounds were obtained as 
the major products in excellent selectivity and yields.  44 
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Scheme 36 
2.5 Conclusions 
In conclusion a new class of activated sulfonate ester has been described and it was 
demonstrated that they  could be synthesised directly from the sulfonic acid salts 
using the activating agent triphenylphosphine ditriflate. This avoids the need to use 
sulfonyl  chlorides.  An  efficient  and  high  yielding  method  of  synthesising  aryl 
sulfonamides  from  these  TCP  sulfonates  under  microwave  conditions  has  been 
developed,  which  would  allow  sulfonamide  libraries  to  be  rapidly  synthesised. 
Unfortunately this protocol failed for less nucleophilic amines such as aniline and so 
an alternative method was established. The use of LHMDS allows anilines to react 
with  the  TCP  sulfonate  esters  under  microwave  conditions  to  give  the  resultant 
sulfonamides in good yields. This was demonstrated by the synthesis of three small 
libraries of sulfonamides.  
The differing reactivity of the PFP and TCP sulfonates was investigated, and amines 
were shown to react selectively with a PFP sulfonate ester in the presence of a TCP 
sulfonate  ester.  This  idea  was  expanded  on  and  the  differing  reactivities  of  a 
sulfonate chloride, a PFP sulfonate and a TCP sulfonate were exploited in selective 
sulfonamide formation.  
Overall,  TCP  sulfonate  esters  have  been  identified  as  a  new  class  of  activated 
sulfonate ester that can be employed in the synthesis of sulfonamides utilising both 
simple nucleophilic amines and more challenging anilines and hindered amines. The 
issues of cost of pentafluorophenol have been addressed with 2,4,6 trichlorophenol 45 
being  at  least  ten  times  less  expensive.  Finally,  the  perceived  problems  with 
polyfluorinated aromatics have also been avoided by use of the TCP sulfonates. 46 
Chapter Three 
Synthetic Manipulation of TCP Sulfonates 
3.1 Introduction 
In  Chapter  2  the  reactivity  and  selectivity  of  TCP  sulfonates  was  established 
demonstrating  the  greater  stability  of  TCP  sulfonates  in  comparison  to  PFP 
sulfonates  and  sulfonyl  chlorides.  It  is  now  desirable  to  elucidate  whether  this 
improved stability allows more diverse reactions to be performed in its presence, thus 
providing access to a wide range of functionalised sulfonates as intermediates for 
synthesis. 
Section 1.2.3.4 summarised the range of reactions performed with the PFP sulfonate 
in  situ,  thus  demonstrating  the  versatility  of  PFP  sulfonates.  There  are  those 
transformations  which  leave  this  moiety  intact  allowing  for  their  conversion  to 
sulfonamides, for example radical additions and isoxazolidine synthesis, or those as 
in the case of sultam synthesis which involve the sulfonate in the preparation of 
valuable  highly  substituted  compounds.
98,  99,  104  There  are  limitations  to  their 
versatility as shown by  the failure of cycloadditions of vinyl PFP sulfonate with 
azides  and  nitrile  oxides  and  of  the  Heck  and  metathesis  reactions  of  the  same 
compound.
103 
Within the Caddick group, parallel to this project, the application of the majority of 
the  successful  reactions  to  the  TCP  sulfonates has  been  explored.  Intermolecular 
radical  additions  to  TCP  vinylsulfonate  (130)  using  tin  mediated  (Scheme  37, 
Method A) and tin free conditions (Scheme 37, Method B) have been carried out to 
give the alkyl sulfonates in good yields.
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Scheme 37 Intermolecular radical addition reactions 
105 47 
Also, the TCP vinyl sulfonates have been shown to undergo cycloaddition reactions 
to give isoxazolidines in good yields.
106 
This  chapter  describes  alternative  reactions  that  have  been  attempted  in  the 
preparation of novel aromatic TCP sulfonates. 
3.2 Palladium Reactions 
Palladium catalysed  cross coupling  reactions  provide  an  efficient  approach  to 
carbon carbon  bond  formation  in  organic  chemistry.
107  They  have  elicited 
considerable  attention  resulting  in  the  discovery  and  use  of  a  broad  variety  of 
catalysts and ligands in the synthesis of natural products and pharmaceuticals.
108 111    
3.2.1 Suzuki Miyaura Reactions 
The Suzuki Miyaura reaction is a general and powerful synthetic method for the C C 
cross  coupling  of  an  aryl  halide  with  a  boronic  acid  and  is  widely  used  in  the 
synthesis  of  compounds  in  drug  discovery.
112 114  Sulfonyl  chlorides  have  been 
reported to undergo Suzuki cross coupling reactions with aryl boronic acids whereby 
the sulfonyl chloride moiety behaves as a pseudo halide leaving group.
115 Avitabile 
et al. have shown that the PFP sulfonate group is stable to the basic conditions of the 
Suzuki Miyaura  reaction  and  that  it  can  then  be  further  manipulated  to  give  the 
sulfonamides.
100 This led to investigations into whether Suzuki reactions can also be 
performed in the presence of a TCP sulfonate ester. 
Considering the success of the conditions used for the PFP sulfonates by Avitabile et 
al. these were a natural starting point.
100 When this protocol was utilised for the 
Suzuki  reaction  between  4 bromobenzene  TCP  sulfonate  ester  (96)  and  4 
methoxybenzene boronic acid the desired product (131) was obtained  as a white 
solid in a 87% yield. What was particularly of note was that this was an improvement 
on the 71% yield obtained for the analogous reaction with the 4 bromobenzene PFP 
sulfonate ester. Due to this excellent result these conditions were applied to other 
Suzuki reactions, firstly with 4 bromobenzene  TCP sulfonate ester (96) and then 
with 3 bromobenzene TCP sulfonate ester (97) to give the products (131 143) in 
good yields (Figure 26). Both aromatic and heterocyclic boronic acids reacted with 
the only failure being 2,4 dimethylphenyl boronic acid, which was probably due to 
the steric hindrance imposed by the methyl groups. 48 
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Figure 26 
One of the Suzuki products (134) was selected and an aminolysis reaction was tried 
using the conditions developed in section 2.3.3.1. This gave the desired sulfonamide 
144 in an 89% yield.  
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Scheme 38 
Due to the success with 3  and 4 bromobenzene TCP sulfonate the Suzuki reactions 
were attempted with 2 bromobenzene TCP sulfonate (98) (Scheme 39).  49 
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Scheme 39 
The  reaction  between  4 fluorobenzene  boronic  acid  and  2 bromobenzene  TCP 
sulfonate (98) was attempted. After 22 h stirring at reflux the LCMS showed the 
presence of bromide (98). The addition of another 3 mol% of catalyst and further 
heating  did  not  lead  to  a  significant  progression  in  the  reaction  with  the  LCMS 
showing bromide (98) was still present. The reaction was worked up and purification 
was  attempted  using  column  chromatography,  this  yielded  520mg  of  a  3:1 
inseparable mixture of the desired product (145) and the TCP sulfonate (98). At this 
point a different catalyst dichlorobis(tri o tolylphosphine) palladium was employed 
in an effort to drive the reaction to completion. Unfortunately after 14 h of heating at 
reflux the LCMS showed several peaks including bromide (98) and TCPOH. The 
presence of TCPOH indicated that decomposition of the bromide (98) or possibly the 
coupled product (145) was occurring. Bromide (98) is much more hindered than the 
3   and  4 bromo  compounds,  which  would  explain  the  difficulty  in  getting  this 
reaction to go to completion. 
3.2.2 Heck Reactions 
The arylation of olefins, Heck reaction, has been shown to be another powerful use 
of palladium catalysis with applications in many diverse areas of chemistry including 
natural product synthesis
116 and bioorganic chemistry.
117 With this in mind the Heck 
reaction seemed an ideal transformation to investigate for its utility in the presence of 
a TCP sulfonate ester. 
To give continuity with the Suzuki reaction the bis(triphenylphosphine) palladium 
dichloride catalyst was initially selected. 4 Iodobenzene TCP sulfonate (95) in DMF 
and  treated  with  bis(triphenylphosphine)  palladium  dichloride  (3  mol%), 
triethylamine (4 eq) and ethyl acrylate (3 eq) at 80 °C for 24 h to give the desired 
alkene (146) in a 74% yield (Scheme 40). Following this promising result attention 
was turned to the 4 bromobenzene TCP ester (96) and finding appropriate conditions 
for the reaction with ethyl acrylate. The amount of ethyl acrylate was reduced from 3 50 
to 1.2 eq and microwave conditions were explored. The reaction proved to be very 
sensitive to temperature. When heating to 120 °C for 15 min the TLC showed several 
new spots indicating decomposition was occurring and when the temperature was 
reduced to 80 °C no reaction occurred. At 100 °C the reaction proceeded cleanly and 
was complete after 30 min to give alkene 146 in a 71% yield. 
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Scheme 40 
With these encouraging results the next step was to study the effect of different bases 
on the rate of the reaction. As it is difficult to monitor when a microwave reaction 
has gone to completion all reactions were carried out for a specific time. They were 
then  worked  up  to  isolate  the  product  and  determine  how  far  the  reaction  had 
proceeded. The conditions chosen for this were 100 °C for 10 min using 3 mol% 
bis(triphenylphosphine) palladium dichloride, 1.2 eq of ethyl acrylate and 2 eq of 
base in DMF. 
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Scheme 41 
Entry  Base  Yield (%) 
1  Et3N  22 
2 
nBu3N  8 
3  Cy2MeN  46 
4  Cy2MeN + AgOTf  Fail 
5  K2CO3  28 
6  Cs2CO3  32 
7  K2CO3 + TBAC  Fail
 
8  Cs2CO3 + AgOTf  44 
Table 10 
The bases selected were triethylamine, tri n butylamine, methyldicyclohexylamine, 
potassium carbonate and caesium carbonate. Silver salts have been demonstrated to 
improve Heck reactions by complexing to the halide and thus facilitating oxidative 51 
cleavage.
118  Therefore,  silver  triflate  was  tried  in  combination  with  the  two  best 
bases, methyldicyclohexylamine and caesium carbonate. Tri n butylamine (Table 10, 
Entry 2) was the least effective base, giving the lowest yields, whilst the reactions in 
which  methyldicyclohexylamine  (Table  10,  Entry  3)  were  employed  seemed  to 
proceed  at  the  fastest  rate.  Although  similar  results  were  seen  for 
methyldicyclohexylamine and caesium carbonate with silver trifluoroacetate (Table 
10, Entries 3 and 8 respectively) the former was chosen as the preferred base.   
With the optimised conditions (Scheme 42) in place it was now suitable to expand 
the  substrate  range.  Initially,  the  reaction  with  ethyl  acrylate  was  carried  out  to 
completion to give the desired product (146) in a 73% yield (Table 11). The reaction 
with cyanoacrylate  gave the product  (148) in  a 37%  yield and the reaction with 
styrene gave the product (149) in a 51% yield (Table 11).  
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Table 11 
Thus  far,  palladium  reactions  of  bromoaryl  TCP  sulfonate  esters  have  been 
investigated and the Suzuki reactions shown to proceed in good yields when using 3  
and 4 bromobenzene TCP sulfonate ester. Unfortunately the coupling reactions with 
2 bromobenzene TCP sulfonate ester (98) proved more difficult and did not proceed 
to  completion.  The  Heck  reactions  were  also  explored  and  reactions  with 
ethylacrylate, cyanoacrylate and styrene occurred in moderate to good yields. 52 
In the search for alternative reactions for the preparation of novel aromatic TCP 
sulfonates it was considered advantageous to explore the possibility of performing an 
asymmetric  transformation,  hence  incorporating  a  degree  of  chirality  into  these 
compounds. One such asymmetric reaction that has been studied previously within 
the Caddick group is dynamic kinetic resolution (DKR). 
3.3 Dynamic Kinetic Resolution 
3.3.1 Introduction 
With the abundance of chiral natural products and biologically active compounds
119 
the synthesis of chiral  molecules is a significant and challenging part of organic 
synthesis.
120 The administration of a racemate as a pharmaceutical is undesirable as it 
requires higher dosing and the presence of the other enantiomer may result in adverse 
side effects. This has resulted in a trend towards single enantiomer drugs bringing 
asymmetric synthesis to the forefront of drug discovery and development.
119 
There  are  two  major  strategies  in  the  preparation  of  chiral  compounds:  i) 
stereocontrolled  formation  of  the  stereogenic  centre  whereby  the  chirality  is 
determined on formation of the chiral centre using, for example, a chiral catalyst or 
directed by existing chiral centres in the substrate (chiral substrate, auxiliaries); ii) 
resolution of a stereoisomeric mixture. 
Kinetic  resolution  exploits  the  differing  reactivity  of  the  two  isomers,  i.e.  the 
differing rates of formation of the two products (Scheme 43).
121, 122 If efficient one 
isomer will be completely converted to product whilst the other is left unchanged. 
This  results  in  the  maximum  theoretical  yield  being  only  50%,  which  limits  its 
applications. However, dynamic kinetic resolution (DKR) overcomes this issue by 
combining  an  equilibration  step  of  chirally  labile  substrates  with  the  kinetic 
resolution step (Scheme 43). In order for a DKR to be effective the rate the substrates 
equilibrate  (kinv)  must  be  faster  than  the  rate  of  product  formation  (kA,  kB),  the 
resolution step has to be irreversible and the product should be configurationally 
stable under the reaction conditions.  53 
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Scheme 43 Kinetic resolution and dynamic kinetic resolution (DKR) 
There  are  many  methods  of  affecting  DKR  and  these  have  been  explored  and 
reviewed extensively by Pellissier,
123, 124 Ward,
125 Backväll
126 and Caddick.
127 A few 
approaches will be highlighted herein. 
3.3.1.1 Chiral metal catalysts 
In 1989 Noyori’s group was one of the first to report the use of ruthenium catalysed 
hydrogenation  in  the  DKR  of  β keto  esters.
128  Since  then  this  process  has  been 
extensively studied showing the degree of selectivity to be highly dependent upon 
the nature of the chiral ruthenium catalysts, reaction conditions and substrates.
129 In 
2003 Genêt et al. developed a new atropoisomeric chiral ligand, SYNPHOS.
130 This 
proved effective in ruthenium catalysed asymmetric hydrogenations and gave access 
to a range of optically active alcohols (151a d) with ee values of up to 99% (Scheme 
44). 
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Scheme 44 DKR of α amino β keto ester hydrochlorides 
Through  ruthenium catalysed  hydrogenation  Lassaletta  et  al.  accessed  a  range  of 
chiral halohydrins (153) starting from the corresponding cyclic α haloketones (152). 
131  Using  either  HCO2H/Et3N  or  HCO2H/TBAB  as  the  hydrogen  source  they 
prepared bromo , chloro  and fluorohydrins in good yield and optical purity (Scheme 
45).  54 
O
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Scheme 45 Enantioselective synthesis of vicinal halohydrins via DKR 
3.1.1.2 Organocatalysed DKR 
During the last few years there has been a proliferation of interest in organocatalysis 
and this has lead to the development of novel organocatalysed DKR processes. One 
such example was reported by List et al. whereby they developed an enantioselective 
reductive amination of α branched aldehydes (154) via dynamic kinetic resolution. 
Under  acidic  conditions  the  intermediate  imines  (155  and  156)  undergo  facile 
racemisation via the enamine (157) using a BINOL phosphoric acid catalyst. The 
resultant iminium salt (158) is reduced with Hantzsch ester (159) to affect an overall 
stereoselective reduction, which thus furnishes an enantiomerically enriched product 
(160)  (Scheme  46).  This  process  was  broad  in  scope,  with  both  aromatic  and 
aliphatic aldehydes being used, although the enantiomeric ratios were typically lower 
for simple aliphatic aldehydes (Scheme 46).
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Scheme 46 55 
3.1.1.3 Enzymatic DKR 
Due to the mild conditions associated with enzyme catalysed processes enzymatic 
DKR  is  an  attractive  choice.  Williams  et  al.  have  developed  a  DKR  for  the 
hydrolysis of α bromo
133 and α chloro esters.
134 The success of this process is due to 
the greater ease of racemisation of the starting ester via a SN2 pathway than the 
carboxylic  acid  product.  The  resin  based  bromide  proved  to  be  a  good  bromide 
source and along with a commercially available enzyme, DKR was effective yielding 
the acid (e.g. 162) in good yields and enantioselectivity (Scheme 47). 
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Scheme 47 
3.1.1.4 Configurationally labile alkyl halides 
The nucleophilic displacement of the conformationally labile α halo carbonyl can be 
controlled by a chiral auxiliary adjacent to the carbonyl group (Scheme 48).
124, 135, 136 
Racemisation  can  be  induced  by  additives  such  as  halide  salts,  bases  and  polar 
solvents. The importance of this technique is exemplified by its application in the 
asymmetric  synthesis  of  a  variety  of  α substituted  carboxylic  acid  derivatives, 
particularly amino acids. 
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Scheme 48 SN2 reactions on configurationally labile halides  
Durst  et  al.  have  applied  this  methodology  in  the  synthesis  of  β dibenzylamino 
alcohols (165) using the chiral auxiliary (R) pantolactone. (R) pantolactone α bromo 
esters  (163)  were  treated  with  dibenzylamine  and  the  epimerising  agent 
tetrabutylammonium iodide (TBAI) to give S,R 164 with good yields and selectivity 
(Scheme 49). 
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Scheme 49 Synthesis of β dibenzylamino alcohols using DKR 
Recently  Ben  et  al.  have  reported  the  first  example  of  immobilised  amine 
nucleophiles in DKR.
138 α Bromo esters (166), containing (R) pantolactone as the 
chiral auxiliary, were treated under epimerising conditions with amine nucleophiles 
(167) attached to a resin via an organic spacer. In comparison to the solution phase 
DKR superior optical purities were obtained with diastereomeric excesses ranging 
from 84% to 94% and yields between 66% and 98% (Scheme 50).  
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Scheme 50 DKR using immobilised amine nucleophiles 
The chiral auxiliary tert butyl (4S) 1 methyl 2 oxoimidazolidine 4 carboxylate was 
used  by  Nunami  et  al.  for  DKR  reactions,  in  the  stereoselective  synthesis  of  α 
substituted  carboxylic  acids.  Epimerisation  of  the  α bromo  substrates  (169)  was 
achieved under basic conditions and in the highly polar solvent HMPA. Good yields 
and  diastereoselectivity  were  obtained  when  using  both  nitrogen  nucleophiles, 
benzylamine  (products  S,S 170  and  S,R 170)
136  and  sodium  phthlamide  (products 
S,S 171 and S,R 171),
139 and the carbon nucleophile sodium malonate (products S,S 
172  and  S,R 170)  (Scheme  51).
140,  141  The  metallated  nucleophiles  favour  the 
opposite selectivity
139, 141 to the non metallated nucleophile, benzylamine.
136 It was 
postulated that the attack of benzylamine was directed by hydrogen bonding to the 
ester group whilst the metallated nucleophiles which are unable to participate in this 
interaction attack from the least hindered face.
139 The products were easily converted 
to the corresponding α amino acids and α alkylsuccinic acid derivatives.  57 
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Scheme 51 
Caddick  et  al.  utilised  the  chiral  auxiliary  (4R,5S) 1,5 dimethyl 4 
phenylimidazolidin 2 one  (173)  in  the  synthesis  of  amino  acids  via  DKR.  The 
imidazolidinone  auxiliary  173  is  readily  prepared  by  the  thermal  fusion  of 
ephedrinium chloride and urea. The required racemic α bromo derivatives (174 176) 
were synthesised by acylation of 173 with an α bromo acid bromide (Scheme 52).
142 
Epimerisation was affected using TBAI, with THF proving to be the optimal solvent. 
When using benzylamine as the nucleophile the 2'R isomer (177 179) was obtained 
in good yield and selectivity.   
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Scheme 52 
For  DKRs with the metallated nucleophile, sodium malonate, the selectivity was 
poor to moderate. But what was of particular note was the reversal of selectivity, in 
comparison to the amine nucleophile, with the major product being the 2'R isomer.
142  
Further exploration identified an α bromination protocol which allowed access to a 
wider range of α bromo substrates (Scheme 53). This enabled the DKR method to be 58 
extended to the synthesis of a range of phenyl glycine derivatives (184) which were 
obtained in good yields and selectivity.
143  
The bromination was directed by the auxiliary to give the 2'R 181 product. When this 
was  treated  with  TMGA  under  non epimerising  conditions  SN2  displacement 
occurred to furnish 2'S 183, whilst under epimerising conditions double inversion 
took place and the opposite stereoselectivity was seen giving 2’R 182 (Scheme 53).  
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Scheme 53 Complementary DKR and substitution approach to α azido/amino carboxylic acid 
derivatives 
Using the model put forward by Durst et al. whereby it is proposed the substitution 
reactions take place via a dipole opposed conformation, the stereochemical outcome 
from the attack of sodium malonate can be explained  as a result of approach of the 
nucleophile from the least hindered face of the chiral auxiliary (Figure 27).
144, 145 
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Figure 27 
In  order  to  rationalise  the  stereochemical  outcome  of  the  DKR  with  amine 
nucleophiles extensive molecular modelling experiments were carried out.
146 These 
indicated that the selectivity can be attributed to the ease with which the halide can 
leave without undesirable interactions with the bulky phenyl group (Figure 28). The 
steric and electrostatic interactions were shown by the molecular modelling to be 
much greater for the 2'R substrate than the 2'S substrate resulting in faster reaction of 
the latter and giving the 2'R isomer as the dominant product.   59 
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Figure 28 
3.3.2 Towards the synthesis of TCP amino acids 
The objective was to use the imidazolidinone DKR/SN2 protocol, shown in Scheme 
53,  for  the  synthesis  of  optically  active  amino  acids  containing  a  pendant  TCP 
sulfonate on the phenyl ring. The initial targets were novel amino acids 186 and 187 
(Scheme 54) as this would further probe the stability of the TCP sulfonate group 
when performing diverse reactions on remote sites within these molecules.  
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Scheme 54 
To help establish whether this was a feasible goal the known bromide 2'R 189 was 
synthesised. This allowed subsequent investigations into the viability of selective 
bromine displacement in the presence of a TCP sulfonate ester, and optimisation of 
the dynamic kinetic resolution procedure could also be carried out.  
3 Phenylpropionyl chloride was coupled to the imidazolidinone 173 in the presence 
of 2,6 lutidine in DCM to give imide 188 in an 87% yield. This was treated with 
LHMDS  in  THF  giving  the  anion  to  which  bromine  was  added  to  produce  the 
bromide 2'R 189 in a 63% yield. The absolute configuration of 189 was confirmed 
by comparison to previous reported data.
147  60 
LHMDS
Bromine
THF, 78ºC
Cl
O
Ph
N N
O
Ph
O
Ph
Br
N N
O
Ph
O
Ph NH N
Ph
O
2,6 lutidine
DCM, 0ºC rt
173 188
87%
2'R 189
63%
+
 
Scheme 55 
With this compound now in place the DKR could be carried out. An issue with the 
nucleophilic substitution of bromide 189 is the competing elimination pathway to 
form the alkene 191 (Scheme 56). The elimination pathway is particularly favourable 
because the β hydrogens are benzylic and hence, weakly acidic due to the electron 
withdrawing effect of the aromatic ring. Furthermore the resultant double bond is in 
conjugation with the aromatic ring.  
The problem of elimination had been previously reduced by using the conditions 
benzylamine  (6  eq),  tert butylammonium  iodide  (0.2  eq)  at  room  temperature  in 
THF.
147 The reaction was performed over 4 days under these conditions to give the 
DKR product (190) in an unsatisfactory 48% yield and 33% de (calculated by 
1H 
NMR integration) and the elimination product (191) in a 15% (Table 12, Entry 1). 
Both the yield and the de were disappointing but these have been shown to improve 
on heating and so the temperature was raised in an effort to resolve these issues.
145 
Performing the reaction at reflux (6 h) produced a slight increase in the yield (53%) 
of 190 but had a significant effect on the de resulting in a considerable improvement 
from 33% to 85% (Table 12, Entry 2). This thus showed that the temperature has a 
strong influence on the stereocontrol of the reaction.
142 To further investigate this 
trend the reaction was carried out in the microwave at 100 ºC. This produced 190 
with a comparable yield and de but in a much shorter time (30 min) (Table 12, Entry 
3). Attempts to further increase the microwave temperature resulted in a complex 
mixture of products and although 190 could be isolated the yield was reduced. 
Under all conditions investigated the eliminated product (191) was isolated in a 10 
15% yield. The formation of any of the alkene 191 is obviously not ideal but the 
complete suppression of the elimination pathway is in all probability not achievable 
and this amount was considered tolerable.  61 
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      Time  2’R 190
   191 
1  rt  4 days  48%, de 33%  15 % 
2  Reflux   6 h  53 %, de 85%  10 % 
3  Microwave 100 ºC  30 min  57%, de 85%  13 % 
4  Microwave 150 ºC  10 min  49%, de 77%
b  15 % 
Table 12 
Having obtained the DKR product with a good de and in a reasonable yield it was 
now desirable to establish whether the benzylamine would react preferentially with 
the α bromo carbonyl in the presence of a TCP sulfonate. This was achieved by 
performing  the  DKR  reaction  in  the  presence  of  benzene  TCP  sulfonate  (93) 
(Scheme 57).The results are shown in Table 13.  
Promising results were obtained when the reaction was carried out in the microwave 
at 100 ºC (Table 13, entry 1). The desired DKR product (190) was isolated in a 68% 
yield with a de of 77% which are comparable values to those obtained in the absence 
of TCP sulfonate 93 (Table 12, Entry 3). TCP sulfonate 93 was recovered in a 61% 
yield  and  the  sulfonamide  192  was  obtained  in  a  29%  yield.  In  an  attempt  to 
discourage this unwanted reaction the temperature was reduced and the reaction was 
carried out thermally at reflux (Table 13, Entry 2). This reaction again gave 190 in a 
comparable yield (69%) and de (69%) but there was a significant increase in the 
amount of sulfonamide 192 isolated (50% yield) and a lower recovery of the TCP 
sulfonate 93 (39%). When the temperature was reduced to room temperature (Table 
13,  Entry  3)  a  further  increase  in  the  formation  of  sulfonamide  192  (67%)  and 
reduction of recovered TCP sulfonate 93 (18%) was observed.  
A trend has been established whereby there is an increase in sulfonamide formation 
as the temperature is lowered. This trend is believed to be due to the accompanying 
increase in reaction times at lower temperatures resulting in a longer exposure of the 
TCP sulfonate to the nucleophile. Also, as 2'R 189 is consumed in the reaction its 
concentration  is,  of  course,  reduced  whilst  the  relative  concentration  of  TCP 
sulfonate 93 increases.  62 
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Scheme 57 
      2'R 190  191  192  93 
1  Microwave 
100 ºC  20 min  68%, de 77%   13%  29%  61% 
2  Reflux  6 h  69%, de 69%  16%  50%  39 % 
3  Rt  4 days  63%, de 25%  17%  67%  18 % 
Table 13 
Having shown that it could be possible to achieve a degree of selectivity for amine 
formation over sulfonamide synthesis attention was turned to the synthesis of the 
desired alkyl bromides with pendant TCP sulfonates. The two initial targets were 
amines 193 and 194 (Figure 29). 
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It  was  envisaged  that  the  aryl  TCP  sulfonate  could  be  incorporated  via  a  Heck 
reaction  with  alkene  195  (Scheme  58)  which  could  be  formed  by  coupling  the 
auxiliary 173 to acryloyl chloride. The resultant alkene could then be reduced to the 
alkane and bromination should give the required α bromo compounds.  63 
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Scheme 58 
The auxillary was coupled to acryloyl chloride to give alkene 195 in a 49% yield 
(Scheme 59). 
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Scheme 59 
The Heck reaction conditions developed in section 3.2.2 were applied to the coupling 
of  alkene  195  with  3   and  4 bromobenzene  TCP  sulfonates.  The  results  were 
disappointing  isolating  the  3 regioisomer  196  in  only  a  30%  yield  and  the  4 
regioisomer  197  in  a  57%  yield  (Table  14,  Entry  1).  The  Heck  reaction  had 
previously been performed on alkene 195
148 and so these conditions were employed 
to give an improved yield of 48% for the 3 regioisomer 196 but a reduced yield of 
47% for the 4 regioisomer 197 (Table 14, Entry 2). Modification of these conditions 
by reduction of the mol% of catalyst and ligand gratifyingly resulted in improved 
yields of both the 3  and 4  isomers giving yields of 67% and 61%, respectively 
(Table 14, Entry 3).   64 
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    196  197 
1 
Bromobenzene TCP sulfonate (1 eq), 195 (1.2 eq, 
(PPh3)2PdCl2 (3 mol%), N methyldicyclohexylamine 
(2 eq), DMF, MW 
30%  57% 
2 
Bromobenzene TCP sulfonate (1 eq), 195 (1.2 eq, 
(PPh3)2PdCl2 (10 mol%), P(o tolyl)3 (0.4 mol%), 
Toluene:Et3N 2:1 
48%  47% 
3 
Bromobenzene TCP sulfonate (1 eq), 195 (1.2 eq, 
(PPh3)2PdCl2 (1 mol%), P(o tolyl)3 (2 mol%), 
Toluene:Et3N 2:1 
67%  61% 
Table 14 
The next step was the reduction of the alkene. Hydrogenation of the 3 regioisomer 
196 using 5% palladium on carbon in ethyl acetate proved to be slow and a complex 
mixture was obtained from which the desired product (198) was isolated in only a 
23% yield. Changing the solvent to methanol brought no improvement. 
Lee et al. have reported the use of Co2(CO)8 H2O system for the selective reduction 
of  α,β unsaturated  carbonyl  compounds  (204)  (Scheme  60).
149  This  system  was 
successfully  used  in  the  chemoselective  reduction  of  various  α,β unsaturated 
carbonyl compounds (204) including ketones, aldehydes and esters giving the desired 
products (205) in moderate to excellent yields (60 100%).   
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Scheme 60 
These conditions were applied to alkene 196 and initial results were promising with 
the alkane 198 being isolated in a 78% yield (Scheme 61). 65 
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Scheme 61 
For  the  3 isomer  196  the  reaction  consistently  proceeded  with  good  yields  but 
disappointingly when the conditions were applied to the 4 isomer 197 the product 
(199)  was  obtained  in  an  unsatisfactory  18%  yield.  The  reaction  had  gone  to 
completion by TLC and on work up as well as isolating the alkane 199 some 2,4,6  
trichlorophenol was obtained indicating that hydrolysis might have occurred.  
Another  approach  to  the  reduction  of  α,β unsaturated  carbonyls  is  using 
triphenylphosphine  copperhydride  hexamer  in  conjunction  with  water  to  give  the 
carbonyl  or  alternatively  reacting  with  trialkylsilylchloride  to  give  the  silyl  enol 
ether.
150  Both  these  methods  were  applied  to  alkene  197  but  starting  material 
remained unreacted. 
It was decided to proceed with the bromination of the alkane (198). Alkane 198 was 
subjected to the standard bromination conditions and the anticipated 2'R brominated 
product  (2'R 200)  was  isolated  in  a  64%  yield  and  only  2%  of  the  2'S 200  was 
obtained (Scheme 62).  
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With this route (Scheme 63) in place the synthesis of 2'R 200 was scaled up for the 
subsequent DKR reaction. 66 
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Scheme 63 
Previously DKR conditions were optimised for the model system 2'R 189 (Scheme 
56) in the hope that these conditions could be transferred to 2'R 200.  
Although when using microwave conditions a degree of selectivity for substitution 
on the bromine over displacement of the trichlorophenol can be achieved the addition 
of 6 equivalents of benzylamine was deemed undesirable. Therefore before trying the 
DKR on 2'R 200 reduction of the number equivalents of benzylamine was explored. 
Unfortunately, on reduction of the amount of benzylamine the reaction failed to go to 
completion  in  a  reasonable  timescale  even  when  the  reaction  concentration  was 
increased. In order to remedy this the addition of alternative bases was explored but 
for  most  (lutidine,  sodium  carbonate,  sodium  bicarbonate,  caesium  carbonate,  N 
methylmorpholine  and  sodium  tetraborate)  the  reaction  rate  was  not  significantly 
affected. The other bases tried, N methylmorpholine, potassium acetate, DMAP and 
DBU, promoted the unwanted elimination pathway.  
These results were disappointing and it was determined that the DKR should be tried 
with the existing conditions to observe how the reaction preceeded.  
When the existing microwave conditions (0.2 eq nBuNI, 6 eq benzylamine in THF in 
the microwave at 100 °C for 30 min) were used a complex mixture of products was 
obtained. The reaction was then carried out under thermal conditions at reflux and 67 
the reaction was complete after 1.5 h. This was much quicker than for the model 
system 189 for which the reaction took 6 h. A mixture of products was obtained and 
one was identified as the undesired doubly substituted product 206, whereby the 
benzylamine had displaced both the bromide and the TCP. 
As the reaction had gone to completion after only 1.5 h it was believed that it might 
now be possible to reduce the amount of benzylamine. Therefore the reaction was 
carried out with only 2 equivalents of benzylamine and it proceeded to completion 
after 6 h in THF at reflux (Scheme 64). From LCMS and NMR data a mixture of 
products was identified as 202, 196, 206 and 207 and these could not be completely 
separated  due  to  similar  retention  times.  However  a  substantial  amount  of  the 
elimination  products  196  and  207  was  observed  especially  compared  to  the 
anticipated 10 15% which was observed in the previous model studies. This meant 
that unfortunately the selectivity of the DKR reaction over the sulfonamide formation 
could not be properly assessed. 
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In order to establish whether DKR can be performed selectively in the presence of 
TCP the issue of elimination needs to be removed.  
3.3.3 Conclusions 
In conclusion the TCP sulfonate moiety of aryl TCP sulfonates has proven to be 
stable to the required conditions for the palladium reactions studied. The Suzuki 
reactions  were  shown  to  proceed  in  good  yields  when  using  both  the  3   and  4 
bromobenzene TCP sulfonate esters. Exposure of the resultant biaryl sulfonate ester 
to aminolysis conditions furnished the expected sulfonamide in good yield.  Heck 
reactions with ethyl acrylate, cyanoacrylate and styrene also occurred in good yields.   68 
In an effort to incorporate chirality, and hence more diversity, into the aryl TCP 
sulfonates the possibility of selectively performing DKR on the aryl TCP sulfonates 
was investigated. To this end a stereoselective route to give 2’R 200 in good yield 
was established. Issues with the reduction of the alkene 196 were resolved by using 
Co2(CO)8 H2O. The alkene of the 4 regioisomer 197 has been synthesised in good 
yield but problems with the reduction have not yet been resolved. 
The  DKR  reaction  on  bromide  2'R 200  was  attempted,  unfortunately  despite 
promising results on the model system substantial elimination occurred rendering 
this reaction impractical. The increased amount of elimination, for the reaction of 
2'R 200 in comparison to 2'R 189, is most probably due to the electron deficient 
aromatic ring in 2'R 200 increasing the acidity of the benzylic proton.  To fully 
assess the efficacy of this DKR on an aryl TCP sulfonate the issue of elimination 
needs to be removed. This could be achieved by the synthesis of analogue 208 which 
no longer contains the benzylic proton or 209 in which the alkyl chain has been 
extended meaning that the resultant double bond in the elimination product would no 
longer be in conjugation with the aromatic ring. 
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Chapter Four 
Towards the synthesis of β methoxy amino acids 
4.1 Introduction 
In recent years a diverse range of marine derived cyclopeptides and depsipeptides 
have  been  isolated  and  characterised.  Many  of  these  display  biological  activity, 
which combined with unusual amino acids and complex molecular architecture make 
these compounds synthetically interesting.
151,  152 The callipeltins, papuamides and 
neamphamide A are examples of such natural products; these have been reported to 
display  anti HIV,  antifungal,  cytotoxic  and  sodium  ionophore  properties  (Figure 
30).
153 157  The  cyclic  heptapeptides  cyclomarins  were  isolated  in  1999  from  a 
sediment sample in the vicinity of San Diego and have been shown to possess anti 
inflammatory properties (Figure 30).
158 All these compounds contain a β methoxy 
substituted  amino  acid:  (2S,3R) β methoxytyrosine  in  callipeltins
159  and 
papuamides,
160  (2R,3R) β methoxytyrosine  in    neamphamide  A
160  and  (2S,3R) 
methoxyphenylalanine in the cyclomarins.
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Figure 30 70 
4.1.1 Previous syntheses of β methoxy amino acids 
In the initial structural studies of the callipeltins, papuamides and neamphamide A 
the  configuration  of  β methoxytyrosine  was  not  established.  This  resulted  in  the 
majority of research focussing on synthetic strategies for the synthesis of the four 
possible stereoisomers. 
160, 
162, 163 
Using Lajoie’s chiral serine aldehyde equivalent (210) Joullié et al. were able to 
access all four diastereomers of β methoxytyrosine.
162 (S) serine aldehyde (210) was 
treated  with  4 tert butoxyphenylmagnesium  bromide  to  furnish  the  β hydroxy 
intermediate (211) as  a 90:10 mixture of isomers ((2S,3R):(2S,3S)) (Scheme 66).  
Methylation was accomplished by utilising a combination of Me3O
+BF4
  and proton 
sponge, and subsequent deprotection yielded the (2S,3R) β methoxytyrosine (213). 
In order to obtain the (2S,3S) diastereomer intermediate 211 was oxidised to give 
ketone 214, which was reduced with LiBH4 under Felkin Ahn control. This gave 
(2S,3S) 211 which was methylated and deprotected as with (2S,3R) 213. The (2R,3S) 
and (2R,3R) diastereomers were obtained by the same approach only starting with 
Lajoie’s (R) serine aldehyde. 
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Scheme 66 
This  route  was  also  employed  in  the  synthesis  of  (2S,3R)   and  (2S,3S) 
methoxyphenylalanine.
164  
In a similar approach Hamada et al. synthesised the four diastereoisomers from the 
Garner aldehyde (215), which was accessed from (S)  and (R) serine.
163 The (S) 
Garner  aldehyde,  (S) 215,  was  treated  with  4 benzyloxyphenyllithium  in  the 
presence  of  LiBr  to  give  a  3:1,  (2S,3R) 216:(2S,3S) 216,  diastereomeric  mixture 
(Scheme 67). Pure (2S,3R) 216 was obtained by recrystallisation but unfortunately 71 
(2S,3S) 216  could  not  be  separated  from  the  mixture.  Thus,  (2S,3S) 216  was 
synthesised from the diastereomeric mixture by DMP oxidation to give ketone 217 
followed by K Selectride reduction. Methylation was achieved using iodomethane 
sodium  hydride,  the  acetonide  was  removed  using  p TsOH  in  methanol  and  the 
resultant amino alcohol (219) was oxidised to the carboxylic acid 220. The other two 
diastereomers were obtained by application of this route to (R) Garner aldehyde. 
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Scheme 67 
In an alternative route Gustafson et al. formed the two stereocentres by the addition 
of a metalated Schöllkopf’s reagent 221 to 4 benzyloxybenzaldehyde to give a 1:1 
mixture  of    two  epimeric  carbinols  222a  and  222b.
160  These  were  separated 
chromatographically  and  subsequent  methylation  of  the  hydroxyl  group  and 
hydrolysis  of  the  bis lactam  ether  gave  the  stereochemically  pure  (2S,3S)   and 
(2S,3R) O benzyltyrosinemethyl  esters  223.  The  diastereomers  (2R,3S) 223  and 
(2R,3R) 223  were  synthesised  from  the  other  enantiomer  of  Schöllkopf’s  reagent 
using this route.  72 
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Scheme 68 
Yokokawa et al. synthesised (2S,3R) β methoxyphenylalanine methyl ester in high 
yield in four steps via the aldol reaction using Schöllkopf’s chiral bis lactam.
161, 165  
D’Auria et al. treated (2S) O acetyl N phthaloyltyrosine methyl ester (224) with N 
bromosuccinimide  to  give  the  3 bromo  derivatives  (225)  as  1:1  mixture  of 
diastereomers.
159  Treatment  with  silver  triflate  and  methanol  gave  the  two 
diastereomeric  β methoxytyrosine  derivatives  (2S,3S 226  and  2S,3R 226),  which 
were  separated  by  HPLC  and  then  deprotected  to  give  the  desired  β 
methoxytyrosines. The two remaining enantiomers were synthesised using the same 
procedure starting with (2R) O acetyl N phthaloyltyrosine. 
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Scheme 69 
A similar route to β methoxy phenylalanine started with  L phenylalanine 227 and 
again installed the second stereocentre using radical bromination.
166 The bromine 
was displaced with hydroxide and the O methylation was effected with Ag2O and 
MeI (Scheme 70). 
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Scheme 70 
Lipton  et  al.  developed  enantio   and  diastereoselective  synthesis  of  (2R,3R) β 
methoxytyrosine (232) (Scheme 71).
167 An asymmetric aziridination with a chiral 73 
bis(oxazoline) copper complex of p coumarate TBS ether 230 followed by addition 
of methanol gave 231 in a greater than 19:1 dr and 28:1 er. Subsequent deprotection 
yielded (2R,3R) 232. 
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Scheme 71 
4.1.1 Halomethoxylation reaction 
In an alternative route to the β methoxyamino acids Hajra et al. have developed a 
method  for  asymmetric  halomethoxylation  using  the  chiral  auxiliary  (4S) 4 (1 
methylethyl) 2 oxazolidinone  to  direct  the  stereochemistry.
168,  169  The  reaction  is 
carried out with halogens and promoted using silver salts to give the products with 
high regio  and anti selectivity and moderate diastereoselectivity. They demonstrated 
this in the synthesis of both (2S,3S)  and (2R,3R) 2 azido 3 (4 benzoyloxy phenyl) 
3 methoxy propionic  acids  236,  precursors  to  β methoxy  phenylalanine  (Scheme 
72).  
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Scheme 72 
The  aromatic  group  in  the  (4S) N cinnamoyl 4 (1 methylethyl) 2 oxazolidinones 
enhances  the  electrophilicity  of  the  adjacent  carbon,  resulting  in  a  regioselective 
attack of methanol on the halonium intermediate. X ray crystal analysis of (2S,3S) 
237 confirmed this regioselectivity.
169  74 
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Figure 31 
When  alternative  oxazolidinone  auxiliaries,  (3S) 3 phenyl   or  (3S) 3 
(diphenylmethyl) 2 oxazolidinones, were used complex mixtures of products were 
formed.
168  
Cinnamoyl  and  electron deficient  cinnamoyl  substrates  smoothly  underwent 
bromomethoxylation,  whilst  for  electron rich  cinnamoyl  substrates  better  results 
were  achieved  for  iodomethoxylation  (Table  15).  When  AgNO3  was  used  the 
reactions  generally  proceeded  with  a  7:3  dr  in  favour  of  (2R,3S) 239,  similar 
diastereoselectivity was also seen in the presence of AgOAc. However, Ag2O was 
demonstrated  to  reverse  the  diastereoselectivity,  especially  for  cinnamoyl  and 
electron  deficient  cinnamoyl  substrates  (Table  15,  compare  Entries  1  and  2  and 
Entries 3 and 4).   
Ar N
O
O
O
Ar N
O
O
O
Ar N
O
O
O
X
OMe OMe
X
+
AgNO3, X2
MeOH, 0ºC
238 (2S,3S) 239 (2R,3R) 239
 
Scheme 73 
 
  Ar  AgX  X  Ratio 239 
(2S,2S):(2R,3R) 
1  Ph  AgNO3  Br  71:29 
2  Ph  Ag2O  Br  27:73 
3  2 NO2C6H4  AgNO3  Br  65:35 
4  2 NO2C6H4  Ag2O  Br  35:65 
5  4 MeOC6H4  AgNO3  I  62:38 
6  4 MeOC6H4  Ag2O  I  48:52 
7  2 ClC6H4  AgNO3  Br  60:40 
8  2 Naphthyl  AgNO3  I  73:27 
Table 15 
Reactions  of  either  AgNO3  or  AgOAc  with  halogens  in  methanol  generate  acid. 
Therefore,  to  explain  the  diastereoselectivity  Hajra  et  al.  have  proposed  that  for 
reactions  promoted  by  AgNO3  or  AgOAc  the  H
+  chelated  S cis syn dipole 
conformation 238a might be involved in the reaction (Scheme 74).
168, 169 On attack of 75 
X
+ from the Re face and subsequent nucleophilic attack of MeOH at the β position 
(2S,2S) 239 is furnished as the major diastereomer. In the Ag2O promoted reaction 
the  unchelated  S cis anti dipole  conformation  238  might  be  involved  yielding 
(2R,2R) 239 as the major diastereomer. This hypothesis is supported by the Ag2O 
promoted reactions performed in the presence of either HNO3 or AcOH for which 
diastereoselectivities  similar  to  either  the  AgNO3  or  AgOAc promoted  reactions 
were seen. The poor diastereoselectivities of the electron rich substrates in Ag2O 
promoted  reactions  might  be  accounted  for  by  the  involvement  of  both  the 
equilibrated  S cis   and  S trans anti dipole  conformations  238  and  238b,  due  to 
extensive conjugation of the electron donating substituent at the para postion with 
the α,β unsaturated carbonyls. 
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Scheme 74 
Interestingly, the work by Hajra et al. is the only example in which the absolute 
stereochemistry of the halomethoxylation α,β unsaturated carboxylic acid derivatives 
is controlled, although the relative stereochemistry has been shown to be anti under 
various conditions.
170, 171 Using N,N dibromo p toluenesulfonamide (TsNBr2) as the 
bromine source Phukan et al. developed a regio  and stereoselective synthesis of the 
anti alkoxybromo carboxylic acid derivatives.
170 Whilst, Sudalai et al. obtained anti 76 
alkoxybromo carboxylic  acid  derivatives  via  the  sodium  periodate  mediated 
oxidative halogenation of alkenes with metal halides in the presence of methanol.
171  
It is noteworthy that although there is a lack of methods for the asymmetric syntheses 
of the α halo β methoxycarboxylic acid derivatives there are a number of routes to 
the  stereoselective  synthesis  of  halohydrins.  These  include  the  asymmetric 
halohydrin reaction,
171 173 as well as reagent controlled aldol reaction of chiral α 
halogenated  imide  enolates  with  suitable  aldehydes,
174 177  catalytic  asymmetric 
hydrogenation  of  α chloro β ketocarboxylic  acid  esters  and  ring  opening  of 
epoxides
178 184 or cyclic sulphate.
185    
4.2 Towards the synthesis of β methoxy amino acids 
Despite  the  moderate  diastereoselectivity  of  Hajra  et  al’s  bromomethoxylation 
reaction  this  route  was  of  particular  interest  as  it  was  envisaged  that  the 
imidazolidinone auxiliary could be used in place of the oxazolidinone.
168,  169 The 
influence of β substitution on the imidazolidinone DKR protocol (Section 3.1.1.4) 
has not been studied previously. Thus, the synthesis of these β methoxy amino acids 
employing this DKR strategy is appealing. Furthermore, this reaction in combination 
with  the  DKR/SN2  protocol  could  potentially  provide  selective  routes  to  all  four 
diastereomers from a common starting material 191 (Scheme 75).  77 
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Scheme 75 
With this route in mind alkene 191 was synthesised in good yield from the auxliary 
173 and trans cinnamoyl chloride (Scheme 76). 
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Scheme 76 
4.2.1 Asymmetric Halomethoxylation Reaction 
Initially, the bromomethoxylation of 191 was performed at 0 ºC with silver nitrate 
(1.2 eq) and bromine (1.2 eq) in methanol; conditions analogous to those described 
by Hajra et al.
168, 169 The diastereomers were obtained in a 2:1 diastereomeric ratio, 
as  calculated  from  the  crude  proton  NMR  spectrum  (Entry  1,  Table  16).  The 
diastereomers were isolated in 88% total yield with the major isomer being obtained 
in a 58% yield and the minor isomer in a 30% yield.  On reduction of the temperature 78 
to –20 ºC the dr improved to 3:1 (Entry 4, Table 16) and this trend was followed at –
40 ºC with an improved dr of 6:1 (Entry 5, Table 16). Unfortunately, at –60 ºC and –
78  ºC  dibrominated  product  was  seen  and  there  was  no  improvement  in  the 
diasterereomeric ratios, which were 6:1 and 5:1 respectively (Entries 6 and 7, Table 
16). Also at –78 ºC the reaction failed to go to completion. When the reaction was 
carried out in DCM with 20 eq MeOH only the dibrominated product was observed 
(Entry 2, Table 16).  
In reactions where dibromination occurred the reaction mixture retained an orange 
colour rather than turning colourless, indicating that bromine was still present. It was 
hypothesised that this could be due to the lower solubility of the halide scavenger 
silver nitrate in MeOH. To test this theory the more soluble silver trifluoroacetate 
was employed in place of silver nitrate. The reaction was carried out at –78 ºC (Entry 
9, Table 16) and gratifyingly no dibrominated product was seen, moreover, the dr 
had improved to 11:1. There was still a small amount of starting alkene present, but 
nevertheless this was an encouraging result.   
To investigate the influence of the silver salt the reaction was carried out, at 0 ºC, in 
its absence and this gave the opposite selectivity with a dr of 3:5 (Entry 3, Table 16). 
It is also worthy to note that the reaction was much slower taking 2 h 30 min as 
opposed to 40 min when silver nitrate was present (Entry 3 vs Entry 1, Table 16).  
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Entry  Temp 
(ºC)  Time  AgX  Solvent  dr 241 
major:minor 
1  0  40 min  AgNO3  MeOH  2:1 
2  0  1 h  AgNO3  DCM (20 eq MeOH)   
a 
3  0  2 h 30     MeOH  3:5
 
4   20  40 min  AgNO3  MeOH  3:1 
5   40  2 h  AgNO3  MeOH  6:1 
6   60  3 h  AgNO3  MeOH  6:1
a 
7   78  9 h  AgNO3  MeOH  5:1
a, b 
8   78  3 h  AgCO2CF3  MeOH  11:1
b 
Table 16 
a dibrominated product, 
b starting material seen 79 
All diastereomeric ratios are measured from the proton NMR spectra by comparing 
the CHABr signals from the two diastereomers (Figure 32), and all product mixtures 
were obtained in a greater than 80 % yield.  
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Figure 32 
Unfortunately, repetition of the reaction at  78 °C did not give consistent results; one 
explanation for this is the low solubility of the starting alkene in methanol, resulting 
in the reaction mixture being a suspension. In order to resolve this issue the solubility 
of the alkene was investigated and DMF and chloroform were found to be the best 
solvents. Enough methanol needs to be used in order to affect the methoxylation step. 
Initially,  a  solution  mixture  of  2.3:1  chloroform:methanol  was  employed  and 
reactions were carried out at –40 °C. On increasing the amount of silver triflate from 
one equivalent to two there was a complete loss of selectivity from 4:1 to 1:1 (Entries 
1 and 2, Table 17). On cooling to –60 °C the starting material precipitated from 
solution  and  so  to  resolve  this  the  solvent  ratio  was  changed  to  1:1 
chloroform:methanol.  Both  the  alkene  and  the  silver  triflate  were  soluble  in  this 
solvent mixture and on repetition the results were now consistent and so alternative 
silver salts could be evaluated (Scheme 78).  80 
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Scheme 78 
Entry  Temp 
(ºC) 
AgX 
equivalents  AgX  CHCl3:MeOH  dr 241 
major:minor 
1   40  1.2 eq  AgSO3CF3  2.3:1  4:1 
2   40  2.4 eq  AgSO3CF3  2.3:1  1:1
 
3   60  1.2 eq  AgSO3CF3  2.3:1  7:1 
4   60  1.2 eq  AgSO3CF3  1:1  7:1 
5   78  1.2 eq  AgSO3CF3  1:1  8:1 
6   78  1.2 eq  AgOAc  1:1
  1:1
a
 
7   78  1.2 eq  AgCO2CF3  1:1  7:1 
8   78  1.2 eq  AgBF4  1:1  8:1 
9   78  1.2 eq  AgPF6  1:1  6:1 
10   78  1.2 eq  AgClO4  1:1  1:1 
Table 17 
a dibrominated product 
When  the  temperature  was  reduced  from   60  to   78  °C  a  small  improvement  in 
selectivity  was  observed  (Entries  4  and  5,  Table  17),  and  therefore  the  lower 
temperature was chosen for surveying the various silver salts.  
Silver  triflate,  silver  trifluoroacetate,  silver  tetrafluoroborate  and  silver 
hexafluorophosphate (Entries 5, 7, 8 and 9, Table 17) all gave similar selectivity at  
78  °C  (dr  ~7:1).  Silver  acetate  was  not  soluble  in  the  solvent  mixture  and  this 
resulted  in  a  predominance  of  dibrominated  product  245  (Figure  33)  and  no 
selectivity  in  the  bromomethoxylation  (Entry  6,  Table  17).  Although  silver 
perchlorate was in solution no selectivity was seen, with a 1:1 mixture of the two 
isomers being obtained (Entry 10, Table 17). Silver oxide was not soluble in the 
solvent mixture and the reaction didn’t go to completion after 6 h. This resulted in a 
complex  mixture  of  alkene  191,  dibrominated  product  and  bromomethoxylated 
products. 
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Hajra et al. hypothesise that the major diastereomer (2S,3S) 29 is formed via the 
involvement  of  a  H
+  chelated  conformation  28a  (Scheme  74).
168,  169  The  acid
  is 
formed  during  the  reaction  with  AgNO3  or  AgOAc  present.  If  the  H
+  chelated 
conformation is involved in the bromomethoxylation of 191, it was hypothesised that 
addition of an acid before addition of the silver salt and bromine could improve the 
diastereoselectivity (Scheme 80). Unfortunately, when this reaction was tried using 
triflic acid and silver triflate a disappointing dr of 5:1 was obtained, compared to 8:1 
without the acid. 
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Scheme 79 
As most of the dr’s were calculated from the crude NMR the bromomethoxylation 
was carried out using silver trifluoroacetate at  78 °C and the two diastereomers were 
isolated; this gave the 241 major in a 77% yield and 241 minor isomer 10% yield 
(Scheme 80).  
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Scheme 80 
Definitive proof of the regio  and stereochemistry of the products, 241 major and 
241 minor, have not been determined and have, so far, been assumed based on the 
results  of  Hajra  et  al.
168,  169  Reviewing  previous  literature  and  taking  electronic 
factors into consideration it is reasonable to assume that the methanol attacks at the 
benzylic position resulting in bromination of the position α to the carbonyl.
169 171 
Thus, assuming this regioselectivity is correct there are four possible diastereomers 
(Figure 34). In order to assign the absolute stereochemistry an X ray crystal structure 
is required unfortunately these products were foams and therefore, a more crystalline 
analogue would be required.  82 
If, as believed, the anti stereoisomers are being formed, then upon epimerisation of 
the  α position  two  different  isomers  (syn)  will  be  produced.  The  two  isolated 
diastereomers, 241 major and 241 minor, were exposed to epimerising conditions 
(nBu4NBr) and the products were isolated. Four isomers were isolated, 241 major 
and 241 minor plus their epimers. This indicates that the α position is not epimerised 
during the bromomethoxylation reaction and thus, the products of the reaction must 
either be the two anti isomers ((2R,3R) 241 and (2S,2S) 241) or the two syn isomers 
((2R,3S) 241 and (2S,2R) 241) (Figure 34).   
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Figure 34 
Whilst  optimising  the  bromomethoxylation  the  practicality  of  the  DKR  reaction 
needed  to  be  investigated.  Initially  the  SN2  displacement  of  the  bromine  with 
benzylamine  was  attempted;  this  would  allow  a  quick  assessment  of  whether 
elimination would be an issue. 241 major was stirred at room temperature with 6 
equivalents of benzylamine in THF (Scheme 81). After 18 h some product could be 
seen by TLC but it had not gone to completion and so the reaction mixture was 
heated to reflux for 72 h. Even then the reaction had not gone to completion but it 
was worked up at this point. The starting material was recovered in 23% and the 
desired substituted product was obtained as a single isomer in 48% yield. One other 
product  was  obtained  which  has  been  identified  as  the  epimer  of  241 major, 
presumably (2S,3R) 241. 
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The SN2 reaction was then tried using tetrabutylammonium azide as a soluble azide 
source and THF as the solvent (Scheme 82). At room temperature the reaction was 
reluctant to go to completion but upon heating reflux completion was achieved. Two 
products were isolated neither of them was the starting material, 241 major, or its 
epimer; they are believed to be the two azide diastereomers in a 6.5:1 ratio. The 
reaction was also carried out in NMP at 120 °C and the same two products were 
obtained but in a 2:1 ratio.   
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Scheme 82 
The DKR reaction was carried out with the epimerising agent tetrabutylammonium 
iodide in NMP at 70 °C for 24 h and a complex mixture of products was obtained 
containing the starting bromide, 241 major. When it was attempted in the microwave 
at 100 °C the reaction was still not complete after 3 h. 
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Scheme 83 
4.3 Conclusions and Future Work 
In conclusion a bromomethoxylation reaction of chiral α,β unsaturated carboxylic 
acid derivative 191, which proceeds with good diastereoselectivity and yield, has 
been described. Through epimerisation of the products, 241 major and 241 minor, it 
was determined that these diastereomers were either the two syn diastereomers or the 
two anti diastereomers. Based on similar reactions in the literature it is feasible to 
conclude that 241 major and 241 minor are the anti isomers, (2R,3R)  and (2S,3S) 
241 (Figure 35).
169 171 84 
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Figure 35 
Under SN2 conditions 241 major did not give any eliminated product, although under 
the high temperatures required for it to react some epimerisation was observed. This 
resulted in two diastereomers being isolated. The SN2 reaction was also tried but in 
these  initial  attempts  the  reaction  did  not  go  to  completion,  which  resulted  in  a 
complex mixture of products.   
There is opportunity to extend the substrates of the bromomethoxylation reaction by 
trying  alternative  cinnamoyl  substrates;  this  would  allow  the  influence  of 
substitutents on the aromatic ring to be explored. It could also allow access to a 
crystalline  analogue  allowing  the  stereochemistry  to  be  definitively  assigned. 
Although good diastereoselectivity has been achieved there is still opportunity for 
improvement and there is a plethora of alternative bromine sources that could be 
employed. 
For  the  SN2  reaction  alternative  conditions,  different  azide  sources,  solvents  and 
temperatures,  need  to  be  explored  to  assess  whether  the  epimerisation  can  be 
prevented and thus, a single diastereomer obtained. Again, for the DKR reaction 
further conditions, alternative solvents and amines, need to be investigated. 85 
Experimental 
General Experimental 
Solvents  and  reagents  were  commercially  available  and  used  without  further 
purification,  unless  otherwise  noted.  Benzylamine  was  distilled  from  potassium 
hydroxide and tetrabutylammonium iodide was recrystallised from ethanol and dried 
over P2O5.  
Analytical thin layer chromatography (TLC) was performed on SIL G/UV254 silica 
plates  and  visualisation  was  achieved  by  use  of  UV  light  and  potassium 
permanganate solution. Flash chromatography was carried out using BDH silica gel 
(particle  size  33  micron–70  micron)  and  medium  pressure  chromatography  was 
carried out on prepacked Isco RediSep silica cartridges, using the ISCO SQ 16X 
instrument.  
1H NMR spectra were recorded on a Bruker AMX 300 (300 MHz), Bruker Avance 
III 400 (400 MHz), Bruker Avance 500 (500 MHz) or Bruker Avance III 600 (600 
MHz) spectrometer. Chemical shifts (δ) are reported in units parts per million (ppm) 
relative  to  residual  protiated  signals  of  the  solvent  or  to  tetramethylsilane.  Spin 
multiplicities were reported as singlet (s), doublet (d), triplet (t), quartet (q), multiplet 
(m) and coupling constants (J) are given in Hertz (Hz). 
13C NMR spectra and 
13C DEPT 135 NMR spectra were recorded on a Bruker AMX 
300 (75 MHz), Bruker Avance III 400 (101 MHz), Bruker Avance 500 (126 MHz) or 
Bruker  Avance  III  AMX  600  (151  MHz)  and  standard  abbreviations  were  used 
(singlet (s), doublet (d), triplet (t), quartet (q)).  
Mass spectra were performed at the EPRSC National Mass Spectrometry Service 
Centre, University of Wales, Swansea obtained on a Quattro II or a MAT900 XLT 
spectrometer,  at  University  College  London  on  a  VG70 SE  or  a  MAT  900  XP 
spectrometer or at GlaxoSmithKline, Harlow on an Apex spectrometer. 
Infra red spectra were run on a Shimadzu FTIR 8700 spectrometer or PerkinElmer 
Spectrum 100 FT IR spectrometer operating in ATR mode with frequencies given in 
reciprocal centimetres (cm
 1).  86 
All  melting  points  were  recorded  on  a  Gallenkamp  heating  block  and  are 
uncorrected. 
Optical rotation measurements were carried out using a PerkinElmer 343 polarimeter 
with a cell length of 10 cm. 
Microwave reactions utilized a CEM Explorer instrument. 
Experimental for Chapter 2 
Synthesis of 2,4,6 Trichlorophenyl Sulfonyl Esters 
General Procedure A 
To a solution of the sulfonyl chloride (19.6 mmol) in dichloromethane (50 mL) at 0 
°C was added a pre mixed solution of 2,4,6 trichlorophenol (4.6 g, 23.4 mmol) and 
triethylamine  (6.8  mL,  48.9  mmol)  in  dichloromethane  (10  mL)  dropwise.  The 
reaction was stirred at  0 °C for a further 15  min and allowed to warm to room 
temperature over 1 h. The reaction mixture was diluted with dichloromethane (30 
mL), washed with 2 M sodium carbonate solution (2 x 30 mL), 2 M hydrochloric 
acid (2 x 30 mL) and water (30 mL), separated, dried (MgSO4) and filtered. The 
filtrate was concentrated in vacuo to yield the crude product, which was purified as 
described in the individual entries below. 
General Procedure B 
To  a  solution  of  triphenylphosphine  oxide  (1.1  g,  4  mmol)  in  anhydrous 
dichloromethane (20 mL) at 0 °C under nitrogen was added trifluoromethanesulfonic 
anhydride (350 mg, 2 mmol) and the mixture was stirred for 20 min. The pyridinium 
sulfonate  salt  (2  mmol)  was  added  and  the  mixture  was  stirred  for  a  further  20 
minutes.  A  pre mixed  solution  of  2,4,6 trichlorophenol  (390  mg  ,2  mmol)  and 
triethylamine (0.28 mL, 2 mmol) in dichloromethane (5 mL) was added dropwise 
over a period of 10 min. The reaction was allowed to warm to room temperature. It 
was  then  diluted  with  dichloromethane  (30  mL)  and  washed  with  2  M  sodium 
carbonate solution (2 x 30 mL), 2 M hydrochloric acid (2 x 30 mL) and water (30 
mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified as 
described in the individual entries below. 87 
4 Methoxybenzene sulfonic acid 2,4,6 trichlorophenyl ester (89) 
S
O
O O
Cl
Cl Cl
O  
Synthesised using general procedure A. Purified by recrystallisation from acetone to 
yield white crystals (19.0 g, 52 mmol, 86%). 
MP                 116 120 °C 
1H NMR    (400  MHz,  CDCl3)  δ  7.96 7.92  (m,  2H,  ArH),  7.35  (s,  2H,  ArH), 
7.05 7.01 (m, 2H, ArH), 3.92 (s, 3H, OCH3)  
13C NMR  (151 MHz, CDCl3) δ 164.54 (s), 142.42 (s), 132.74 (s), 130.95 (d), 
129.16 (d), 128.20 (s), 114.42 (d), 55.82 (q) 1 x s not observed 
IR (thin film)  νmax 1592, 1576, 1495, 1439, 1380, 1267, 1166, 1093 cm
 1 
LRMS (EI)  370 (20%), 368 (48%), 366 (M
+, 46%), 330 (75%), 251 (70%), 223 
(100%) 
HRMS (CI)  calcd for C13H13Cl3NO4S ([M + NH4]
+): 383.9625 found 383.9629 
4 Nitrobenzene sulfonic acid 2,4,6 trichlorophenyl ester (90) 
S
O
O O
Cl
Cl Cl
O2N  
Synthesised using general procedure A. Purified by recrystallisation from hexane/ 
dichloromethane to yield yellow crystals (17.9 g, 47 mmol, 78%). 
MP    126 128 °C 
1H NMR    (400  MHz,  CDCl3)  δ  8.46 8.43  (m,  2H,  ArH),  8.26 8.22  (m,  2H, 
ArH), 7.41 (s, 2H, ArH)    
13C NMR   (101 MHz, CDCl3) δ 151.18 (s), 142.46 (s), 141.95 (s), 133.57 (s), 
130.63 (s), 129.89 (d), 129.35 (d), 124.43 (d) 
IR (thin film)  νmax 3055, 1562, 1537, 1393, 1265, 1194, 1136, 1092 cm
 1 
LRMS (EI)  385 (4%), 383 ([M+H]
+, 10%), 381 (8%), 199 (25%), 197 (100%), 
195 (92%) 
HRMS (EI)  calcd for C12H6Cl3NO5S (M
+): 380.9027 found 380.9026 88 
Benzene sulfonic acid 2,4,6 trichlorophenyl ester (93) 
S
O
O O
Cl
Cl Cl
 
Synthesised  using  general  procedure  A.  Purified  by  recrystallisation  from 
dichloromethane/hexane to yield pale brown crystals (13.7 g, 41 mmol, 67%). 
MP    62 63 °C 
1H NMR    (400  MHz,  CDCl3)  δ  8.04 8.02  (m,  2H,  ArH),  7.75 7.71  (m,  1H, 
ArH), 7.62 7.58 (m, 2H, ArH), 7.36 (s, 2H, ArH)     
13C NMR   (101 MHz, CDCl3) δ 142.31 (s), 136.97 (s), 134.66 (d), 132.91 (s), 
130.90 (s), 129.24 (d), 129.18 (d), 128.53 (d) 
IR (thin film)  νmax 1562, 1443, 1387, 1265, 1190, 1092 cm
 1 
LRMS (EI)  338 (2%), 336 (M
+, 1%), 141 (20%), 77 (100%) 
HRMS (EI)  calcd for C12H7Cl3O3S (M
+):
 335.9176 found 335.9177   
5 Dimethylaminonaphthalene 2,4,6 trichlorophenylsulfonyl ester (94) 
S
O
O O
Cl
Cl Cl
N
 
Synthesised  using  general  procedure  A.  Purification  by  column  chromatography 
(petroleum ether/diethyl ether) gave the product as a white solid (2.7 g, 6.3 mmol, 
65%).  
MP    130 132 °C 
1H NMR  (600 MHz, CDCl3) δ 8.66 (d, 1H, J = 8.5 Hz, ArH), 8.49 (d, 1H, J = 
8.6 Hz, ArH), 8.22 (dd, 1H, J = 1.2, 7.4 Hz, ArH), 7.68 (dd, 1H, J = 
7.6, 8.6 Hz, ArH), 7.55 (dd, 1H, J = 7.4, 8.5 Hz, ArH), 7.32 (s, 2H, 
ArH), 7.26 (d, 1H, J = 7.6 Hz, ArH), 2.91 (s, 6H, CH3)   
13C NMR   (151 MHz, CDCl3) δ 151.76 (s), 142.62 (s), 133.69 (s), 132.80 (s), 
132.22 (d), 131.01 (s), 130.28 (s), 129.77 (d), 129.73 (s), 129.04 (d), 
129.01 (d), 122.96 (d), 119.67 (d), 115.7 (d), 45.47 (q) 
IR (thin film)  νmax 3055, 2986, 2835, 1568, 1441, 1379, 1265, 1184 cm
 1 89 
LRMS (EI)  431 (15%), 429 (M
+, 15%), 170 (100%), 149 (30%) 
HRMS (EI)  calcd for C18H14Cl3NO3S (M
+): 428.9755 found 428.9743 
4 Iodobenzene sulfonic acid 2,4,6 trichlorophenyl ester (95) 
S
O
O O
Cl
Cl Cl
I  
Synthesised  using  general  procedure  A.  Purified  by  recrystallisation  from 
hexane/dichloromethane to yield the product as white solid (20.9 g, 45 mmol 62%).  
MP                  124 126 °C 
1H NMR          (300  MHz,  CDCl3)  δ  7.98 7.93  (m,  2H,  ArH),  7.74 7.69  (m,  2H, 
ArH), 7.36 (s, 2H, ArH) 
13C NMR   (75 MHz, CDCl3) δ 142.1 (s), 138.6 (d), 136.6 (s), 133.1 (s), 130.8 (s), 
129.7 (d), 129.2 (d), 102.8 (s) 
IR (thin film)  νmax 3053, 2986, 1570, 1445, 1391, 1265, 1055 cm
 1 
LRMS (CI)  484  (25%),  482  (70%),  480  ([M+NH4]
+,  68%),  358  (35%),  356 
(100%), 354 (98%) 
HRMS (EI)  calcd for C12H6Cl3IO3S (M
+): 461.8142 found 461.8146 
4 Bromobenzene sulfonic acid 2,4,6 trichlorophenyl ester (96) 
S
O
O O
Cl
Cl Cl
Br  
Synthesised  using  general  procedure  A.  Purified  by  recrystallisation  from 
dichloromethane/hexane to yield a white solid (18.1 g, 44 mmol, 72%). 
MP    109 111 °C 
1H NMR    (400  MHz,  CDCl3)  δ  7.90 7.87  (m,  2H,  ArH),  7.76 7.72  (m,  2H, 
ArH), 7.36 (s, 2H, ArH)  
13C NMR   (101 MHz, CDCl3) δ 142.16 (s), 135.95 (s), 133.14 (s), 132.61 (d), 
130.80 (s), 130.12 (s), 129.95 (d), 129.24 (d) 
IR (thin film)  νmax 3053, 1576, 1445, 1394, 1265, 1194, 1069 cm
 1 
LRMS (EI)  418 (7%), 416 (10%),  414 (M
+, 5%), 219 (65%), 217  (65%), 155 
(100%), 157 (100%) 90 
HRMS (EI)   calcd for C12H6BrCl3O3S (M
+): 413.8281 found 413.8281 
3 Bromobenzene sulfonic acid 2,4,6 trichlorophenyl ester (97) 
S
O
O O
Cl
Cl Cl
Br
 
Synthesised using general procedure A. Purified by trituration with hexane to yield a 
white solid (14.1 g, 34 mmol, 87%). 
MP     119 121 °C   
1H NMR    (400 MHz, CDCl3) δ 8.17 (app. t, 1H, J = 1.8 Hz, ArH), 7.97 (ddd, 
1H, J = 1.0, 1.6, 7.9 Hz, ArH), 7.86 (ddd, 1H, J = 0.9, 1.8, 8.0 Hz, 
ArH), 7.48 (app. t, 1H, J = 8.0 Hz, ArH), 7.38 (s, 2H, ArH),  
13C NMR   (101 MHz, CDCl3) δ 142.15 (s), 138.63 (s), 137.69 (d), 133.20 (s), 
131.32 (d), 130.77 (s), 130.68 (d), 129.26 (d), 127.03 (d), 123.06 (s)   
IR (thin film)  νmax 3055, 1562, 1443, 1391, 1265, 1190 cm
 1 
LRMS (CI)  421 (20%), 419 (65%), 417 (100%), 415 ([M+H]
+, 50%), 221 (38%), 
219 (36%), 199 (40%), 197 (62%), 195 (30%) 
HRMS (CI)  calcd for C12H7BrCl3O3S ([M + H]
+): 414.8359 found 414.8348 
2 Bromobenzene sulfonic acid 2,4,6 trichlorophenyl ester (98) 
S
O
O O
Cl
Cl Cl
Br
 
Synthesised using general procedure A. Purified by trituration with hexane to yield a 
white solid (14.0 g, 34 mmol, 86%). 
MP    139   141 °C 
1H NMR    (400 MHz, CDCl3) δ 8.03 (dd, 1H, J = 2.1, 7.5 Hz, ArH), 7.85 (dd, 
1H, J = 1.6, 7.6 Hz, ArH), 7.55 7.46 (m, 2H, ArH), 7.35 (s, 2H, ArH)  
13C NMR   (101 MHz, CDCl3) δ 142.49 (s), 138.09 (s), 135.71 (d), 135.11 (d), 
133.10 (s), 131.38 (d), 130.85 (s), 129.10 (d), 127.59 (d), 121.55 (s)  
IR (thin film)  νmax 1568, 1443, 1387, 1265, 1192, 1128 cm
 1 
LRMS  421 (20%), 419 (62%), 417 (100%), 415 ([M+H]
+, 45%), 221 (58%), 
219 (54%), 199 (40%), 197 (75%), 195 (40%) 91 
HRMS (CI)     calcd for C12H7BrCl3O3S ([M + H]
+): 414.8359 found 414.8348 
Toluene 4 sulfonic acid 2,4,6 trichlorophenyl ester (88) 
S
O
O O
Cl
Cl Cl
 
Synthesised using general procedure B. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(495 mg, 1.4 mmol, 69%). 
 
MP                  84 87 ºC 
1H NMR   (300 MHz, CDCl3) δ 7.90 (d, 2H, J = 8.4 Hz, ArH), 7.39 (d, 2H, J = 
8.4 Hz, ArH), 7.35 (s, 2H, ArH), 2.48 (s, 3H, CH3) 
13C NMR   (75 MHz, CDCl3) δ 145.93 (s), 142.41 (s), 134.02 (s), 132.81 (s), 
130.48 (s), 129.85 (d), 129.16 (d), 128.61 (d), 21.83 (q)   
IR (thin film)  νmax 3055, 2988, 1562, 1439, 1387, 1265, 1192, 1180 cm
 1   
LRMS (EI)  352 (8%), 350 (M
+, 10%), 200 (30%), 155 (45%), 91 (100%) 
HRMS (EI)  calcd for C13H9Cl3O3S (M
+): 349.9338 found 349.9342 
3 Nitrophenyl 2,4,6 trichlorophenyl sulfonyl ester (99) 
S
O
O O
Cl
Cl Cl
O2N
 
Synthesised  using  general  procedure  B.  The  product  was  purified  by  column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(689 mg, 1.8 mmol, 72 %). 
MP    129 130 ºC 
1H NMR   (500 MHz, CDCl3) δ 8.88 (app. t, 1H, J = 1.9 Hz, ArH), 8.59 (ddd, 
1H,  J = 1.0, 2.2, 8.2 Hz, ArH), 8.37 (ddd, 1H, J = 1.1, 1.7, 7.9 Hz, 
ArH), 7.85 (app.t, 1H, J = 8.1 Hz, ArH), 7.39 (s, 2H, ArH) 
13C NMR  (151 MHz, CDCl3) δ 148.23 (s), 141.98 (s), 139.01 (s), 133.88 (d), 
133.61 (s), 130.76 (d), 130.60 (s), 129.41 (d), 129.03 (d), 123.86 (d) 
IR (thin film)  νmax 3053, 1541, 1396, 1354, 1265, 1196 cm
 1 92 
LRMS (EI)  381  (M
+,  8%)  323  (82%),  313  (35%),  135  (35%)  81  (100%),  79 
(58%)  
HRMS (EI)  calcd for C12H6Cl3NO5S (M
+): 380.9027 found 380.8905 
Methyl 2,4,6 trichlorophenylsulfonyl ester (100) 
S
O
O O
Cl
Cl Cl
 
Synthesised  using  general  procedure  B.  The  product  was  purified  by  column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(629 mg, 2.3 mmol, 44 %). 
MP    63 66 ºC 
1H NMR   (300 MHz, CDCl3) δ 7.41 (s, 2H, ArH), 3.46 (s, 3H, CH3)  
13C NMR   (75 MHz, CDCl3) δ 142.06 (s), 133.14 (s), 130.65 (s), 129.24 (d), 
41.10 (q) 
IR (thin film)  νmax 3055, 1562, 1447, 1379, 1184 cm
 1 
LRMS (CI)  277 (80%), 275 (M
+, 80%), 199 (100%), 197 (100%), 167 (80%), 165 
(85%), 97 (72%) 
HRMS (CI)  calcd for C7H6Cl3O3S ([M+H]
+):  274.9103 found 274.9110 
4 Chlorobenzenesulfonic acid 2,4,6 trichlorophenyl ester (101) 
S
O
O O
Cl
Cl Cl
Cl  
Synthesised  using  general  procedure  B.  The  product  was  purified  by  column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(555 mg, 1.5 mmol, 80%). 
 
MP    100 103 ºC 
1H NMR  (500  MHz,  CDCl3)  δ  7.97 7.95  (m,  2H,  ArH),  7.58 7.56  (m,  2H, 
ArH), 7.37 (s, 2H, ArH) 
13C NMR  (101 MHz, CDCl3) δ 142.26 (s), 141.60 (s), 135.49 (s), 133.20 (s), 
130.88 (s), 130.02 (d), 129.69 (d), 129.32 (d) 
IR (thin film)  νmax 3055, 1558, 1435, 1391, 1192, 1088 cm
 1 93 
LRMS  375 (55%), 373 (100%), 371 (M
+, 75%), 197 (20%), 195 (18%), 177 
(15%), 175 (35%) 
HRMS (CI)  calcd for C12H7Cl4O3S ([M+H]
+):  370.8870 found 370.8881 
Aminolysis  
General Procedure C 
To a solution of the TCP sulfonate (0.28 mmol) in NMP (1 mL) was added the amine 
(0.56 mmol) and triethylamine (0.31 mmol). The resultant mixture was heated in the 
microwave for 10 minutes at 140 ºC. The reaction mixture was diluted with Et2O (20 
mL)  and  washed  with  10%  lithium  chloride  solution  (2  x  10  mL),  2  M  sodium 
carbonate solution (2 x 10 mL), 2 M hydrochloric acid (2 x 10 mL) and water (10 
mL). The organic portion was separated, dried (MgSO4) and the solvent removed in 
vacuo. 
General Procedure D 
To a solution of the TCP sulfonate (0.28 mmol) in anhydrous THF (2 mL) under 
nitrogen was added the amine (0.56 mmol) and LHMDS (1M solution in THF) (0.56 
mmol). The mixture was stirred for 4 h at 50 ºC. The reaction mixture was diluted 
with Et2O (20 mL) and washed with 2 M sodium carbonate solution (2 x 10 mL), 2 
M  hydrochloric  acid  (2  x  10  mL)  and  water  (10  mL).  The  organic  portion  was 
separated, dried (MgSO4) and the solvent removed in vacuo.  
General Procedure E 
To a solution of the TCP sulfonate (0.62 mmol) in THF (3.5 mL) was added the 
amine (0.53 mmol) and a 1 M solution of LHMDS in THF (1.24 mmol). The mixture 
was heated in the microwave at 120ºC for 30 minutes. The reaction mixture was 
concentrated in vacuo and then partitioned between ethyl acetate (20 mL) and 1 M 
hydrochloric acid (10 mL). The organic layer was washed with water (10 mL x 2), 
dried (Na2SO4) and concentrated in vacuo. 
General Procedure F 
To a solution of the PFP sulfonate (0.31 mmol) in anhydrous THF (2 mL) under 
nitrogen  was  added  the  amine  (0.46  mmol)  and  triethylamine  (0.93  mmol).  The 
mixture was stirred for 6 h at reflux. The reaction mixture was diluted with Et2O (20 94 
mL) and washed with saturated sodium hydrogencarbonate solution (2 x 10 mL), 2M 
hydrochloric  acid  (2  x  10  mL)  and  water  (10  mL).  The  organic  portion  was 
separated, dried (MgSO4) and the solvent removed in vacuo.  
N (4 Methyl benzyl) benzenesulfonamide (80) 
S
N
H
O O
 
Synthesised using general procedure F. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a pale yellow 
solid (56 mg, 0.21 mmol, 69%). 
MP    84 86 °C, Lit.
186 85 87 °C (hexane/ethyl acetate) 
1H NMR    (500  MHz,  CDCl3)  δ  7.89 7.87  (m,  2H,  ArH),  7.61 7.58  (m,  1H, 
ArH), 7.54 7.51 (m, 2H, ArH), 7.09 7.05 (m, 4H, ArH), 4.57 (t, 1H, J 
= 5.0 Hz, NH), 4.11 (d, 2H, J = 5.9 Hz, CH2), 2.31 (s, 3H, CH3)  
13C NMR   (126 MHz, CDCl3) δ 139.98 (s), 137.89 (s), 133.14 (s), 132.77 (d), 
129.48 (d), 129.22 (d), 127.93 (d), 127.21 (d), 47.19 (t), 21.15 (q) 
IR (thin film)  νmax 3265, 1446, 1420, 1320, 1157 cm
 1 
LRMS (CI)  279 ([M + NH4]
+, 100%), 262 (50%)  
HRMS (ES)    calcd for C14H19N2O2S ([M + NH4]
+):  279.1162 found 279.1168 
4 Methyl N (4 methylbenzyl)benzenesulfonamide (81) 
S
N
H
O O
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(73 mg, 94 %). 
 
MP    93 96 ºC, Lit.
187 86.7 ºC 
1H NMR   (500  MHz,  CDCl3)  δ  7.77 7.75  (m,  2H,  ArH),  7.32 7.30  (m,  2H, 
ArH), 7.10 7.06 (m, 4H, ArH), 4.53 (br t, 1H, J = 5.6 Hz, NH), 4.08 
(d, 2H, J = 6.0 Hz, CH2), 2.44 (s, 3H, CH3), 2.31 (s, 3H, CH3) 95 
13C NMR   (126 MHz, CDCl3) δ 143.59 (s), 137.84 (s), 136.93 (s), 133.24 (s), 
129.81 (d), 129.43 (d), 127.94 (d), 127.28 (d), 47.16 (t), 21.62 (q), 
21.15 (q) 
IR (thin film)  νmax 3053, 2986, 1421, 1331, 1265, 1161, 1094, 1057 cm
 1 
LRMS (EI):  275 (M
+, 5%), 139 (40%), 120 (100%), 105 (70%), 91 (85%) 
HRMS (EI):  calcd for C15H17NO2S (M
+): 275.0980 found 275.0981 
N Allyl 4 methylbenzenesulfonamide (102) 
S
N
H
O O
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield a yellow solid (50 mg, 0.24 
mmol, 83%).
 
MP    63 64 ºC, Lit.
188 63 65 ºC (aq. MeOH) 
1H NMR   (300  MHz,  CDCl3)  δ  7.77 7.74  (m,  2H,  ArH),  7.31 7.29  (m,  2H, 
ArH), 5.71 (ddt, 1H, J = 17.0, 10.2, 5.8 Hz, CH2HC=CH2), 5.15 (app. 
dq, 1H, J = 17.1, 1.6 Hz, CH=CHH), 5.08 (app. dq, 1H, J = 10.2, 1.3 
Hz, CH=CHH), 4.77 (t, 1H, J = 6.0, NH), 3.57 (app. tt, 2H, J = 1.5, 
7.5 Hz , CH2 CH=CH2), 2.42 (s, 3H, CH3) 
13C NMR   (75 MHz, CDCl3) δ 143.52 (s), 136.98 (s), 133.02 (d), 129.75 (d), 
127.18 (d), 117.68 (t), 45.79 (t), 21.55 (q) 
IR (thin film)  νmax 3055, 2987, 1421, 1333, 1265, 1163, 1094 cm
 1 
LRMS (EI)  211 (M
+, 8%) 155 (25%), 91 (100%) 
HRMS (EI)     calcd for C10H13NO2S (M
+): 211.0667 found 211.0664 
1 (Toluene 4 sulfonyl) piperidine (103) 
S
N
O O
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to give the product as a white solid 
(60 mg, 88 %).  
MP    92 95 ºC, Lit.
87 93 ºC (ethyl acetate)
 96 
1H NMR   (500  MHz,  CDCl3)  δ  7.64 7.62  (m,  2H,  ArH),  7.32 7.30  (m,  2H, 
ArH), 2.96 (t, 4H, J = 5.5 Hz, CH2), 2.42 (s, 3H, CH3), 1.65 1.61 (m, 
4H, CH2), 1.43–1.38 (m, 2H, CH2) 
13C NMR   (126 MHz, CDCl3) δ 143.35 (s), 133.35 (s), 129.60 (d), 127.79 (d), 
47.01 (t), 25.24 (t), 23.60 (t), 21.59 (q) 
IR (thin film)  νmax 3055, 2928, 1339, 1165 cm
 1 
LRMS (EI)  239 (M
+, 80%), 238 (90%), 155 (100%), 91 (98%) 
HRMS (EI)  calcd for C12H17NO2S (M
+): 239.0980 found 239.0973 
4 Bromo N (4 methylbenzyl)benzenesulfonamide (104) 
S
N
H
O O
Br  
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to give the product as a yellow solid 
(69 mg, 0.25 mmol, 84%). 
MP    124 128 ºC 
 
1H NMR  (500  MHz,  CDCl3)  δ  7.72 7.70  (m,  2H,  ArH),  7.64 7.61  (m,  2H, 
ArH), 7.09 7.04 (m, 4H, ArH), 4.68 (br t, 1H, J = 5.6 Hz, NH), 4.09 
(d, 2H, J = 6.0 Hz, CH2), 2.31 (s, 3H, CH3) 
13C NMR  (151 MHz, CDCl3) δ 139.04 (s), 137.99 (s), 132.75 (s), 132.38 (d), 
129.46 (d), 128.71 (d), 127.88 (d), 127.65 (s), 47.12 (t), 21.11 (q) 
IR (thin film)  νmax 3053, 1575, 1421, 1335, 1265, 1165 cm
 1 
LRMS (EI)  221 (16%), 219 (14%), 120 (24%), 86 (64%), 84 (100%)   
HRMS (EI)  calcd for C14H14BrNO2S (M
+): 338.9923 found 338.9910 
N Allyl 4 bromobenzenesulfonamide (105) 
 
S
N
H
O O
Br  
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a brown solid 
(57 mg, 0.21 mmol, 78%). 
MP    62 64 ºC, Lit.
189 60 61 ºC 
 97 
1H NMR   (300  MHz,  CDCl3)  δ  7.76 7.71  (m,  2H,  ArH),  7.67 7.63  (m,  2H, 
ArH), 5.71 (ddt, 1H, J = 16.0, 10.2, 5.8 Hz, CH2HC=CH2), 5.17 (app. 
dq, 1H, J = 17.1, 1.6 Hz, CH=CHH), 5.10 (app. dq, 1H, J = 10.2, 1.3 
Hz, CH=CHH), 4.83 (t, 1H, J = 6.0 Hz, NH), 3.60 (app. tt, 2H, J = 
1.5, 6.0 Hz , CH2 CH=CH2) 
13C NMR   (75 MHz, CDCl3) δ 139.1 (s), 132.7 (d), 132.4 (d), 128.7 (d), 127.7 
(s), 118.0 (t), 45.8 (t) 
IR (thin film)  νmax 3055, 1578, 1421, 1339, 1265, 1167 cm
 1 
LRMS (EI)  278 (10%), 276 ([M + H]
+, 10%), 221 (50%), 219 (46%), 157 (95%), 
155 (100%) 
HRMS (EI)  calcd for C9H10BrNO2S (M
+): 274.9610 found 274.9607 
1 (4 Bromobenzenesulfonyl)piperidine (106) 
S
N
O O
Br  
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(60 mg, 0.20 mmol, 82%).
 
MP    87 90 ºC, Lit.
190 90 91 ºC 
 
1H NMR  (300 MHz, CDCl3) δ 7.67 7.58 (m, 4H, ArH), 2.97 (t, 4H, J = 5.3 Hz, 
CH2), 1.62 (app. quintet, 4H, J = 5.7 Hz, CH2), 1.37 1.45 (m, 2H, 
CH2) 
13C NMR   (75 MHz, CDCl3) δ 135.5 (s), 132.3 (d), 129.2 (d), 127.6 (s), 46.9 (t), 
25.1 (t), 23.5 (t) 
IR (thin film)  νmax 3055, 2945, 2854, 1576, 1467, 1342, 1265, 1171 cm
 1 
LRMS (EI)  305 (72%), 304 (100%), 303 (M
+, 72%), 302 (86%), 223 (47%), 221 
(48%), 155 (46%), 157 (45%) 
HRMS (EI)  calcd for C11H14BrNO2S (M
+): 302.9923 found 302.9928 98 
5 Dimethylaminonaphthalene 1 sulfonic acid 4 methylbenzylamide (107) 
S
N
H
O O
N
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield a yellow oil (74 mg, 0.21 
mmol, 91%). 
 
1H NMR   (500 MHz, CDCl3) δ 8.55 (d, 1H, J = 8.5 Hz, ArH), 8.28 (d, 2H, J = 
8.6 Hz, ArH), 7.57 7.50 (m, 2H, ArH), 7.20 (d, 1H, J = 7.5 Hz, ArH), 
6.99 6.94 (m, 4H, ArH), 4.97 (t, 1H, J = 6.0 Hz, NH), 4.02 (d, 2H, J = 
6.0 Hz, CH2), 2.90 (s, 6H, CH3), 2.25 (s, 3H, CH3)  
13C NMR   (151 MHz, CDCl3) δ 152.05 (s), 137.59 (s), 134.44 (s), 133.06 (s), 
130.54 (d), 129.97 (d), 129.87 (s), 129.61 (s), 129.20 (d), 128.47 (d), 
127.82 (d), 123.22 (d), 118.61 (d), 115.18 (d), 47.17 (t), 45.45 (q), 
21.06 (q)  
IR (thin film)  νmax 3055, 2986, 1574, 1421, 1331, 1146 cm
 1 
LRMS (EI)  354 (M
+, 15%), 171 (100%) 
HRMS (EI)  calcd for C20H22N2O2S (M
+): 354.1397 found 354.1388 
5 Dimethylaminonaphthalene 1 sulfonic acid allylamide (108) 
S
N
H
O O
N
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a yellow oil 
(51 mg, 0.18 mmol, 77 %). 
 
1H NMR   (300 MHz, CDCl3) δ 8.56 (d, 1H, J = 8.5 Hz, ArH), 8.31 (d, 1H, J = 
8.6 Hz, ArH), 8.26 (dd, 1H, J = 1.2, 7.3 Hz, ArH), 7.49 7.59 (m, 2H, 
ArH), 7.20 (d, 1H, J = 7.5 Hz, ArH), 5.62 (ddt, 1H, J = 16.1, 10.2, 5.9 
Hz, CH=CH2), 5.08 (app. dq, 1H, J = 17.1, 1.6 Hz, CH=C(H)H), 5.00 99 
(app. dq, 1H, J = 10.2, 1.2 Hz, CH=C(H)H), 4.80 (br. s, 1H, NH), 
3.53 (app. tt, 2H, J = 1.4, 6.0 Hz, CH2), 2.89 (s, 6H, CH3) 
13C NMR   (75 MHz, CDCl3) δ 152.0 (s), 134.7 (s), 133.1 (d), 130.6 (d), 129.9 
(s), 129.8 (d), 129.7 (s), 128.5 (d), 123.3 (d), 118.8 (d), 117.7 (t), 
115.3 (d), 45.9 (t), 45.5 (q)  
IR (thin film)  νmax 1576, 1456, 1412, 1327, 1265, 1163, 1146, 1063 cm
 1 
LRMS (EI)  290 (M
+, 20%), 171 (100%), 170 (45%) 
HRMS (EI)  calcd for C15H18N2O2S (M
+): 290.1084 found 290.1070 
Dimethyl [5 (piperidine 1 sulfonyl)napthalen 1 yl]amine (109) 
S
N
O O
N
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a yellow oil 
(65 mg, 0.20 mmol, 89 %). 
1H NMR   (500 MHz, CDCl3) δ 8.54 (app. dt, 1H, J = 1.0, 8.5 Hz, ArH), 8.42 
(m, 1H, ArH), 8.20 (dd, 1H, J = 1.3, 7.3 Hz, ArH), 7.55 7.50 (m, 2H, 
ArH), 7.18 (dd, 1H, J = 0.7, 7.5 Hz, ArH), 3.18 (t, 4H, J = 5.5 Hz, 
CH2), 2.88 (s, 6H, CH3), 1.62 1.56 (m, 4H, CH2), 1.46 1.42 (m, 2H, 
CH2) 
13C NMR   (125 MHz, CDCl3) δ 151.70 (s), 135.56 (s), 130.52 (s), 130.44 (d), 
130.38 (d), 130.10 (s), 127.87 (d), 123.22 (d), 120.02 (d), 115.19 (d), 
46.40 (t), 45.51 (q), 25.48 (t), 23.76 (t)  
IR (thin film)  νmax 3055, 2945, 1574, 1456, 1335, 1163, 1140, 1061, 932 cm
 1 
LRMS (EI)  318 (M
+, 25%), 171 (100%) 
HRMS (EI)  calcd for C17H22N2O2S (M
+): 318.1397 found 318.1379 100 
4 (4 Bromobenzenesulfonyl)morpholine (110) 
S
N
O O
Br
O 
To a solution of 4 bromobenzene TCP sulfonate (100 mg, 0.26 mmol) in THF (1 
mL) was added morpholine (55  l, 0.36 mmol) and LHMDS (1M solution in THF) 
(360  l, 0.36 mmol). The mixture was stirred for 30min at rt. The reaction mixture 
was diluted with Et2O (20 mL) and washed with 2M sodium carbonate solution (2 x 
10 mL), 2M hydrochloric acid (2 x 10 mL) and water (10 mL). The organic portion 
was separated, dried (MgSO4), filtered and the solvent removed in vacuo. The crude 
product was purified by column chromatography (Petroleum ether/diethyl ether) to 
yield a white solid (71 mg, 0.23 mmol, 97%). 
MP    147 149 °C, Lit.
191 151 155 °C  
1H NMR   (300  MHz,  CDCl3)  δ  7.72 7.59  (m,  4H,  ArH),  3.72–3.75  (m,  4H, 
CH2), 2.98 3.01 (m, 4H, CH2) 
13C NMR   (75 MHz, CDCl3) δ 134.3 (s), 132.5 (d), 129.3 (d), 128.3 (s), 66.1 (t), 
46.0 (t) 
IR (thin film)  νmax 3055, 2886, 1576, 1354, 1171 cm
 1 
LRMS (EI)  307 (30%), 305 (M
+, 30%), 221 (20%), 219 (20%), 157 (20%), 155 
(22%), 86 (100%) 
HRMS (EI)  calcd for C10H12BrNO2S (M
+): 304.9716 found 304.9710 
N Allyl 4,N dimethylbenzenesulfonamide (111) 
S
N
O O
 
Synthesised using general method D. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield a yellow solid (32 mg, 0.14 
mmol, 51%). 
1H NMR   (300 MHz, CDCl3) δ 7.67 (d, 2H, J = 8.2 Hz, ArH), 7.32 (d, 2H, J = 
7.9 Hz, ArH), 5.71 (ddt, 1H, J = 16.2, 9.8, 6.3 Hz, CH2HC=CH2), 
5.21 5.15  (m,  2H,  CH2HC=CH2),  3.62  (d,  2H,  J  =  6.2  Hz  , 
CH2CH=CH2), 2.65 (s, 3H, CH3), 2.43 (s, 3H, CH3) 101 
13C NMR   (75 MHz, CDCl3) δ 143.4 (s), 134.5 (s), 132.6 (d), 129.7 (d), 127.5 
(d), 119.1 (t), 53.1 (t), 34.2 (q), 21.6 (q) 
IR (thin film)  νmax 3055, 2986, 1421, 1339, 1265, 1163 cm
 1 
LRMS (ES)  226 ([M + H]
+, 100), 473 (10%)   
HRMS (ES)  calcd for C11H16NO2S ([M + H]
+): 226.0896 found 226.0901 
N tert Butyl 4 methyl benzenesulfonamide (112) 
S
N
H
O O
 
Synthesised using general method D. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a brown solid 
(49 mg, 0.22 mmol, 75%). 
MP    111 114 ºC, Lit.
192 115 115.5 (ethanol) 
1H NMR   (300 MHz, CDCl3) δ 7.77 (d, 2H, J = 7.8 Hz, ArH), 7.26 (d, 2H, J= 
7.3 Hz, ArH), 4.70 (br. s, 1H, NH), 2.45 (3H, s, ArCH3), 1.24 (s, 9H, 
C(CH3)3) 
13C NMR   (75 MHz, CDCl3) δ 142.8 (s), 140.5 (s), 129.5 (d), 127.0 (d), 54.6 (s), 
30.2 (q), 21.5 (q) 
IR (thin film)  νmax 3055, 2984, 1421, 1323, 1151 cm
 1 
LRMS (CI)  228 ([M+H]
+, 38%), 172 (100%) 
HRMS (CI)  calcd for C11H17NO2S ([M+H]
+): 228.1058 found 228.1055 
4 Methyl N phenylbenzenesulfonamide (113) 
S
N
H
O O
 
Synthesised using general method D. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield a white solid (54 mg, 0.22 
mmol, 78%). 
 
MP    93 – 96 ºC, Lit.
193 102 ºC 
1H NMR   (400  MHz,  CDCl3)  δ  7.66 7.64  (m,  2H,  ArH),  7.26 7.23  (m,  4H, 
ArH), 7.15 7.06 (m, 3H, ArH), 6.47 (br s, 1H, NH), 2.39 (s, 3H, CH3) 102 
13C NMR   (126 MHz, CDCl3) δ 143.95 (s), 136.50 (s), 136.18 (s), 129.70 (d), 
129.40 (d), 127.33 (d), 125.53 (d), 121.82 (d), 21.61 (q)  
IR (thin film)  νmax 3234, 2918, 1597, 1482, 1415, 1335, 1294, 1154 cm
 1 
LRMS (EI):  247 (M
+, 20%), 99 (58%), 86 (100%) 
HRMS (EI):  calcd for C13H13NO2S (M
+): 247.0662 found 247.0673 
4,N Dimethyl N phenyl benzenesulfonamide (114) 
S
N
O O
 
Synthesised using general method D. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to yield the product as a white solid 
(68 mg, 0.26 mmol, 92 %).  
MP    92 94 ºC, Lit.
194 95 97 ºC 
1H NMR   (300 MHz, CDCl3) δ 7.42 (d, 2H, J = 8.3 Hz, ArH), 7.30 7.22 (m, 5H, 
ArH), 7.08 7.11 (m, 2H, ArH), 3.16 (s, 3H, CH3), 2.41 (s, 3H, CH3). 
13C NMR  (75 MHz, CDCl3) δ 143.5 (s), 141.6 (s), 133.6 (s), 129.3 (d), 128.8 
(d), 127.9 (d), 127.3 (d), 126.6 (d), 38.1 (q), 21.6 (q) 
IR (thin film)  νmax 2924, 1598, 1455, 1336, 1156, 1088 cm
 1 
LRMS (ES)  262 ([M + H]
+, 100%), 540 (20%) 
HRMS (ES)  calcd for C14H16NO2S ([M + H]
+): 262.0896 found 262.0897 
N (4 Methoxyphenyl) 4 nitrobenzenesulfonamide (116a) 
S
N
H
O O
O2N
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a pale brown solid (84 mg, 
0.27 mmol, 51%). 
MP    183 185 °C, Lit.
195 187 189 °C 
1H NMR  (400 MHz, DMSO) δ 10.24 (s, 1H, NH), 8.38 8.35 (m, 2H, ArH), 
7.93 7.89 (m, 2H, ArH), 7.00 6.96 (m, 2H, ArH), 6.84 6.80 (m, 2H, 
ArH), 3.67 (s, 3H, CH3) 103 
13C NMR   (101 MHz, DMSO) δ 156.88 (s), 149.62 (s), 144.76 (s), 120.04 (s), 
128.20 (d), 124.45 (d), 124.00 (d), 114.37 (d), 55.07 (q) 
IR (thin film)  νmax 3277, 1524, 1507, 1347, 1243, 1158 cm
 1 
LRMS (ES)  307 (([M– H]
 , 100%) 
HRMS (ES)   calcd for C13H11N2O5S ([M– H]
 )
 : 307.0383 found 307.0392 
N (1 Methyl 1H indol 5 yl) 4 nitrobenzenesulfonamide (116b) 
S
N
H
O O
O2N
N
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (55 mg, 0.17 
mmol, 31%). 
MP    159 161 °C  
1H NMR    (400 MHz, DMSO) δ 10.19 (s, 1H, NH), 8.35 8.31 (m, 2H, ArH), 
7.92 7.88 (m, 2H, ArH), 7.30 (d, 1H, J = 8.7 Hz, ArH), 7.30 (d, 1H, J 
= 3.0 Hz, ArH), 7.24 (d, 1H, J = 2.0 Hz, ArH), 6.85 (dd, 1H, J = 2.0, 
8.7 Hz, ArH), 6.34 (dd, 1H, J = 0.7, 3.0 Hz, ArH), 3.72 (s, 3H, CH3) 
13C NMR   (101 MHz, DMSO) δ 149.50 (s), 145.02 (s), 134.32 (s), 130.62 (d), 
128.23 (d), 128.03 (s), 127.91 (s), 124.33 (d), 117.21 (d), 114.63 (d), 
110.06 (d), 100.26 (d), 32.44 (q) 
IR (thin film)  νmax 3255, 1530, 1347, 1310, 1166 cm
 1   
LRMS (CI)  332 ([M + H]
+, 32%), 145 (100%)  
HRMS (CI)   calcd for C15H14N3O4S ([M + H]
+): 332.0705 found 332.0720 
N (4 Fluorophenyl) 4 nitrobenzenesulfonamide (116d) 
S
N
H
O O
O2N
F
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (118 mg, 0.40 
mmol, 75%).   
MP    181 184 °C, Lit.
196 189.5 190 °C  104 
1H NMR  (400 MHz, DMSO) δ 10.56 (s, 1H, NH), 8.39 8.36 (m, 2H, ArH), 
7.96 7.93 (m, 2H, ArH), 7.15 7.07 (m, 4H, ArH) 
13C NMR   (101 MHz, DMSO) δ 159.37 (d, 
1JCF = 241.9 Hz), 149.76 (s), 144.43 
(s), 132.92 (d, 
4JCF = 2.7 Hz), 128.19 (d), 124.6 (d), 123.58 (dd, 
3JCF = 
8.5 Hz), 116.05 (dd, 
2JCF = 22.7 Hz)  
IR (thin film)  νmax 3055, 1526, 1504, 1421, 1350, 1265, 1167 cm
 1 
LRMS (ES)  295 ([M   H]
 , 100%) 
HRMS (ES)   calcd for C12H8FN2O4S ([M   H]
 ): 295.0183 found 295.0188 
4 Nitro N phenylbenzenesulfonamide (116e) 
S
N
H
O O
O2N  
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (104 mg, 0.37 
mmol, 70%). Data in agreement with literature.
196   
MP    170 173 °C, Lit.
196 172.5 173 °C  
1H NMR    (400  MHz,  CDCl3)  δ  8.30 8.26  (m,  2H,  ArH),  7.94 7.91  (m,  2H, 
ArH), 7.29 7.26 (2H, m, ArH), 7.21 7.18 (1H, m, ArH), 7.09 7.06 
(2H, m, ArH), 6.79 (br s, 1H, NH) 
13C NMR   (101 MHz, CDCl3) δ 150.26 (s), 144.62 (s), 125.27 (s), 129.71 (d), 
128.53 (d), 126.56 (d), 124.30 (d), 122.47 (d) 
IR (thin film)  νmax 2852, 1522, 1464, 1377, 1337, 1313, 1159 cm
 1 
LRMS (ES)  277 ([M   H]
 , 100%) 
HRMS (ES)   calcd for C12H9N2O4S ([M   H]
 ): 277.0278 found 277.0276  
N (2 Methoxyphenyl)4 nitrobenzenesulfonamide (116f) 
S
N
H
O O
O2N
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (124 mg, 0.40 
mmol, 76%). 105 
MP    155 158 °C 
1H NMR    (400  MHz,  CDCl3)  δ  8.25 8.22  (m,  2H,  ArH),  7.93 7.90  (m,  2H, 
ArH), 7.56 (dd, 1H, J = 1.6, 7.9 Hz, ArH), 7.11 (ddd, 1H, J = 1.6, 7.6, 
8.2 Hz, ArH), 7.08 (br. s, 1H, NH), 6.94 (app. dt, 1H, J = 1.2, 7.7 Hz, 
ArH), 6.75 (dd, 1H, J = 1.3, 7.7 Hz, ArH), 3.62 (s, 3H, OCH3) 
13C NMR   (101 MHz, CDCl3) δ 150.11 (s), 149.89 (s), 144.84 (s), 128.53 (d), 
126.62 (d), 124.63 (s), 123.92 (d), 122.25 (d), 121.32 (d), 110.75 (d), 
55.60 (q)  
IR (thin film)  νmax 3277, 1608. 1525, 1507, 1347, 1243, 1158 cm
 1 
LRMS (ES)  331 ([M + Na]
+, 100%), 262 (85%) 
HRMS (ES)   calcd for C13H16N3O5S ([M + NH4]
+): 326.0805 found 326.0803 
N (3 Methoxyphenyl)4 nitrobenzenesulfonamide (116g) 
S
N
H
O O
O2N
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (115 mg, 0.37 
mmol, 70%). 
MP    118 121 °C 
1H NMR    (400  MHz,  CDCl3)  δ  8.30 8.26  (m,  2H,  ArH),  7.99 7.96  (m,  2H, 
ArH), 7.18 7.13 (m, 1H, ArH), 7.11 (br. s, 1H, NH), 6.71 6.69 (m, 
2H, ArH), 6.64 6.61 (m, 1H, ArH), 3.75 (s, 3H, OCH3) 
13C NMR   (101 MHz, CDCl3) δ 160.48 (s), 150.26 (s), 144.50 (s), 136.55 (s), 
130.44 (d), 128.57 (d), 124.34 (d), 113.88 (d), 111.55 (d), 107.97 (d), 
55.41 (q) 
IR (thin film)  νmax 3246, 1606, 1593, 1529, 1348, 1261, 1155 cm
 1 
LRMS (ES)  307 ([M – H]
 , 100%) 
HRMS (ES)  calcd for C13H11N2O5S ([M – H]
 ): 307.0383 found 307.0371 106 
N [3 (2 Amino 1 hydroxyvinyl) phenyl]4 nitrobenzenesulfonamide (116h) 
S
N
H
O O
O2N N
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow oil (116 mg, 0.34 
mmol, 64%). 
MP    177 180 °C 
1H NMR    (400 MHz, DMSO) δ 10.83 (s, 1H, NH), 8.45 (s, 1H, ArH), 8.38 (d, 
2H, J = 8.9 Hz, ArH), 8.03 (d, 2H, J = 8.9 Hz, ArH), 7.66 (s, 1H, 
ArH), 7.48 7.46 (m, 2H, ArH), 7.36 (app. t, 1H, J = 8.2 Hz, ArH), 
7.10 7.08 (m, 1H, ArH)    
13C NMR   (101 MHz, DMSO) δ 152.47 (d), 150.31 (s), 150.06 (s), 144.98 (s), 
138.14 (s), 130.71 (d), 128.81 (d), 128.67(s), 125.15 (d), 123.00 (d), 
120.95 (d), 120.95 (d), 115.91 (d) 
IR (thin film)  νmax 3141, 1609, 1516, 1494, 1347, 1158 cm
 1 
LRMS (ES)  344 ([M – H]
 , 100%) 
HRMS (ES)  calcd for C15H10N3O5S ([M – H]
 ): 344.0336 found 344.0329 
N (3 Fluorophenyl)4 nitrobenzenesulfonamide (116i) 
S
N
H
O O
O2N
F
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (122 mg, 0.41 
mmol, 77%). 
MP    136 138 °C, Lit.
197 131 132 °C 
1H NMR   (400 MHz, DMSO) δ 10.92 (s, 1H, NH), 8.40 8.38 (m, 2H, ArH), 
8.05 8.02 (m, 2H, ArH), 7.33 7.27 (m, 1H, ArH), 6.96 6.89 (m, 3H, 
ArH) 
13C NMR   (101 MHz, DMSO) δ 162.13 (d, 
1JCF = 241.1), 149.90 (s), 144.33  (s), 
138.65 (d, 
3JCF = 10.3 Hz), 131.13 (dd, 
3JCF = 9.5 Hz), 128.19 (d), 107 
124.71 (d), 115.78 (dd, 
4JCF = 2.8 Hz), 111.18 (dd, 
2JCF = 21.0 Hz), 
106.79 (dd, 
2JCF  = 25.3 Hz) 
IR (thin film)  νmax 3262,
 1600, 1522, 1485, 1332, 1306, 1156, 1132 cm
 1 
LRMS (ES)  295 ([M – H]
 , 100%), 231 (15%) 
HRMS (ES)   calcd for C12H8FN2O4S ([M – H]
 ): 295.0183 found 295.0178 
4 Nitro N (3 trifluoromethylphenyl)benzenesulfonamide (116j) 
S
N
H
O O
O2N
CF3
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (135 mg, 0.39 
mmol, 74%). 
MP    148 150 °C, Lit.
197 148 149 °C 
1H NMR  (400 MHz, DMSO) δ 11.07 (s, 1H, NH), 8.41 8.38 (m, 2H, ArH), 
8.05 8.02 (m, 2H, ArH), 7.55 7.40 (m, 4H, ArH) 
13C NMR   (101 MHz, DMSO) δ 149.96 (s), 144.21 (s), 137.76 (s), 130.78 (d), 
129.92 (q, 
2JCF = 37.0 Hz), 128.20 (d), 124.78 (d), 123.64 (d), 123.57 
(q, 
1JCF = 272.5 Hz), 121.06 (dq, 
3JCF = 3.8 Hz), 116.1 (dq, 
3JCF = 4.0 
Hz) 
IR (thin film)  νmax 3267, 3055, 1533, 1331, 1265, 1171 cm
 1 
LRMS (ES)  345 ([M – H]
 , 100%),  
HRMS (ES)   calcd for C13H8F3N2O4S ([M – H]
 ): 345.0151 found 345.0145 
N (3,4 Dichlorophenyl) 4 nitrobenzenesulfonamide (116k) 
S
N
H
O O
O2N
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a orange solid (136 mg, 0.39 
mmol, 74%). 
MP    169 171 °C, Lit.
198 178 °C 108 
1H NMR    (400 MHz, DMSO) δ 11.03 (s, 1H, NH), 8.42 8.38 (m, 2H, ArH), 
8.04 8.01 (m, 2H, ArH), 7.55 (d, 1H, J = 8.7 Hz, ArH), 7.30 (d, 1H, J 
= 2.5 Hz, ArH), 7.11 (dd, 1H, J = 2.5, 8.7 Hz, ArH) 
13C NMR   (101 MHz, DMSO) δ 149.99 (s), 144.05 (s), 137.05 (s), 131.52 (s), 
131.34 (d), 128.18 (d), 126.70 (s), 124.81 (d), 121.42 (d), 121.09 (d) 
IR (thin film)  νmax 3240, 1523, 1471, 1350, 1312, 1169 cm
 1 
LRMS (ES)  345 ([M – H]
 , 100%), 347 (45%) 
HRMS (ES)   calcd for C12H7Cl2N2O4S ([M – H]
 ): 344.9498 found 344.9502 
N (4 Cyanophenyl)4 nitrobenzenesulfonamide (116m) 
S
N
H
O O
O2N
CN
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate)  to give an orange solid (120 mg, 
0.40 mmol, 75%). 
MP    190 193 °C, Lit.
199 193 196 (aq. Ethanol) 
1H NMR    (400 MHz, DMSO) δ 11.36 (s, 1H, NH), 8.42 8.38 (m, 2H, ArH), 
8.10 8.07 (m, 2H, ArH), 7.76 7.73 (m, 2H, ArH), 7.29 7.26 (m, 2H, 
ArH) 
13C NMR   (101 MHz, DMSO) δ 150.05 (s), 144.22 (s), 141.42 (s), 133.78 (d), 
128.22 (d), 124.86 (d), 119.02 (d), 118.47 (s), 106.09 (s) 
IR (thin film)  νmax 3215, 2225, 1606, 1532, 1348, 1167 cm
 1 
LRMS (CI)  304 ([M+H]
+, 100%), 119 (30%) 
HRMS (CI)  calcd for C13H10N3O4S ([M+H]
+): 304.0392 found 304.0411 
N (2,5 Dichlorophenyl)4 nitrobenzenesulfonamide (116n) 
S
N
H
O O
O2N
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate)  to give an orange solid (162 mg, 
0.47 mmol, 88%). 109 
MP    168 170 °C 
1H NMR    (400 MHz, DMSO) δ 10.75 (br. s, 1H, NH), 8.42 8.38 (m, 2H, ArH), 
7.99 7.95 (m, 2H, ArH), 7.49 7.47 (m, 1H, ArH), 7.38 7.35 (m, 2H, 
ArH) 
13C NMR   (151 MHz, CDCl3) δ 150.55 (s), 144.18 (s), 134.04 (s), 133.30 (s), 
130.40 (d), 128.57 (d), 127.13 (d), 124.49 (d), 123.89 (s), 123.27(d) 
IR (thin film)  νmax 3055, 1537, 1479, 1350, 1175 cm
 1 
LRMS (ES)  345 ([M – H]
 , 100%), 347 (40%) 
HRMS (ES)   calcd for C12H7Cl2N2O4S ([M – H]
 ): 344.9498 found 344.9501  
4 Nitro N (2 trifluoromethylphenyl)benzenesulfonamide (116o) 
S
N
H
O O
O2N
CF3 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (128 mg, 0.37 
mmol, 70%). 
MP    147 148 °C 
1H NMR    (400 MHz, DMSO) δ 10.46 (s, 1H, NH), 8.47 8.44 (m, 2H, ArH), 
8.05 8.02 (m, 2H, ArH), 7.75 (dd, 1H, J = 1.3, 7.8 Hz, ArH), 7.62 
7.58 (m, 1H, ArH), 7.50 (app. t, 1H, J = 7.6 Hz, ArH), 7.02 (d, 1H, J  
= 8.0 Hz, ArH)   
13C NMR   (101 MHz, DMSO) δ 149.67 (s), 146.46 (s), 133.44 (d), 133.25 (s), 
129.06 (d), 128.14 (d), 127.94 (d), 127.14 (dq, 
3JCF = 5.1 Hz), 126.52 
(q, 
2JCF = 29.6 Hz), 124.69 (d), 123.06 (q, 
1JCF = 274 Hz)  
IR (thin film)  νmax 3285, 3055, 1533, 1418, 1350, 1175, 1113 cm
 1 
LRMS (ES)  345 ([M   H]
 , 100%) 
HRMS (ES)   calcd for C13H8F3N2O4S ([M   H]
 ): 345.0151 found 345.0145 110 
N (4 Methoxyphenyl)benzenesulfonamide (117a) 
S
N
H
O O
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (110 mg, 0.42 
mmol, 79%). 
MP    96 99 °C, Lit.
200 95 96 °C 
1H NMR    (400 MHz, CDCl3) δ 7.74  7.71 (m, 2H, ArH), 7.53 (app. tt, 1H, J = 
1.3, 7.4 Hz, ArH), 7.44  7.40 (m, 2H, ArH), 7.00 6.96 (m, 2H, ArH), 
6.88 (br. s, 1H, NH), 6.77 6.73 (m, 2H, ArH), 3.74 (s, 3H, OCH3)  
13C NMR   (101 MHz, CDCl3) δ 157.98 (s), 138.86 (s), 132.88 (d), 128.94 (d), 
128.74 (s), 127.30 (d), 125.49 (d), 114.42 (d), 55.42 (q)  
IR (thin film)  νmax 3261, 3055, 1510, 1448, 1331, 1165cm
 1 
HRMS (CI)    264 ([M + H]
+, 18%), 124 (100%) 
HRMS (CI)    calcd for C13H14NO3S ([M + H]
+): 264.0689 found 264.0680 
N (1 methyl 1H indol 5 yl)benzenesulfonamide (117b) 
S
N
H
O O
N
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (129 mg, 0.45 
mmol, 85%). 
MP    139–141 °C 
1H NMR    (400 MHz, DMSO) δ 9.85 (s, 1H, NH), 7.68 7.47 (m, 4H, ArH), 7.28 
7.26 (m, 2H, ArH), 7.22 (d, 1H, J = 2.0 Hz, ArH), 6.86 (dd, 1H, J = 
2.0, 8.7 Hz, ArH), 6.32 (dd, 1H, J = 0.7, 3.1 Hz, ArH), 3.69 (s, 3H, 
CH3)  
13C NMR   (101 MHz, DMSO) δ 140.05 (s), 134.61 (s), 132.94 (d), 130.96 (d), 
129.48 (s), 129.44 (d), 128.39 (s), 127.15 (d), 117.52 (d), 114.56 (d), 
110.37 (d), 100.67 (d), 32.97 (q)  111 
IR (thin film)  νmax 3255, 1530, 1347, 1310, 1166 cm
 1 
LRMS (CI)  287 ([M + H]
+, 60%), 145 (100%) 
HRMS (CI)  calcd for C15H15N2O2S ([M + H]
+): 287.0854 found 287.0842 
N Methyl N phenyl benzenesulfonamide (117c) 
S
N
O O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (104 mg, 0.42 
mmol, 79%). 
MP    79 81 °C, Lit.
201 78 79 °C 
1H NMR    (400  MHz,  DMSO)  δ  7.73 7.49  (m,  5H,  ArH),  7.37 7.26  (m,  3H, 
ArH), 7.10 7.08 (m, 2H, ArH), 3.14 (s, 3H, CH3)   
13C NMR   (101 MHz, DMSO) δ 140.98 (s), 135.84 (s), 133.19 (d), 129.11 (d), 
128.80 (d), 127.28 (d), 127.14 (d), 126.05 (d), 37.80 (q) 
IR (thin film)  νmax 3055, 2985, 1597, 1495, 1447, 1352, 1265, 1180, 1067 cm
 1 
LRMS (CI)  248 ([M + H]
+, 95%), 106 (100%) 
HRMS (CI)   calcd for C13H14NO2S ([M + H]
+): 248.0745 found 248.0736 
N (4 Fluorophenyl)benzenesulfonamide (117d) 
S
N
H
O O
F
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (106 mg, 0.42 
mmol, 80%). 
MP    106 109 °C 
1H NMR    (400 MHz, DMSO) δ 10.24 (br s, 1H, NH), 7.72 7.50 (m, 2H, ArH), 
7.64 7.52 (m, 3H, ArH), 7.08 (d, 4H, J = 6.7 Hz, ArH) 
13C NMR   (100 MHz, DMSO) δ 158.86 (d, 
1JCF = 241.0 Hz), 139.05 (s), 133.72 
(d, 
4JCF = 2.7 Hz), 132.85 (d), 129.16 (d), 126.54 (d), 122.74 (dd, 
3JCF 
= 7.3 Hz), 115.79 (dd, 
2JCF = 22.9 Hz) 112 
IR (thin film)  νmax 3055, 2987, 1506, 1448, 1387, 1265, 1167, 1092 cm
 1 
LRMS (CI)  252 ([M + H]
+, 25%), 164 (100%), 112 (80%) 
HRMS (CI)  calcd for C12H11FNO2S ([M + H]
+): 252.0489 found 252.0479 
N Phenylbenzenesulfonamide (117e) 
S
N
H
O O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (118 mg, 0.51 
mmol, 96%). 
MP    112 114 °C, Lit.
202 112 113 °C 
1H NMR    (400  MHz,  CDCl3)  δ  7.82 7.80  (m,  2H,  ArH),  7.54 7.40  (m,  3H, 
ArH), 7.31 (br. s, 1H, NH), 7.25 7.07 (m, 5H, ArH) 
13C NMR   δC (100 MHz, CDCl3) 138.90 (s), 136.41 (s), 133.04 (d), 129.32 (d), 
129.05 (d), 127.23 (d), 125.39 (d), 121.61 (d) 
IR (thin film)  νmax 3204, 1596, 1474, 1413, 1329, 1303, 1152 cm
 1 
LRMS (CI)  234 ([M + H]
+, 35%), 94 (100%)   
HRMS (CI)   calcd for C12H12NO2S ([M + H]
+): 234.0583 found 234.0593     
N (2 Methoxyphenyl)benzenesulfonamide (117f) 
S
N
H
O O
O  
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (125 mg, 0.47 
mmol, 89%). Data in agreement with literature. 
203 
MP    91 94 °C, Lit.
203  88 89 °C  
1H NMR  (400 MHz, DMSO) δ 9.48 (s, 1H, NH), 7.71 7.49 (m, 5H, ArH), 7.20 
(dd, 1H, J = 1.7, 7.8 Hz, ArH), 7.11 (ddd, 1H, J = 1.7, 7.5, 8.2 Hz, 
ArH), 6.90–6.84 (m, 2H, ArH), 3.46 (s, 3H, OCH3)  
13C NMR   (101 MHz, DMSO) δ 152.24 (s), 140.43 (s), 132.38 (d), 128.67 (d), 
126.59 (d), 126.51 (d), 125.17 (d), 125.09 (s), 120.27 (d), 111.66 (d), 
55.26 (q) 113 
IR (thin film)  νmax 3055, 1501, 1448, 1344, 1167, 1113 cm
 1 
LRMS (CI)  263 ([M + H]
+, 35%), 123 (100%), 94 (30%) 
HRMS (CI)  calcd for C13H14NO3S ([M + H]
+): 264.0694 found 264.0679   
N (3 Methoxyphenyl)benzenesulfonamide (117g) 
S
N
H
O O
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (112 mg, 0.43 
mmol, 80 %). 
MP    82 84 °C, Lit.
204 82.5 83.5 °C (aq. Ethanol) 
1H NMR    (400 MHz, DMSO) δ 10.31 (s, 1H, NH), 7.78 7.76 (m, 2H, ArH), 
7.63 7.53 (m, 3H, ArH), 7.14 7.10 (m, 1H, ArH), 6.68 6.57 (m, 3H, 
ArH), 3.65 (s, 3H, OCH3) 
13C NMR   (101 MHz, DMSO) δ 159.55 (s), 139.34 (s), 138.78 (s), 132.83 (d), 
129.91 (d), 129.17 (d), 126.56 (d), 111.78 (d), 108.93 (d), 105.57 (d), 
54.88 (q)  
IR (thin film)  νmax 3250, 1611, 1494, 1448, 1411, 1329, 1284, 1145 cm
 1 
LRMS (CI)  264 ([M + H]
+, 75%), 124 (100%) 
HRMS (CI)    calcd for C13H14NO3S ([M + H]
+): 264.0689 found 264.0690  
N (3 Fluorophenyl)benzenesulfonamide (117i) 
S
N
H
O O
F
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (130 mg, 0.52 
mmol, 98%). 
MP    101 103 °C, Lit.
205 97 98 °C 
1H NMR    (400 MHz, DMSO) δ 10.61 (s, 1H, NH), 7.80 7.78 (m, 2H, ArH), 
7.66 7.55 (m, 3H, ArH), 7.29 7.24 (m, 1H, ArH), 6.93 6.82 (m, 3H, 
ArH)  114 
13C NMR   (101 MHz, DMSO) δ 162.10 (d, 
1JCF  = 242.5 Hz), 139.46 (d, 
3JCF = 
10.5 Hz), 139.03 (s), 133.08 (d), 130.89 (dd, 
3JCF = 9.5 Hz), 129.31 
(d), 126.55 (d), 115.24 (dd, 
4JCF = 2.8 Hz), 110.42 (dd, 
2JCF = 20.1 
Hz), 106.42 (dd, 
2JCF = 25.4 Hz) 
IR (thin film)  νmax 3251, 1614, 1606, 1494, 1409, 1328, 1140, 1090 cm
 1  
LRMS (CI)  252 ([M + H]
+, 65%), 143 (50%), 112 (100%) 
HRMS (CI)    calcd for C12H11FNO2S ([M + H]
+): 252.0489 found 252.0496  
N (3 trifluoromethylphenyl)benzenesulfonamide (117j) 
S
N
H
O O
CF3
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (140 mg, 0.46 
mmol, 88%). 
MP    77 79 °C 
1H NMR    (400 MHz, DMSO) δ 10.75 (s, 1H, NH), 7.80 7.78 (m, 2H, ArH), 
7.66 7.56 (m, 3H, ArH), 7.51 7.49 (m, 1H, ArH), 7.39 7.37 (m, 3H, 
ArH) 
13C NMR   (101 MHz, DMSO) δ 138.86 (s), 138.51 (s), 133.21 (d), 130.33 (d), 
129.74 (q, 
2JCF = 32.9 Hz), 129.37 (d), 126.55 (d), 123.64 (q, 
1JCF = 
278.8 Hz), 123.18 (d), 120.35 (dq, 
3JCF = 3.9 Hz), 115.51 (dq, 
3JCF = 
4.0 Hz) 
IR (thin film)  νmax 3252, 1409, 1327, 1159, 1091 cm
 1 
LRMS (CI)  ([M + H]
+, 90%), 162 (88%), 142 (100%) 
HRMS (CI)    calcd for C13H11F3NO2S ([M + H]
+): 302.0463 found 302.0459 
N (3,4 Dichlorophenyl)benzenesulfonamide (117k) 
S
N
H
O O
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (142 mg, 0.47 
mmol, 89%). 115 
MP    128 130 °C, Lit.
206 130 130.5 °C 
1H NMR    (400 MHz, DMSO) δ 10.72 (s, 1H, NH), 7.80 7.77 (m, 2H, ArH), 
7.68 7.63 (m, 1H, ArH), 7.61 7.57 (m, 2H, ArH), 7.51 (d, 1H, J = 8.8 Hz, ArH), 7.28 
(d, 1H, J = 2.6 Hz, ArH), 7.10 (dd, 1H, J = 2.6, 8.8 Hz, ArH) 
13C NMR   (101 MHz, DMSO) δ 138.74 (s), 137.82 (s), 133.28 (d), 131.32 (s), 
131.16 (d), 129.43 (d), 126.54 (d), 125.91 (s), 120.74 (d), 119.53 (d) 
IR (thin film)  νmax 3055, 1593, 1475, 1377, 1329, 1267, 1167 cm
 1 
LRMS (CI)  304 (70%), 302 ([M + H]
+, 100%), 163 (32%), 161 (45%) 
HRMS (CI)    calcd for C12H10Cl2NO2S ([M + H]
+): 301.9809 found 301.9812   
N (4 Trifluoromethylphenyl)benzenesulfonamide (117l) 
S
N
H
O O
CF3
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (66 mg, 0.22 
mmol, 41%). 
MP    103 105 °C 
1H NMR    (300 MHz, DMSO) δ 10.89 (s, 1H, NH), 7.83 7.80 (m, 2H, ArH), 
7.65 7.54 (m, 5H, ArH), 7.27 (d, 2H, J = 8.7 Hz, ArH) 
13C NMR    (151 MHz, DMSO) δ 139.65 (s), 138.72 (s), 133.53 (d), 129.33 (d), 
127.17 (d), 126.98 (q, 
2JCF = 32.8 Hz), 126.71 (dq, 
3JCF = 3.4 Hz), 
123.84 (q, 
1JCF = 271.5 Hz), 120.01 (d)   
IR (thin film)  νmax 3055, 1618, 1448, 1327, 1265, 1167, 1124, 1070, 916 cm
 1   
LRMS (CI)  302 ([M + H]
+, 80%), 282 (64%), 171 (75%), 142 (100%) 
HRMS (CI)    calcd for C13H11F3NO2S ([M + H]
+): 302.0463 found 302.0471    
N (4 Cyanophenyl)benzenesulfonamide (117m) 
S
N
H
O O
CN
 
Synthesised using general procedure E. The crude product was purified by column 
qchromatography (petroleum ether/ethyl acetate) to give a pale brown solid (116 mg, 
0.45 mmol, 85%). 116 
MP    172 175 °C, Lit.
207 175 176 °C (ethanol) 
1H NMR    (400 MHz, DMSO) δ 11.07 (s, 1H, NH), 7.85 7.83 (m, 2H, ArH), 
7.72 7.57 (m, 5H, ArH), 7.27 7.23 (m, 2H, ArH) 
13C NMR   (101 MHz, DMSO) δ 142.08 (s), 138.92 (s), 133.61 (d), 133.37 (d), 
129.48 (d), 126.56 (d), 118.58 (s), 118.41 (d), 105.35 (s) 
IR (thin film)  νmax 3247, 2222, 1606, 1507, 1464, 1329, 1155, 1089 cm
 1 
LRMS (CI)  259 ([M + H]
+, 100%), 141 (60%), 119 (35%) 
HRMS (CI)    calcd for C13H11N2O2S ([M + H]
+): 259.0536 found 259.0539   
N (2,5 Dichlorophenyl)benzenesulfonamide (117n) 
S
N
H
O O
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a pale brown solid (139 mg, 
0.46 mmol, 87%). 
MP    131 134 °C 
1H NMR    (300 MHz, DMSO) δ 10.29 (s, 1H, NH), 7.73 7.54 (m, 5H, ArH), 
7.43 (d, 1H, J = 8.1 Hz, ArH), 7.30 7.26 (m, 2H, ArH)  
13C NMR   (75 MHz, DMSO) δ 139.8 (s), 134.8 (s), 133.1 (d), 131.6 (s), 131.2 
(d), 129.3 (d), 127.5 (s), 127.3 (d), 126.6 (d), 126.5 (d)  
IR (thin film)  νmax 3055, 2986, 1585, 1481, 1391, 1342, 1265, 1169 cm
 1 
LRMS (CI)  304 (34%), 302 ([M + H]
+, 45%), 279 (75%), 141 (100%), 84 (45%) 
HRMS (CI)    calcd for C12H10C12NO2S ([M + H]
+): 301.9809 found 301.9815 
N (4 Methoxyphenyl)4 methoxybenzenesulfonamide (118a) 
S
N
H
O O
O
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown glass (95 mg, 0.32 
mmol, 61%). Data in agreement with literature.
208 117 
1H NMR    (400 MHz, DMSO) δ 9.76 (s, 1H, NH), 7.62 7.58 (m, 2H, ArH), 7.05 
7.02 (m, 2H, ArH), 6.97 6.94 (m, 2H, ArH), 6.81 6.77 (m, 2H, ArH), 
3.79 (s, 3H, OCH3), 3.66 (s, 3H, OCH3)   
13C NMR   (101 MHz, DMSO) δ 162.14 (s), 156.28 (s), 131.00 (s), 130.26 (s), 
128.75 (d), 123.15 (d), 114.13 (d), 55.49 (q), 55.02 (q) missing 1x d 
LRMS (CI)  294 ([M + H]
+, 100%), 123 (95%) 
HRMS (CI)    calcd for C14H16NO4S ([M + H]
+)
 : 294.0800 found 294.0798 
4 Methoxy N methyl N phenyl benzenesulfonamide (118c) 
S
N
O O
O  
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (132 mg, 0.48 
mmol, 90%). 
MP    102 107 °C, Lit.
209 109 110.3 °C 
1H NMR    (400  MHz,  DMSO)  δ  7.44 7.40  (m,  2H,  ArH),  7.36 7.26  (m,  3H, 
ArH),  7.11 7.07  (m,  4H,  ArH),  3.83  (s,  3H,  OCH3),  3.10  (s,  3H, 
NCH3) 
13C NMR   (101 MHz, DMSO) δ 162.63 (s), 141.21 (s), 129.53 (d), 128.74 (d), 
127.40 (s), 126.99 (d), 126.03 (d), 114.22 (d), 55.60 (q), 37.64 (q),   
IR (thin film)  νmax 3055, 2987, 1597, 1497, 1348, 1265, 1169, 1151 cm
 1 
LRMS (CI)    278 ([M + H]
+, 45%), 107 (100%) 
HRMS (CI)    calcd for C14H16NO3S ([M + H]
+): 278.0845 found 2.0849 
N (4 Fluorophenyl) 4 methoxybenzenesulfonamide (118d) 
S
N
H
O O
O
F
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (132 mg, 0.47 
mmol, 89%). 
MP    114 116 °C 118 
1H NMR    (400 MHz, DMSO) δ 10.09 (s, 1H, NH), 7.66 7.62 (m, 2H, ArH), 
7.08 7.03 (m, 6H, ArH), 3.79 (s, 3H, OCH3)  
13C NMR   (101 MHz, DMSO) δ 162.39 (s), 158.94 (d, 
1JCF = 240.9 Hz), 134.08 
(d, 
4JCF = 2.6 Hz), 130.77 (s), 128.84 (d), 122.60 (dd, 
3JCF = 8.2 Hz), 
115.82 (dd, 
2JCF = 22.7 Hz), 114.34 (d), 55.60 (q) 
IR (thin film)  νmax 3258, 3055, 1597, 1508, 1387, 1331, 1265, 1159, 1094 cm
 1 
LRMS (CI)  282 ([M + H]
+, 35%), 171 (60%), 111 (65%), 97 (95%), 85 (90%), 71 
(100%)   
HRMS (CI)    calcd for C13H13FNO3S ([M + H]
+): 282.0600 found 282.0589   
4 Methoxy N phenylbenzenesulfonamide (118e) 
S
N
H
O O
O  
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (120 mg, 0.46 
mmol, 86%). 
MP  104 106 °C, Lit.
208 105 106 °C  
1H NMR    (300 MHz, DMSO) δ 10.14 (s, 1H, NH), 7.68 (d, 2H, J = 8.8 Hz, 
ArH), 7.23 7.17 (m, 2H, ArH), 7.08 6.96 (m, 5H, ArH), 3.77 (s, 3H, 
OCH3) 
13C NMR    (75 MHz, DMSO) δ 162.3 (s), 137.9 (s), 131.1 (s), 129.1 (d), 128.8 
(d), 123.8 (d), 119.8 (d), 114.3 (d), 55.5 (q) 
IR (thin film)  νmax 3055, 1597, 1497, 1421, 1265, 1159, 1095, 1028 cm
 1 
LRMS (CI)    264 ([M + H]
+, 55%), 171 (100%) 
HRMS (CI)    calcd for C13H14NO3S ([M + H]
+): 264.0694 found 264.0684   
N (2 Methoxyphenyl) 4 methoxybenzenesulfonamide (118f) 
S
N
H
O O
O
O  
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (111 mg, 0.38 
mmol, 72%). 119 
MP    103 105 °C 
1H NMR    (400 MHz, DMSO) δ 9.28 (s, 1H, NH), 7.63 7.61 (m, 2H, ArH), 7.20 
(dd, 1H, J = 1.6, 7.9 Hz, ArH), 7.10 (ddd, 1H, J = 1.7, 7.5, 8.2 Hz, 
ArH), 7.05 7.01 (m, 2H, ArH), 6.91 5.83 (m, 2H, ArH), 3.79 (s, 3H, 
OCH3), 3.52 (s, 3H, OCH3)   
13C NMR   (101 MHz, DMSO) δ 162.10 (s), 151.90 (s), 132.03 (s), 128.76 (d), 
126.20 (d), 125.50 (s), 124.34 (d), 120.26 (d), 113.82 (d), 111.63 (d), 
55.51 (q), 55.37 (q) 
IR (thin film)  νmax 3055, 2972, 1597, 1499, 1464, 1342, 1265, 1159, 1113 cm
 1 
LRMS (CI)    293 ([M + H]
+, 20%), 122 (100%), 94 (48%) 
HRMS (CI)    calcd for C14H16NO4S ([M + H]
+): 293.0716 found 293.0719 
N (3 Methoxyphenyl)4 methoxybenzenesulfonamide (118g) 
S
N
H
O O
O
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown oil (140 mg, 0.48 
mmol, 90%). 
1H NMR    (400 MHz, DMSO) δ 10.16 (s, 1H, NH), 7.72 7.68 (m, 2H, ArH), 
7.13 7.04 (m, 3H, ArH), 6.67 6.64 (m, 2H, ArH), 6.58 (ddd, 1H, J = 
0.9, 2.4, 8.3 Hz, ArH), 3.79 (s, 3H, OCH3), 3.66 (s, 3H, OCH3) 
13C NMR   (101 MHz, DMSO) δ 162.32 (s), 159.55 (s), 139.05 (s), 130.99 (s), 
129.87 (d), 128.79 (d), 114.29 (d), 111.58 (d), 108.69 (d), 105.34 (d), 
55.52 (q), 54.88 (q) 
IR (thin film)  νmax 3055, 1597, 1498, 1394, 1331, 1261, 1151, 1093 cm
 1 
LRMS (CI)  294 ([M + H]
+, 100%), 123 (95%) 
HRMS (CI)    calcd for C14H16NO4S ([M + H]
+): 294.0800 found 294.0798    120 
N [3 (2 Amino 1 hydroxyvinyl) phenyl] 4 methoxybenzenesulfonamide (118h) 
S
N
H
O O
O N
O
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a yellow solid (116 mg, 0.35 
mmol, 66%). 
MP    154 157 °C 
1H NMR    (400 MHz, DMSO) δ 10.37 (s, 1H, NH), 8.45 (s, 1H, ArH), 7.74 7.71 
(m, 2H, ArH) 7.63 (s, 1H, ArH), 7.45 7.38 (m, 2H, ArH), 7.33 (app. t, 
1H, J = 7.9 Hz, ArH), 7.09 7.05 (m, 3H, ArH), 3.78 (s, 3H, OCH3) 
13C NMR   (101 MHz, DMSO) δ 162.41 (s), 151.91 (d), 149.80 (s), 138.67 (s), 
130.78 (s), 129.96 (d), 128.81 (d), 128.09 (s), 122.28 (d), 119.61 (d), 
119.47 (d), 114.37 (d), 114.62 (d), 55.53 (q)  
IR (nujol)  νmax 2850, 1593, 1464, 1377, 1339, 1258, 1161, 1089 cm
 1 
LRMS (CI)    331 ([M + H]
+, 100%), 266 (50%), 171 (50%) 
HRMS (CI)    calcd for C16H15N2O4S ([M + H]
+): 331.0753 found 331.0733   
N (3 Fluorophenyl) 4 methoxybenzenesulfonamide (118i) 
S
N
H
O O
O
F
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown oil (117 mg, 0.42 
mmol, 78%). 
1H NMR    (400 MHz, DMSO) δ 10.46 (s, 1H, NH), 7.74 7.70 (m, 2H, ArH), 
7.29 7.23 (m, 1H, ArH), 7.10 7.06 (m, 2H, ArH), 6.92 6.81 (m, 3H, 
ArH), 3.80 (s, 3H, OCH3) 
13C NMR   (101 MHz, DMSO) δ 162.57 (s), 162.20 (d, 
1JCF = 243.6 Hz), 139.81 
(d, 
3JCF = 10.6 Hz), 130.92 (dd, 
3JCF = 9.5 Hz), 130.70 (s), 128.89 (d), 
115.10 (dd, 
4JCF = 2.7 Hz), 114.5 (d), 110.2 (dd, 
2JCF = 21.0 Hz), 
105.97 (dd, 
2JCF = 25.4 Hz), 55.63 (q) 121 
IR (thin film)  νmax 3258, 1597, 1499, 1331, 1265, 1161, 1094 cm
 1 
LRMS (CI)  282 ([M + H]
+, 52%), 171 (100%), 112 (50%) 
HRMS (CI)   calcd for C13H13FO3S ([M + H]
+): 282.3060 found 282.0589  
4 Methoxy N (3 trifluoromethylphenyl)benzenesulfonamide (118j) 
S
N
H
O O
O
CF3
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown oil (121 mg, 0.37 
mmol, 69%). 
1H NMR    (400 MHz, DMSO) δ 10.61 (s, 1H, NH), 7.73 7.70 (m, 2H, ArH), 
7.50 7.46 (m, 1H, ArH), 7.38 7.36 (m, 3H, ArH), 7.10 7.06 (m, 2H, 
ArH), 3.79 (s, 3H, OCH3) 
13C NMR   (101 MHz, DMSO) δ 162.58 (s), 138.77 (s), 130.47 (d), 130.43 (s), 
129.71 (q, 
2JCF = 31.5 Hz), 128.82 (d), 123.67 (q, 
1JCF = 271.6 Hz), 
122.86 (d), 120.06 (dq, 
3JCF = 3.8 Hz), 115.23 (dq, 
3JCF = 3.9 Hz), 
114.47 (d), 55.59 (q)  
IR (thin film)  νmax 3055, 1597, 1499, 1418, 1331, 1265, 1157, 1130, 1094 cm
 1 
LRMS (CI)    332 ([M + H]
+, 100%), 171 (80%), 162 (25%) 
HRMS (CI)    calcd for C14H13F3NO3S ([M + H]
+): 332.0568 found 332.0580   
N (3,4 Dichlorophenyl) 4 methoxybenzenesulfonamide (118k) 
S
N
H
O O
O
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (149 mg, 0.45 
mmol, 85%). 
MP    98 100 °C 
1H NMR    (400 MHz, DMSO) δ 10.58 (s, 1H, NH), 7.73 7.70 (m, 2H, ArH), 
7.51 (d, 1H, J = 8.8 Hz, ArH), 7.27 (d, 1H, J = 2.5 Hz, ArH), 7.11 
7.07 (m, 3H, ArH), 3.81 (s, 3H, OCH3)  122 
13C NMR   (101 MHz, DMSO) δ 162.63 (s), 138.10 (s), 131.28 (s), 131.12 (d), 
130.30 (s), 128.82 (d), 125.63 (s), 120.49 (d), 119.30 (d), 114.54 (d), 
56.59 (q)  
IR (thin film)  νmax 3252, 3055, 1597, 1475, 1323, 1265, 1159, 1094 cm
 1 
LRMS (CI)  333 (55%), 331([M + H]
+, 25%), 123 (70%), 107 (100%) 
HRMS (CI)    calcd for C13H12Cl2NO3S ([M + H]
+): 331.9915 found 331.9914 
N (4 Cyanophenyl) 4 methoxybenzenesulfonamide (118m) 
S
N
H
O O
O
CN
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a brown solid (129 mg, 0.45 
mmol, 84%). 
MP    191 193 °C 
1H NMR    (400 MHz, DMSO) δ 10.92 (s, 1H, NH), 7.79 7.75 (m, 2H, ArH), 
7.72 7.68 (m, 2H, ArH), 7.25 7.21 (m, 2H, ArH), 7.11 7.08 (m, 2H, 
ArH), 3.80 (s, 3H, OCH3)   
13C NMR   (101 MHz, DMSO) δ 162.70 (s), 142.32 (s), 133.57 (d), 130.44 (s), 
128.88 (d), 118.65 (s), 118.22 (d), 114.58 (d), 105.07 (s), 55.61 (q)   
IR (thin film)  νmax 3274, 2226, 1607, 1593, 1508, 1495, 1332, 1266, 1144 cm
 1   
LRMS (CI)    289 ([M + H]
+, 100%), 171 (65%), 119 (55%)  
HRMS (CI)    calcd for C14H13N2O3S ([M + H]
+): 289.0647 found 289.0655 
N (2,5 Dichlorophenyl) 4 methoxybenzenesulfonamide (118n) 
S
N
H
O O
O
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a pale brown solid (153 mg, 
0.46 mmol, 97%). 
MP     115 117 °C 123 
1H NMR    (400 MHz, DMSO) δ 10.11 (s, 1H, NH), 7.68 7.65 (m, 2H, ArH), 
7.46 7.43 (m, 1H, ArH), 7.30 7.26 (m, 2H, ArH), 7.11 7.07 (m, 2H, 
ArH), 3.82 (s, 3H, OCH3) 
13C NMR   (100 MHz, DMSO) δ 162.59 (s), 135.02 (s), 131.50 (s), 131.35 (s), 
131.17 (d), 128.82 (d), 127.03 (s), 126.94 (d), 125.99 (d), 114.35 (d), 
55.61 (q)   
IR (thin film)  νmax 3055, 1597, 1481, 1391, 1339, 1265, 1163, 1096 cm
 1 
LRMS (EI)    331 (M
+, 25%), 171 (100%), 107 (45%)  
HRMS (EI)    calcd for C13H11Cl2NO3S (M
+): 330.9831 found 330.9835
 
1 Benzenesulfonylpiperidine (124) 
S
N
O O
  
Synthesised using general procedure F. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to give a pale yellow solid (51 mg, 
0.23 mmol, 73%). 
MP  89 92 °C, Lit.
210 86 87 °C  
1H NMR    (500  MHz,  CDCl3)  δ  7.77 7.75  (m,  2H,  ArH),  7.61 7.57  (m,  1H, 
ArH), 7.54 7.51 (m, 2H, ArH), 2.99 (t, 4H, J = 5.5 Hz, CH2), 1.66 
1.60 (m, 4H, CH2), 1.44 1.39 (m, 2H, CH2) 
13C NMR   (126 MHz, CDCl3) δ 136.43 (s), 132.61 (d), 128.99 (d), 127.73 (d), 
47.01 (t), 25.243 (t), 23.58 (t)   
IR (thin film)  νmax 2928, 2840, 1445, 1335, 1164, 1093 cm
 1 
LRMS (ES)  226 ([M + H]
+, 100%), 473 (15%) 
HRMS (ES)    calcd for C11H16NO2S ([M + H]
+): 226.0896 found 226.0901 
N Allyl N methyl benzenesulfonamide (125) 
S
N
O O
 
Synthesised using general procedure F. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to give colourless oil (35 mg, 0.17 
mmol, 53%). Data in agreement with literature.
211 124 
1H NMR    (500  MHz,  CDCl3)  δ  7.81 7.79  (m,  2H,  ArH),  7.61 7.58  (m,  1H, 
ArH), 7.55 7.52 (m, 2H, ArH), 5.75 5.67 (m, 1H, CH2HC=CH2), 5.21 
(app dq, 1H, J=5.0, 1.3 Hz, CH=CHH), 5.18 5.20 (m, 1H, CH=CHH), 
3.65 (d, 2H, J = 6.6 Hz, CH2 CH=CH2), 2.67 (s, 3H, CH3) 
13C NMR   (126 MHz, CDCl3) δ 137.62 (s), 132.68 (d), 132.56 (d), 129.15 (d), 
127.50 (d), 119.27 (t), 53.11 (t), 34.27 (q) 
IR (thin film)  νmax 2920, 1447, 1336, 1165 cm
 1 
LRMS (ES)  212 ([M + H]
+, 100%) 
HRMS (ES)    calcd for C10H14NO2S ([M + H]
+):  212.0740 found 212.0744  
4 Methyl N propylbenzenesulfonamide (126) 
S
N
H
O O
 
Synthesised using general procedure C. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to give a colourless oil (45 mg, 0.21 
mmol, 75%). Data in agreement with literature.
212 
1H NMR    (500  MHz,  CDCl3)  δ  7.76 7.74  (m,  2H,  ArH),  7.30 7.29  (m,  2H, 
ArH), 4.74 (1H, t, J = 6.0 Hz, NH), 2.90 2.86 (m, 2H, CH2CH2CH3), 
2.42 (s, 3H, ArCH3), 1.50 1.42 (m, 2H, CH2CH2CH3), 0.87 (t, 3H, J = 
7.4 Hz, CH3) 
13C NMR   (126 MHz, CDCl3) δ 143.37 (s), 137.10 (s), 129.75 (d), 127.17 (d), 
45.02 (t), 22.97 (t), 21.58 (q), 11.18 (q) 
IR (thin film)  νmax 3281, 2966, 1599, 1425, 1320, 1155, 1091 cm
 1 
LRMS (ES)  214 ([M + H]
+, 100%), 231 (55%) 
HRMS (ES)    calcd for C10H16NO2S ([M + H]
+): 214.0896 found 214.0898 
N Propylbenzenesulfonamide (127) 
S
N
H
O O
 
Synthesised using general procedure F. The crude product was purified by column 
chromatography (petroleum ether/diethyl ether) to give a colourless oil (28 mg, 0.14 
mmol, 45%). 125 
1H NMR    (500  MHz,  CDCl3)  δ  7.89 7.86  (m,  2H,  ArH),  7.60 7.56  (m,  1H, 
ArH), 7.54 7.50 (m, 2H, ArH), 4.49 (1H, br. s, NH), 2.93 (app. q, 2H, 
J = 6.6 Hz, CH2CH2CH3), 1.52 1.45 (m, 2H, CH2CH2CH3), 0.87 (t, 
3H, J = 7.3 Hz, CH3) 
13C NMR   (151 MHz, CDCl3) δ 140.11 (s), 132.65 (d), 129.16 (d), 127.10 (d), 
45.06 (t), 23.04 (t), 11.15 (q) 
IR (thin film)  νmax 3283, 2966, 1447, 1424, 1320, 1155, 1092 cm
 1 
LRMS (CI)  200 ([M + H]
+, 100%), 421 (30%) 
HRMS (CI)    calcd for C9H14NO2S ([M + H]
+): 200.0740 found 200.0743 
Experimental for Chapter 3 
Biphenyl 4 sulfonic acid (3,4 dichlorophenyl)amide (144) 
S
N
H
O O
Cl
Cl
Cl
 
Synthesised using general procedure E. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a pale brown solid (139 mg, 
0.34 mmol, 89%). 
MP    139 141 °C 
1H NMR    (400 MHz, CDCl3) δ 10.81 (br. s, 1H, NH), 7.95 7.93 (m, 2H, ArH), 
7.88 7.85 (m, 2H, ArH), 7.81 7.80 (m, 1H, ArH), 7.71 7.68 (m, 1H, 
ArH), 7.55 7.48 (m, 3H, ArH), 7.33 (d, 1H, J = 2.5 Hz, ArH), 7.14 
(dd, 1H, J = 2.5, 8.8 Hz, ArH)  
13C NMR   (101 MHz, CDCl3) δ 143.06 (s), 140.24 (s), 138.26 (s), 137.88 (s), 
133.90 (s), 131.48 (s), 131.32 (d), 130.92 (d), 128.48 (d), 127.93 (d), 
127.30 (d), 126.89 (d), 126.03 (s), 125.84 (d), 120.76 (d), 119.53 (d) 
IR (thin film)  νmax 3243, 1592, 1561, 1470, 1383, 1326, 1158, 1095 cm
 1 
LRMS (CI)  416 (22%), 414 (55%), 412 ([M + H]
+, 55%), 164 (65%), 162 (100%) 
HRMS (CI)    calcd for C18H13Cl3NO2S ([M + H]
+): 411.9727 found 411.9716 126 
Suzuki Reactions 
General Procedure G 
To a solution of the 2,4,6 trichlorophenyl ester (2.4 mmol) in anhydrous dioxane (20 
mL)  was  added  bis(triphenylphosphine)palladiumdichloride  (3  mol%),  sodium 
tetraborate (7.2 mmol) and a solution of the boronic acid (2.9 mmol) in ethanol (4 
mL). The reaction mixture was heated to reflux for 14h and then cooled to room 
temperature and filtered through a pad of celite. The filtrate was concentrated in 
vacuo to yield the crude product.  
4’ Fluorobiphenyl 4 sulfonic acid 2,4,6 trichlorophenyl ester (132) 
S
O
O O
Cl Cl
Cl
F  
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (770 mg, 1.8 
mmol, 74%). 
MP    156 157 °C 
1H NMR    (400  MHz,  CDCl3)  δ  8.10 8.06  (m,  2H,  ArH),  7.76 7.73  (m,  2H, 
ArH), 7.65 7.60 (m, 2H, ArH), 7.37 (s, 2H, ArH), 7.23 7.17 (m, 2H, 
ArH) 
13C NMR   (101 MHz, CDCl3) δ 163.39 (d, 
1JCF = 248.9 Hz), 146.53 (s), 142.33 
(s),  135.45  (s),  134.96  (d, 
4JCF  =  3.3  Hz),  132.97  (s),  130.93  (s), 
129.22 (d), 129.21 (dd, 
3JCF = 8.2 Hz), 129.19 (d), 127.59 (d), 116.23 
(dd, 
2JCF = 21.8 Hz) 
IR (thin film)  νmax 3069, 1594, 1560, 1435, 1378, 1228, 1180 cm
 1 
LRMS (CI)  435 (10%), 433 (30%), 431 ([M + H]
+, 29%), 235 (100%), 199 (12%), 
197 (15%) 
HRMS (CI)   calcd for C18H11Cl3FO3S ([M + H]
+): 430.9479 found 430.9479 127 
4’ Cyanobiphenyl 4 sulfonic acid 2,4,6 trichlorophenyl ester (133) 
S
O
O O
Cl Cl
Cl
NC  
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (800 mg, 1.8 
mmol, 76%). 
MP    161 164 °C 
1H NMR    (300 MHz, CDCl3) δ 8.13 (d, 2H, J = 8.1 Hz, ArH), 7.82 7.70 (m, 6H, 
ArH), 7.37 (s, 2H, ArH) 
13C NMR   (75 MHz, CDCl3) δ 145.4 (s), 143.2 (s), 142.3 (s), 136.9 (s), 133.1 (s), 
132.9 (d), 130.9 (s), 129.4 (d), 129.3 (d), 128.2 (d), 128.0 (d), 118.4 
(s), 112.7 (s) 
IR (thin film)  νmax 3071, 2225, 1560, 1437, 1379, 1230, 1186, 1137, 1094 cm
 1 
LRMS (CI)    440 (67%), 438 ([M + H]
+, 68%), 242 (100%), 199 (35%), 197 (40%), 
180 (46%) 
HRMS (CI)    calcd for C19H11Cl3NO3S ([M + H]
+): 437.9525 found 437.9543 
3’ Chlorobiphenyl 4 sulfonic acid 2,4,6 trichlorophenyl ester (134) 
S
O
O O
Cl Cl
Cl Cl
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (1.02 g, 2.3 
mmol, 94%). 
1H NMR    (400  MHz,  CDCl3)  δ  8.11 8.08  (m,  2H,  ArH),  7.79 7.75  (m,  2H, 
ArH), 7.64 7.62 (m, 1H, ArH), 7.54 7.50 (m, 1H, ArH), 7.45 7.42 (m, 
2H, ArH), 7.37 (s, 2H, ArH) 
13C NMR    (101 MHz, CDCl3) δ 146.1 (s), 140.6 (s), 136.1 (s), 135.2 (s), 133.0 
(s), 130.9 (s), 130.4 (d), 129.2 (d), 129.2 (d), 129.0 (d), 127.8 (d), 
127.6 (d), 125.6 (d) 128 
IR (thin film)  νmax 1607, 1562, 1441, 1379, 1231, 1173, 1136 cm
 1 
LRMS (CI)  448 (10%), 446 ([M + H]
+, 8%), 253 (86%), 251 (35%), 187 (43%), 
152 (100%) 
HRMS (CI)   calcd for C18H12Cl3NO2S ([M + H]
+): 446.9183 found 411.9195 
4 Furan 3 yl benzenesulfonic acid 2,4,6 trichlorophenyl ester (135) 
S
O
O O
Cl Cl
Cl
O  
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (917 mg, 2.3 
mmol, 95%). 
MP    132 134 °C 
1H NMR    (400 MHz, CDCl3) δ 8.02 7.99 (m, 2H, ArH), 7.89 (dd, 1H, J = 1.0, 
1.4 Hz, ArH), 7.69 7.66 (m, 2H, ArH), 7.55 (app. t, 1H, J = 1.8 Hz, 
ArH), 7.36 (s, 2H, ArH), 6.77 (dd, 1H, J = 0.9, 1.9 Hz, ArH)              
13C NMR   (101 MHz, CDCl3) δ 144.54 (d), 142.36 (s), 140.32 (d), 139.05 (s), 
134.77 (s), 132.91 (s), 130.94 (s), 129.27 (d), 129.20 (d), 126.14 (d), 
124.88 (s), 108.52 (d) 
IR (thin film)  νmax 1601, 1559, 1420, 1379, 1170 cm
 1 
LRMS (CI)  407 (10%), 405 (24%), 403 ([M + H]
+, 25%), 207 (100%) 
HRMS (CI)   calcd for C16H10Cl3O4S ([M + H]
+): 402.9365 found 402.9357 
3’ Methylbiphenyl 4 sulfonic acid 2,4,6 trichlorophenyl ester (136) 
S
O
O O
Cl Cl
Cl
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (570 mg, 1.3 
mmol, 55%). 
MP    137 138 °C 129 
1H NMR    (400  MHz,  CDCl3)  δ  8.08 8.05  (m,  2H,  ArH),  7.80 7.77  (m,  2H, 
ArH), 7.46 7.39 (m, 3H, ArH), 7.37 (s, 2H, ArH), 7.28 (br. s, 1H, 
ArH), 2.45 (s, 3H, CH3)  
13C NMR   (151 MHz, CDCl3) δ 147.77 (s), 142.35 (s), 138.91 (s), 138.79 (s), 
135.19 (s), 132.91 (s), 130.94 (s), 129.70 (d), 129.20 (d), 129.08 (d), 
129.05 (d), 128.17 (d), 127.75 (d), 124.55 (d), 21.54 (q)  
IR (thin film)  νmax 1561, 1443, 1376, 1182, 1137, 1096 cm
 1 
LRMS (CI)  430 (12%), 428 (30%), 426 (M
+, 28%), 231 (100%), 167 (62%) 
HRMS (CI)   calcd for C19H13Cl3O3S (M
+): 425.9651 found 425.9658 
4 Pyridin 4 yl benzenesulfonic acid 2,4,6 trichlorophenyl ester (137) 
S
O
O O
N
Cl Cl
Cl
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a pink solid (843 mg, 2.0 
mmol, 85%). 
MP    173 175 °C 
1H NMR    (400  MHz,  CDCl3)  δ  8.77 8.76  (m,  2H,  ArH),  8.17 8.13  (m,  2H, 
ArH), 7.86 7.83 (m, 2H, ArH), 7.56 7.55 (m, 2H, ArH), 7.38 (s, 2H, 
ArH)    
13C NMR   (101 MHz, CDCl3) δ 150.73 (d), 146.02 (s), 144.50 (s), 142.25 (s), 
137.28 (s), 133.12 (s), 130.87 (s), 129.37 (d), 129.26 (d), 127.85 (d), 
121.78 (d) 
IR (thin film)  νmax 3040, 1590, 1445, 1384, 1181 cm
 1 
LRMS (CI)  416 (20%), 414 ([M + H]
+, 18%), 391 (20%), 149 (100%) 
HRMS (CI)    calcd for C17H11Cl3NO3S ([M + H]
+): 413.9525 found 413.9517 130 
4 Thionphen 3 yl benzenesulfonic acid 2,4,6 trichlorophenyl ester (138) 
S
O
O O
Cl Cl
Cl
S  
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (899 mg, 2.1 
mmol, 89%). 
MP    134 136 °C
 
1H NMR    (400  MHz,  CDCl3)  δ  8.02 7.99  (m,  2H,  ArH),  7.81 7.78  (m,  2H, 
ArH), 7.51 (dd, 1H, J = 1.1, 3.7 Hz, ArH), 7.45 (dd, 1H, J = 1.1, 5.1 
Hz, ArH), 7.36 (s, 2H, ArH), 7.16 (dd, 1H, J = 3.7, 5.1 Hz, ArH) 
13C NMR   (100 MHz, CDCl3) δ 142.34 (s), 141.67 (s), 140.51 (s), 134.93 (s), 
132.93 (s), 130.93 (s), 129.35 (d), 129.21 (d), 128.65 (d), 127.55 (d), 
125.97 (d), 125.67 (d)  
IR (thin film)  νmax 3077, 1591, 1561, 1438, 1368, 1176 cm
 1 
LRMS (CI)  421 (62%), 419 ([M+H]
+, 60%), 225 (100%), 199 (50%), 197 (52%) 
HRMS (CI)   calcd for C16H10Cl3O3S ([M + H])
+: 418.9137 found 418.9125 
4’ Cyano biphenyl 3 sulfonic acid 2,4,6 trichlorophenyl ester (139) 
S
O
O O
Cl Cl
Cl
NC
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (782 mg, 1.8 
mmol, 74%). 
MP    154 155 °C 
1H NMR    (400 MHz, CDCl3) δ 8.23 (app. t, 1H, J = 1.8 Hz, ArH), 8.09 (ddd, 
1H, J = 1.1, 1.8, 7.9 Hz, ArH), 7.94 (ddd, 1H, J = 1.1, 1.7, 7.8 Hz, 
ArH), 7.82 7.79 (m, 2H, ArH), 7.75 7.71 (m, 3H, ArH), 7.38 (s, 2H, 
ArH) 131 
13C NMR   (100 MHz, CDCl3) δ 143.07 (s), 142.25 (s), 140.58 (s), 138.12 (s), 
133.18 (d), 132.99 (d), 130.82 (s), 130.15 (d), 129.29 (d), 128.35 (d), 
127.92 (d), 127.09 (d), 118.43 (s), 112.41 (s)  
IR (thin film)  νmax 2228, 1561, 1444, 1380, 1229, 1181 cm
 1  
LRMS (CI)  440 (100%), 438 ([M + H]
+, 40%), 226 (85%), 199 (98%) 
HRMS (CI)   calcd for C19H11Cl3NO3S ([M + H]
+): 437.9525 found 437.9514 
4’ Fluorobiphenyl 3 sulfonic acid 2,4,6 trichlorophenyl ester (140) 
S
O
O O
Cl Cl
Cl
F
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (775 mg, 1.8 
mmol, 75%). 
MP    82 85 °C 
1H NMR    (400 MHz, CDCl3) δ 8.19 (app. t, 1H, J = 1.7 Hz, ArH), 8.00 (ddd, 
1H, J = 1.1, 1.8, 7.9 Hz, ArH), 7.89 (ddd, 1H, J = 1.1, 1.8, 7.9 Hz, 
ArH), 7.66 (app. t, 1H, J = 7.9 Hz, ArH), 7.60 7.55 (m, 2H, ArH), 
7.37 (s, 2H, ArH), 7.21 7.16 (m, 2H, ArH)  
13C NMR   (101 MHz, CDCl3) δ 163.14 (d, 
1JCF = 248.4 Hz), 142.33 (s), 141.64 
(s,), 134.89 (d, 
4JCF  =  3.3 Hz), 133.03 (s), 133.00 (d), 130.90 (s), 
129.79 (d), 129.24 (d), 128.93 (d, 
2JCF = 8.3 Hz), 127.06 (d), 126.81 
(d), 116.20 (d, 
3JCF = 21.6 Hz) 
IR (thin film)  νmax 1561, 1515, 1442, 1379, 1228, 1184 cm
 1 
LRMS (CI)    434 (100%), 432 (75%), 197 (85%) 
HRMS (CI)    calcd for C18H11Cl3FO3S ([M + H]
+): 430.9479 found 430.9462    
3’ Chlorobiphenyl 3 sulfonic acid 2,4,6 trichlorophenyl ester (141) 
S
O
O O
Cl Cl
Cl
Cl
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (800 mg, 1.8 
mmol, 74%). 132 
MP    101 104 °C 
1H NMR    (400 MHz, CDCl3) δ 8.20 (app. t, 1H, J = 1.8 Hz, ArH), 8.03 (ddd, 
1H, J = 1.1, 1.8, 7.9 Hz, ArH), 7.91 (ddd, 1H, J = 1.1, 1.7, 7.8 Hz, 
ArH), 7.68, (app. t, 1H, J = 7.9 Hz, ArH), 7.60 7.59 (m, 1H, ArH), 
7.50 7.39 (m, 3H, ArH), 7.37 (s, 2H, ArH)  
13C NMR   (101 MHz, CDCl3) δ 142.31 (s), 141.23 (s), 140.51 (s), 137.80 (s), 
135.16 (s), 133.11 (d), 133.07 (s), 130.88 (s), 130.45 (d), 129.89 (d), 
129.26 (d), 128.60 (d), 127.63 (d), 127.36 (d), 126.97 (d), 125.38 (d) 
IR (thin film)  νmax 1563, 1441, 1377, 1231, 1188 cm
 1 
LRMS (EI)    448 (25%), 446 (M
+, 25%), 251 (75%), 187 (100%), 152 (90%)   
HRMS (EI)    calcd for C18H10Cl4O3S (M
+): 445.9099 found 445.9104 
3 Furan 3 yl benzenesulfonic acid 2,4,6 trichlorophenyl ester (142) 
S
O
O O
Cl Cl
Cl
O
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (380 mg, 0.94 
mmol, 39%). 
MP    130 131 °C 
1H NMR    (400 MHz, CDCl3) δ 8.11 (app. t, 1H, J = 1.7 Hz, ArH), 790 (ddd, 1H, 
J = 1.1, 1.8, 7.9 Hz, ArH), 7.83 7.80 (m, 2H, ArH), 7.59 (app. t, 1H, J 
= 7.9 Hz, ArH), 7.54 (app. t, 1H, J = 1.7 Hz, ArH), 7.37 (s, 2H, ArH), 
6.75 (dd, 1H, J = 0.9, 1.8 Hz, ArH)  
13C NMR   (101 MHz, CDCl3) δ 144.40 (d), 142.34 (s), 139.52 (d), 137.63 (s), 
134.10 (s), 133.00 (s), 131.69 (d), 130.91 (s), 129.72 (d), 129.23 (d), 
126.68 (d), 125.50 (d), 124.70 (s), 108.53 (d) 
IR (thin film)  νmax 1561, 1442, 1231, 1185, 1136 cm
 1 
LRMS (CI)  405 (64%), 403 ([M + H]
+, 64%), 207 (100%) 
HRMS (CI)   calcd for C16H9Cl3O4S ([M + H]
+): 402.9365 found 402.9352 133 
3 Thionphen 3 yl benzenesulfonic acid 2,4,6 trichlorophenyl ester (143) 
S
O
O O
Cl Cl
Cl
S
 
Synthesised using general procedure G. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate) to give a white solid (860 mg, 2.0 
mmol, 85%). 
MP    86 89 °C 
1H NMR    (400 MHz, CDCl3) δ 8.23 (app. t, 1H, J = 1.7 Hz, ArH), 7.94 7.90 (m, 
2H, ArH), 7.60 (app. t, 1H, J = 7.9, ArH), 7.43 (dd, 2H, J = 1.1, 3.7 
Hz, ArH), 7.39 (dd, 2H, J = 1.1, 5.1 Hz, ArH), 7.37 (s, 2H, ArH), 7.13 
(dd, 1H, J = 3.7, 5.1 Hz, ArH)  
13C NMR   (101 MHz, CDCl3) δ 142.32 (s), 141.56 (s), 137.74 (s), 135.89 (s), 
133.03 (s), 131.66 (d), 130.91 (s), 129.83 (d), 129.24 (d), 128.48 (d), 
126.90 (d), 126.58 (d), 125.40 (d), 124.81 (d) 
IR (thin film)  νmax 1565, 1444, 1381, 1231, 1184, 1136 cm
 1 
LRMS (CI)    423 (35%), 421 (100%), 419 ([M + H]
+, 92%), 223 (95%) 159 (60%) 
HRMS (CI)    calcd for C16H10Cl3O3S2 ([M + H]
+): 418.9137 found 418.9120 
Heck Reactions 
3 [4 (2,4,6 Trichlorophenoxysulfonyl)phenyl]acrylic acid ethyl ester (146) 
S
O
O O
Cl Cl
Cl O
O  
To a solution of 4 bromobenzene TCP sulfonate (96) (1.08 mmol) in DMF (4 mL) 
was  added  bis(triphenylphosphine)palladium  dichloride  (3  mol%),  N 
methyldicyclohexylamine (2.16 mmol) and ethyl acrylate (1.30 mmol). The resultant 
mixture was heated in the microwave for 20 minutes at 100 ºC. The reaction mixture 
was diluted with EtOAc (20 mL) and washed with 10% lithium chloride solution (3 x 
10  mL)  and  water  (10  mL).  The  organic  portion  was  separated,  dried  (MgSO4), 
filtered and the solvent removed in vacuo. The crude product was purified by column 134 
chromatography (petroleum ether/diethyl ether) to give a white solid (345 mg, 0.79 
mmol, 73%). 
MP    128 130 °C 
1H NMR   (400 MHz, CDCl3) δ 8.11 7.99 (m, 2H, ArH), 7.73 (d, J = 15.9 Hz, 
1H, CHCH), 7.73 7.71 (m, 2H, ArH), 7.38 (s, 2H, ArH), 6.60 (d, J = 
16.0 Hz, 1H, CHCH), 4.31 (q, J = 7.1 Hz, 2H, OCH2CH3), 1.37 (t, J = 
7.1 Hz, 3H, CH3) 
13C NMR   (151 MHz, CDCl3) δ 166.06 (s), 142.21 (s), 141.79 (d), 140.53 (s), 
137.67 (s), 133.08 (s), 130.83 (s), 129.23 (d), 129.12 (d), 128.45 (d), 
122.64 (d), 61.04 (t), 14.29 (q) 
IR (thin film)  νmax 3076, 1714, 1641, 1560, 1440, 1388, 1314, 1195, 1177 cm
 1 
LRMS (EI)    436 ([M+H]
+, 1%), 239 (50%), 102 (100%) 
HRMS (EI)    calcd for C17H13Cl3O5S (M
+): 433.9544 found 433.9545 
4 (2 Cyanovinyl)benzenesulfonic acid 2,4,6 trichlorophenyl ester (148) 
S
O
O O
Cl Cl
Cl
NC  
To a solution of 4 bromobenzene TCP sulfonate (96) (0.54 mmol) in DMF (2 mL) 
was  added  bistriphenylphosphinepalladium  dichloride  (3  mol%),  N 
methyldicyclohexylamine (1.08 mmol) and acrylonitrile (0.65 mmol). The resultant 
mixture was heated in the microwave for 30 minutes at 100 ºC. The reaction mixture 
was diluted with EtOAc (10 mL) and washed with 10% lithium chloride solution (3 x 
5 mL) and water (5 mL). The organic portion was separated, dried (MgSO4), filtered 
and  the  solvent  removed  in  vacuo.  The  crude  product  was  purified  by  column 
chromatography (petroleum ether/diethyl ether) to give a pale yellow solid (77 mg, 
0.20 mmol, 37%). 
1H NMR   (400  MHz,  CDCl3)  δ  8.21 7.95  (m,  2H,  ArH),  7.79 7.59  (m,  2H, 
ArH), 7.48 (d, J = 16.7, 1H, CHCH), 7.38 (s, 2H, ArH), 6.09 (d, J = 
16.7, 1H, CHCH) 
13C NMR   (126 MHz, CDCl3) δ 147.99 (d), 142.21 (s), 139.17 (s), 138.90 (s), 
133.30 (s), 130.84 (s), 129.39 (d), 129.33 (d), 127.94 (d), 117.02 (s), 
101.17 (d) 135 
IR (thin film)  νmax 3078, 2220, 1559 1442, 1386, 1193, 1178, 1135, 1090 cm
 1 
LRMS (CES)    389 (50%), 386 ([M H]
 , 50%), 208 (100%) 
HRMS (ES)    calcd for C15H7Cl3NO3S ([M H]
 ): 385.9218 found 385.9222 
4 Styryl benzenesulfonic acid 2,4,6 trichloro phenyl ester (149) 
S
O
O O
Cl Cl
Cl
 
To a solution of 4 bromobenzene TCP sulfonate (96) (1.08 mmol) in DMF (4 mL) 
was  added  bis(triphenylphosphine)palladium  dichloride  (3  mol%),  N 
methyldicyclohexylamine  (2.16  mmol)  and  styrene  (1.30  mmol).  The  resultant 
mixture  was  heated  in  the  microwave  for  150  minutes  at  100  ºC.  The  reaction 
mixture  was  diluted  with  Et2O  (20  mL)  and  washed  with  10%  lithium  chloride 
solution (3 x 10 mL) and water (10 mL). The organic portion was separated, dried 
(MgSO4), filtered and the solvent removed in vacuo. The crude product was purified 
by column chromatography (petroleum ether/diethyl ether) to give a white solid (243 
mg, 0.55 mmol, 51%). 
MP    129 132 °C 
1H NMR   (400  MHz,  CDCl3)  δ  8.02 7.98  (m,  2H,  ArH),  7.72 7.68  (m,  2H, 
ArH), 7.58 7.56 (m, 2H, ArH), 7.44 7.33 (m, 3H, ArH), 7.37 (s, 2H, 
ArH), 7.31 (d, J = 16.4, 1H, CHCH), 7.16 (d, J = 16.4, 1H, CHCH) 
13C NMR   (126 MHz, CDCl3) δ 143.76 (s), 142.35 (s), 136.15 (s), 134.91 (s), 
133.26 (d), 132.88 (s), 130.94 (s), 129.19 (d), 129.07 (d), 128.92 (d), 
128.85 (d), 127.03 (d), 126.86 (d), 126.37 (d) 
IR (thin film)  νmax 3081, 1591, 1560, 1439, 1383, 1177 cm
 1 
LRMS (EI)    440 (5%), 438 (5%, M
+), 195 (52%), 178 (100%), 152 (48%) 
HRMS (EI)    calcd for C20H13Cl3O3S (M
+): 437.9645 found 437.9642  136 
DKR 
(4R, 5S) 1,5 dimethyl 4 phenylimidazolidin 2 one (173) 
NH N
O
Ph 
(1R, 2S) ( ) Ephedrine hydrochloride (10.0 g, 49.6 mmol) and urea (8.9 g, 148.7 
mmol) were heated under an atmosphere of argon at 190 ºC for 5h. The reaction 
mixture was cooled to room temperature and then the crude product was purified by 
column chromatography (petroleum  ether/ethyl  acetate). The desired product was 
obtained as a white solid (4.66 g, 24 mmol, 49%). Data in agreement with Jenkins.
145 
MP                  171 173 ºC, Lit.
213 175 177 ºC 
 
[α]
24
D                43.3 º (c = 1, MeOH), Lit.
213 [α]
25
D  44.5 (c = 0.90, MeOH) 
1H NMR   (500 MHz, CDCl3) δ 7.40 7.15 (m, 5H, ArH), 4.75 (d, J = 8.4 Hz, 1H, 
CHPh), 4.67 (s, 1H, NH), 3.88 (dq, J = 6.6, 8.4 Hz, 1H, CHCH3), 2.75 
(s, 3H, CH3N), 0.74 (d, J = 6.6 Hz, 3H, CH3CH) 
13C NMR   (126 MHz, CDCl3) δ 162.25 (s), 138.19 (s), 128.53 (d), 128.11 (d), 
127.16 (d), 58.19 (d), 57.63 (d), 28.18 (q), 14.28 (q) 
IR (thin film)  νmax 3264, 1701, 1663, 1438, 1382, 762 cm
 1  
LRMS (ES)  381 (35%), 191 (100%, [M+H]
+) 
1,5 Dimethyl 4 phenyl 3 (3 phenylpropionyl)imidazolidin 2 one (188) 
N N
O
Ph
O
Ph
 
To a stirred solution of (4R, 5S) 1,5 dimethyl 4 phenylimidazolidin 2 one (1.35 g, 
7.1 mmol) in dichloromethane (40 mL) at 0 ºC under an argon atmosphere was added 
2,6 lutidine (0.82 mL, 7.8 mmol) and 3 phenylpropionyl chloride (1.58 mL, 10.6 
mmol) dropwise. The reaction mixture was allowed to warm to room temperature 
and  then  heated  to  reflux  for  18  h.  After  cooling  the  reaction  mixture  to  room 
temperature saturated aqueous ammonium chloride solution (20 mL) was added. The 
organic layer was washed with saturated aqueous ammonium chloride solution (2 x 
20 mL), saturated sodium bicarbonate solution (3 x 20 mL) and water (1 x 20 mL), 137 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography  (petroleum ether/ethyl acetate)  to  yield a  white solid (2.0 g, 6.2 
mmol, 87%). Data in agreement with Treweeke.
147  
MP                  120 122 ºC, Lit. 
147 118 120 ºC 
[α]
20
D                33.5º (c = 10.0, CHCl3), Lit. 
147 [α]
25
D =  40.5º (c = 1.0, CHCl3)   
1H NMR   (500 MHz, CDCl3) δ 7.44 6.84 (m, 10H, ArCH), 5.26 (d, J = 8.6 Hz, 
1H, CHPh), 3.85 (dq, J = 6.6, 8.5 Hz, 1H, CHCH3), 3.38 3.22 (m, 2H, 
CH2CO), 3.02 2.84 (m, 2H, CH2Ph), 2.79 (s, 3H, CH3N), 0.77 (d, J = 
6.6 Hz, 3H, CH3CH) 
13C NMR   (126 MHz, CDCl3) δ 171.86 (s), 155.89 (s), 141.12 (s), 136.64 (s), 
128.57 (d), 128.52 (d), 128.30 (d), 128.06 (d), 126.94 (d), 125.92 (d), 
59.31 (d), 53.99 (d), 37.40 (t), 30.55 (t), 28.15 (q), 14.94 (q) 
IR (thin film)  νmax 1717, 1678, 1382, 752, 699 cm
 1  
LRMS (ES)  323 ([M+H]
+, 100%) 
1 (2 Bromo 3 phenylprpionyl)3,4 dimethyl  5 phenylimidazolidin 2 one  (2'R 
189) 
N N
O
Ph
O
Ph
Br
 
To a solution of 1,5 dimethyl 4 phenyl 3 (3 phenylpropionyl)imidazolidin 2 one (2.0 
g,  6.2  mmol)  in  THF  (20  mL)  at   78  ºC  under  argon  was  added  LHMDS  (1M 
solution in THF) (6.8 mL, 6.8 mmol) dropwise and then after 45 minutes bromine 
was added dropwise. After stirring for 1h at –78 ºC the reaction was quenched with 
saturated aqueous ammonium chloride solution (40 mL) and EtOAc (100 mL). The 
organic layer was washed with saturated aqueous ammonium chloride solution (2 x 
40 mL) and the combined aqueous layers were extracted with EtOAc (20 mL). The 
organic layers were combined, dried (MgSO4) and concentrated in vacuo. The crude 
product  was  purified  by  flash  column  chromatography  (petroleum  ether/ethyl 
acetate) to yield a white solid (1.57 g, 3.9 mmol, 63%). Data in agreement with 
Treweeke.
147 
MP                   99 101 ºC, Lit. 
147 93 95 ºC 
[α]
20
D                125.8 (c = 1.0, MeOH), Lit. [α]
30
D  128.8 (c = 1.0, MeOH)  
 138 
1H NMR   (500 MHz, CDCl3) δ 7.44 – 7.10 (m, 10H, ArCH), 6.16 (dd, J = 6.4, 
9.1 Hz, 1H, CHBr), 5.21 (d, J = 8.8 Hz, 1H, CHPh), 3.78 (dq, J = 6.6, 
8.8 Hz, 1H, CHCH3), 3.50 (dd, J = 9.1, 14.0 Hz, 1H, CHAHBPh), 3.21 
(dd, J = 6.4, 14.0 Hz, 1H, CHAHBPh), 2.78 (s, 3H, CH3N), 0.75 (d, J = 
6.6 Hz, 3H, CH3CH) 
13C NMR   (126 MHz, CDCl3) δ 167.52 (s), 154.59 (s), 137.54 (s), 135.34 (s), 
129.61 (d), 128.50 (d), 128.45 (d), 128.27 (d), 126.98 (d), 126.86 (d), 
59.28 (d), 53.66 (d), 44.23 (d), 40.04 (t), 28.26 (q), 15.11 (q) 
IR (thin film)  νmax 1713, 1679, 1377, 748 cm
 1  
LRMS (ES)  418 (15), 403 (100%), 401 ([M + H]
+, 100%) 
1 Acryloyl 3,4 dimethyl 5 phenylimidazolidin 2 one (195) 
N N
O
Ph
O
 
To a stirred solution of (4R, 5S) 1,5 dimethyl 4 phenylimidazolidin 2 one (2.90 g, 
15.2 mmol) in dichloromethane (100 mL) at 0 ºC under an argon atmosphere was 
added 2,6 lutidine (1.95 mL, 16.7 mmol) and then acryloyl chloride (1.85 mL, 22.9 
mmol) dropwise. The reaction mixture was allowed to warm to room temperature 
and  then  heated  to  reflux  for  24h.  After  cooling  the  reaction  mixture  to  room 
temperature saturated aqueous ammonium chloride solution (40 mL) was added. The 
organic layer was washed with saturated aqueous ammonium chloride solution (2 x 
40 mL), sodium bicarbonate solution (3 x 40 mL) and water (1 x 40 mL), dried 
(Na2SO4) and concentrated in vacuo. The crude product was purified by  column 
chromatography  (petroleum ether/ethyl acetate)  to  yield a  white solid (1.8 g, 7.4 
mmol, 49%).  
MP                  145 148 ºC, Lit. 
214 135 140 ºC
 
[α]
20
D                103.1º (c = 10.0, CHCl3), Lit. 
214 [α]D =  100.6º (c = 1.0, CHCl3)           
 
1H NMR   (400 MHz, CDCl3) δ 7.71 (dd, J = 10.4, 17.1 Hz, 1H, COCHCH2), 
7.44  –  7.09  (m,  5H,  ArH),  6.39  (dd,  J  =  2.0,  17.1  Hz,  1H, 
CHAHBCH2), 5.76 (dd, J = 2.0, 10.4 Hz, 1H, CHAHBCH2), 5.36 (d, J = 
8.5 Hz, 1H, CHPh), 3.93 (dq, J = 6.6, 8.5 Hz, 1H, PhCHCH3), 2.84 (s, 
3H, CH3N), 0.82 (d, J = 6.6 Hz, 3H, CH3CH) 139 
13C NMR   (101 MHz, CDCl3) δ 164.53 (s), 155.70 (s), 136.40 (s), 129.72 (t), 
128.67 (d), 128.47 (d), 128.04 (d), 126.91 (d), 59.40 (d), 53.95 (d), 
28.14 (q), 14.92 (q) 
IR (thin film)  νmax 1708, 1668, 1395, 971, 750, 697 cm
 1  
LRMS (EI)  244 (M
+, 25%), 189 (60%), 132 (100%) 
HRMS (CI)  calcd for C14H17N2O2 ([M + H]
+): 245.1285 found 245.1287 
3 [3 (3,4 Dimethyl 2 oxo 5 phenylimidazolidin 1 yl) 3 oxopropenyl]benzene 
sulfonic acid 2,4,6 trichlorophenyl ester (196) 
N N
O
Ph
O
S
TCPO O
O  
A  solution  of  1 acryloyl  3,4 dimethyl  5 phenylimidazolidin 2 one  (250  mg, 
1.0mmo),  3 bromobenzene  TCP  sulfonate  ester  (355  mg,  0.85  mmol), 
bis(triphenylphosphine)palladiumdichloride  (6  mg,  0.09  mmol)  and  P(o tolyl)3  (5 
mg,  0.34  mmol)  in  toluene  (4  mL)  and  triethylamine  (2  mL)  was  heated  in  a 
microwave at 160 ºC for 30 min. This reaction was carried out six times and the 
resulting reaction mixtures were combined and concentrated in vacuo. The residue 
was purified by column chromatography (petroleum ether/ethyl acetate) to give a 
white foam (2.31 g, 5.2 mmol, 65%). 
[α]
20
D                21.0º (c = 1.0, CHCl3)
 
1H NMR   (400 MHz, CDCl3) δ 8.27 (d, J = 15.8 Hz, 1H, COCHCHAr), 8.14 (t, 
J = 1.7 Hz, 1H, ArH), 8.00 (ddd, J = 1.0, 1.7, 7.9 Hz, 1H, ArH), 7.94 
(app.  d,  J  =  7.9  Hz,  1H,  ArH),  7.70  (d,  J  =  15.8  Hz,  1H, 
COCHCHAr), 7.60 (app. t, J = 7.9 Hz, 1H, ArH), 7.43 6.93 (m, 7H, 
ArH), 5.44 (d, J = 8.5 Hz, 1H, CHPh), 4.00 (dq, J = 6.6, 8.4 Hz, 1H, 
CHCH3), 2.90 (s, 3H, CH3N), 0.86 (d, J = 6.6, 3H, CH3CH) 
13C NMR  (101 MHz, CDCl3) δ 164.14 (s), 155.79 (s), 142.25 (s), 141.25 (d), 
137.79 (s), 136.70 (s), 136.34 (s), 133.55 (d), 133.02 (s), 130.84 (s), 
129.69 (d), 129.28 (d), 129.25 (d), 128.64 (d), 128.25 (d), 128.16 (d), 
127.00 (d), 121.94 (d), 59.63 (d), 54.07 (d), 28.26 (q), 15.03 (q) 
IR (thin film)  νmax 1722, 1668, 1622, 1562, 1355, 1181, 995 cm
 1  
LRMS (ES)  581 ([M+H]
+, 100%)   140 
HRMS (ES):  calcd for C26H22Cl3N2O5S ([M + H]
+): 579.0310 found 579.0317 
4 [3 (3,4 Dimethyl 2 oxo 5 phenylimidazolidin 1 yl) 3 oxopropenyl]benzene 
sulfonic acid 2,4,6 trichlorophenyl ester (197) 
N N
O
Ph
O
S
OTCP
O
O
 
Prepared as for 196 to give a white foam (2.18 g, 6.4 mmol, 61%) 
MP    185 187 ºC
 
[α]
20
D     1.1 (c = 10.0, CHCl3)            
1H NMR   (500 MHz, CDCl3) δ 8.31 (d, J = 15.8 Hz, 1H), 7.97 (d, J = 8.5 Hz, 
2H, ArH), 7.73 (d, J = 8.5 Hz, 2H, ArH), 7.67 (d, J = 15.8 Hz, 1H), 
7.40 – 7.12 (m, 7H, ArH), 5.41 (d, J = 8.5 Hz, 1H, CHPh), 3.97 (dq, J 
= 6.6, 8.5 Hz, 1H, CHCH3), 2.87 (s, 3H, CH3N), 0.84 (d, J = 6.6 Hz, 
3H, CH3CH) 
13C NMR   (126 MHz, CDCl3) δ 164.00 (s), 155.78 (s), 142.25 (s), 141.27 (s), 
141.14 (d), 137.29 (s), 136.26 (s), 132.98 (s), 130.86 (s), 129.19 (d), 
128.96 (d), 128.68 (d), 128.63 (d), 128.26 (d), 127.00 (d), 123.19 (d), 
59.62 (d), 54.07 (d), 28.23 (q), 15.00 (q) 
IR (thin film)  νmax 1720, 1669, 1622, 1561, 1355, 1193 cm
 1 
LRMS (CI)  583 (12%), 581 (20%), 579 (M+H
+, 15%), 355 (100%), 353 (70%) 
HRMS (EI)  calcd for C11H14N2O (M
+): C26H21Cl3N2O5S 578.0231 found 578.0233 
 
3 [3 (3,4 Dimethyl 2 oxo 5 phenylimidazolidin 1 yl) 3 oxopropyl]benzene 
sulfonic acid 2,4,6 trichlorophenyl ester (198) 
N N
O
Ph
O
S
TCPO O
O  
A  suspension  of  3 [3 (3,4 Dimethyl  2 oxo 5 phenylimidazolidin 1 yl)  3 
oxopropenyl]benzenesulfonic acid 2,4,6 trichlorophenyl ester 5 (100 mg, 0.17 mmol) 
and dicolbalt octacarbonyl (59 mg, 0.17 mmol) in DME (255  L) and H2O (100  L) 
was heated to reflux for 3 h. The reaction mixture was cooled and concentrated in 141 
vacuo and the crude product was purified by column chromatography (petroleum 
ether/ethyl acetate) to give the product as a white foam (78 mg, 0.17 mmol, 78 %).  
[α]
20
D                249.2 º (c = 1.0, CHCl3)
 
1H NMR   (600 MHz, CDCl3) δ 8.05–7.95 (m, 2H, ArH), 7.73 (app. d, J = 8.0 
Hz, 1H, ArH), 7.61 (t, J = 7.8 Hz, 1H, ArH), 7.54 – 7.40 (m, 5H, 
ArH), 7.28 (d, J = 6.9 Hz, 2H, ArH), 5.43 (d, J = 8.6 Hz, 1H, CHPh), 
4.06 (dq,  J  = 6.6, 8.5  Hz, 1H, CHCH3), 3.51  (t, J  = 7.6 Hz, 2H, 
CH2CH2), 3.19 (t, J = 7.6 Hz, 2H, CH2CH2), 2.99 (s, 3H, CH3N), 0.96 
(d, J = 6.6 Hz, 3H, CH3CH) 
13C NMR  (151 MHz, CDCl3) δ 170.99 (s), 155.80 (s), 143.03 (s), 142.31 (s), 
136.71 (s), 136.47 (s), 135.23 (d), 132.80 (s), 130.95 (s), 129.22 (d), 
129.19 (d), 128.61 (d), 128.40 (d), 128.19 (d), 126.90 (d), 126.25 (d), 
59.32 (d), 54.04 (d), 36.95 (t), 30.09 (t), 28.17 (q), 14.93 (q) 
IR (thin film)  νmax  1724, 1682, 1380, 1179 cm
 1   
LRMS (EI)  584 (15%), 582([M+H]
+, 30%) , 580 (30%), 385 (100%)  
HRMS (ES)  calcd for C26H23Cl3N2O5S (M
+): 581.0466 found 581.0469 
3 [2 Bromo 3 (3,4 dimethyl 2 oxo 5 phenylimidazolidin 1 yl) 3 oxopropyl] 
benzenesulfonic acid 2,4,6 trichlorophenyl ester (200) 
N N
O
Ph
O
S
TCPO O
O
Br
 
To  a  solution  of  3 [3 (3,4 dimethyl  2 oxo  5 phenylimidazolidin 1 yl)  3 
oxopropyl]benzene sulfonic acid 2,4,6 trichlorophenyl ester (200 mg, 0.34 mmol) in 
THF (1 mL) at  78 ºC under argon was added LHMDS (1M solution in THF) (380 
 L, 0.38 mmol) dropwise.The mixture was stirred for 1 h and then bromine (21  L, 
0.41 mmol) was added dropwise. After stirring for 1 h at  78 ºC the reaction was 
quenched with sat. NH4Cl (aq) (10 mL) and EtOAc (20 mL). The organic layer was 
washed with sat. NH4Cl (aq) (2 x 10 mL) and the combined aqueous layers were 
back  extracted  with  EtOAc  (20  mL).  The  organic  layers  were  combined,  dried 
(Na2SO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (petroleum ether/ethyl acetate) to yield a white foam (146 mg, 0.28 
mmol, 64%). 142 
 [α]
20
D    0.54 º (c = 1.0, CHCl3)     
 
1H NMR   (600 MHz, CDCl3) δ 7.93 7.90 (m, 2H, ArH), 7.64 (d, 1H, J = 8.0 Hz, 
ArH), 7.54 (app. t, 1H, J = 7.8 Hz, ArH), 7.39 (s, 2H, ArH), 7.39 7.32 
(m, 3H, ArH), 7.23 7.22 (m, 2H, ArH), 6.14 (app. t, 1H, J = 7.6 Hz, 
CHBr), 5.29 (d, 1H, J = 8.7 Hz, CHPh), 3.90 (dq, 1H, J = 6.6, 8.7 Hz, 
CHCH3), 3.60 (dd, 1H, J = 8.0, 14.3 Hz, PhCHHCHBr), 3.33 (dd, 1H, 
J = 8.0, 14.3 Hz, PhCHHCHBr), 2.05 (s, 3H, CH3N), 0.82 (d, 3H, J = 
6.6 Hz, CH3CHCHPh) 
13C NMR  (151 MHz, CDCl3) δ 167.09 (s), 154.45 (s), 142.26 (s), 139.36 (s), 
137.07 (s), 136.22 (d), 135.19 (s), 132.92 (s), 130.89 (s), 129.46 (d), 
129.32 (d), 129.24 (d), 128.61 (d), 128.42 (d), 127.17 (d), 127.00 (d), 
59.28 (d), 53.77 (d), 43.81 (d), 39.42 (t), 28.34 (q), 15.17 (q) 
IR (thin film)  νmax 1729, 1686, 1441, 1387, 1181 cm
 1
   
LRMS (ES)  663 (70%), 661 (100%), 659 (50%, M
+) 
HRMS (ES)  calcd for C26H23Cl3N2O5S (M
+): 658.9577 found 658.9606 
Experimental for Chapter 4 
1,5 Dimethyl 4 phenyl 3 (3 phenylacryloyl)imidazolidin 2 one (191)  
N N
O
Ph
O
Ph
 
To a stirred solution of 173 (2.00 g, 10.1 mmol) in dichloromethane (100 mL) at 0 ºC 
under an argon atmosphere was added 2,6 lutidine (1.34 mL, 11.6 mmol) and then 
acryloyl chloride (2.63 g, 15.8 mmol) dropwise. The reaction mixture was allowed to 
warm  to  room  temperature  and  then  heated  to  reflux  for  24h.  After  cooling  the 
reaction mixture to room temperature saturated aqueous ammonium chloride solution 
(40  mL)  was  added.  The  organic  layer  was  washed  with  saturated  aqueous 
ammonium chloride solution (2 x 40 mL), saturated sodium bicarbonate solution (3 x 
40 mL) and water (1 x 40 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was purified by column chromatography (petroleum ether/ethyl acetate) to 
yield a white solid (2.3 g, 7.1 mmol, 67 %). Data in agreement with Treweeke.
147 
MP    165 167 ºC, Lit.
215 160 ºC
 143 
[α]
20
D                23.9˚ (c = 1.0, CHCl3), Lit.
215 [α]D  23.9˚ (c = 1.1, CHCl3) 
1H NMR  (400 MHz, CDCl3) δ 8.20 (d, J = 15.8 Hz, 1H, COCHCHPh), 7.72 (d, 
J = 15.8 Hz, 1H, COCHCHPh), 7.62 7.58 (m, 2H, ArH), 7.43 – 7.09 
(m, 8H, ArH), 5.44 (d, J = 8.5 Hz, 1H, CHPh), 3.97 (dq, J = 6.6, 8.4 
Hz,  1H,  CHCH3),  2.89  (s,  3H,  CH3N),  0.85  (d,  J  =  6.6  Hz,  3H, 
CH3CH) 
13C NMR   (101 MHz, CDCl3) δ 164.96 (s), 156.02 (s), 144.40 (d), 136.63 (s), 
135.13 (s), 130.05 (d), 128.74 (d), 128.56 (d), 128.42 (d), 128.10 (d), 
127.01 (d), 118.81 (d), 59.61 (d), 54.02 (d), 28.25 (q), 15.05 (q) 
IR (thin film)  νmax 1716, 1665, 1615, 1360, 998, 755 cm
 1   
LRMS (EI)  320 (M
+, 100%), 292 (70%) 
HRMS (ES)  calcd for C20H20N2O2 ([M + H]
+): 321.1598 found 321.1600 
1 (2 Bromo 3 methoxy 3 phenyl propionyl) 3,4 dimethyl 5 phenyl 
imidazolidin 2 one (241)  
N N
O
Ph
O
Ph
Br
OMe
 
To  a  mixture  of  1,5 Dimethyl 4 phenyl 3 (3 phenyl acryloyl) imidazolidin 2 one 
(160 mg, 0.5 mmol) and silver triflate (154 mg, 0.6 mmol) was added chloroform (5 
mL) and methanol (5 mL). The resultant solution was cooled to  78 ºC, bromine (31 
 L, 0.6 mmol) was added and the mixture was stirred for 2 h. H2O (10 mL) was 
added and the organic solvents were removed in vacuo. Et2O (10 mL) was added and 
the  aqueous  layer  was  extracted  with  Et2O  (3  x  10  mL).  The  combined  organic 
extracts were dried (Na2SO4) and concentrated  in vacuo. The  crude mixture was 
purified by column chromatography (diethyl ether/petroleum ether).   
241 major 
N N
O
Ph
O
Ph
Br
OMe
 
Tentative assignment 
White foam (167 mg, 0.39 mmol, 77 %) 144 
[α]
20
D                0.28 º (c = 1.0, CHCl3)
 
1H NMR   (600 MHz, CDCl3) δ 7.79 – 7.10 (m, 10H, ArH), 6.36 (d, J = 10.0 Hz, 
1H, CHBr), 5.42 (d, J = 8.7 Hz, 1H, CHPh), 4.50 (d, J = 10.0 Hz, 1H, 
CHOMe), 3.99 (dq, J = 6.6, 8.7 Hz, 1H, CHCH3), 2.97 (s, 3H, OCH3), 
2.90 (s, 3H, CH3N), 0.86 (d, J = 6.6 Hz, 3H, CH3CH) 
13C NMR  (151 MHz, CDCl3) δ 168.36 (s), 155.08 (s), 137.61 (s), 135.80 (s), 
128.71 (d), 128.44 (d), 128.30 (d), 128.26 (d), 128.04 (d), 127.22 (d), 
85.15 (d), 59.9 2 (d), 57.40 (d), 53.69 (d), 45.16 (q), 28.32 (q), 15.13 
(q) 
IR (thin film)  νmax 1726, 1688, 1380, 1087 cm
 1     
LRMS (CI)  433 (5%), 431([M + H]
+, 5%), 191 (100%) 
HRMS (ES)  calcd for C21H24BrN2O3 ([M + H]
+): 431.0965 found 431.0968 
241 minor 
N N
O
Ph
O
Ph
Br
OMe
 
Tentative assignment 
White foam (22 mg, 0.051 mmol, 10 %) 
[α]
20
D               0.93 º (c = 1.0, CHCl3)
 
1H NMR   (600 MHz, CDCl3) δ 7.73 7.00 (m, 10H, ArH), 6.12 (d, J = 10.2 Hz, 
1H, CHBr), 5.43 (d, J = 8.7 Hz, 1H, CHPh), 4.67 (d, J = 10.2 Hz, 1H, 
CHOMe), 4.00 (dq, J = 6.6, 8.7 Hz, 1H, CHCH3), 3.20 (s, 3H, OCH3), 
2.88 (s, 3H, CH3N), 0.84 (d, J = 6.6 Hz, 3H, CH3CH) 
13C NMR  (151 MHz, CDCl3) δ 167.31 (s), 154.77 (s), 137.50 (s), 135.51 (s), 
128.70 (d), 128.56 (d), 128.49 (d), 128.26 (d), 126.92 (d), 83.31 (d), 
59.49 (d), 57.64 (d), 53.69 (d), 45.13 (q), 28.30 (q), 15.17 (q) 
IR (thin film)  νmax 1731, 1685, 1375, 1090 cm
 1   
LRMS (CI)  433 (5%), 431([M + H]
+, 5%), 191 (100%) 
HRMS (ES):  calcd for C21H24BrN2O3 ([M + H]
+):  431.0965 found 431.0962 145 
1 (2 Bromo 3 methoxy 3 phenyl propionyl) 3,4 dimethyl 5 phenyl 
imidazolidin 2 one (2R,3S 241) 
N N
O
Ph
O
Ph
Br
OMe
 
Epimer of 241 major – tentative assignment  
241 major (1.04 mmol) and tetra butyl ammonium bromide (5.22 mmol) in NMP (5 
mL) were heated in the microwave for 60 min at 120 °C. The reaction mixture was 
portioned between Et2O (20 mL) and 10% lithium chloride solution (10 mL). The 
aqueous layer was extracted with with Et2O (2 x 10 mL). The combined organic 
extracts were washed with water (1 x 10 mL), dried (Na2SO4) and concentrated in 
vacuo. The product was isolated by column chromatography (petroleum ether/diethyl 
ether) as a white foam (54 mg, 0.13 mmol, 25%). 
 [α]
20
D                1.04 º (c = 1.0, CHCl3)
 
1H NMR   (500  MHz,  CDCl3)  δ  7.40 7.26  (m,  8H,  ArH),  7.14 7.12  (m,  2H, 
ArH),  6.36  (d,  J  =  9.8  Hz,  1H,  CHBr),  4.97  (d,  J  =  8.7  Hz,  1H, 
CHPh), 4.57 (d, J = 9.8 Hz, 1H, CHOMe), 3.55 (dq, J = 6.6, 8.5 Hz, 
1H, CHCH3), 3.23 (s, 3H, OCH3), 2.72 (s, 3H, CH3N), 0.70 (d, J = 6.6 
Hz, 3H, CH3CH) 
13C NMR  (126 MHz, CDCl3) δ 166.17 (s), 154.34 (s), 137.59 (s), 135.26 (s), 
128.63 (d), 128.56 (d), 128.48 (d), 128.32 (d), 127.01 (d), 83.53 (d), 
59.26 (d), 57.14 (d), 53.48 (d), 45.27 (q), 28.23 (q), 15.01 (q) missing 
1 x d 
IR (thin film)  νmax 3031, 1725, 1683, 1380, 1194, 1107 cm
 1   
LRMS   433 (100%), 431 (100%, [M+H]
+), 401 (40%), 399 (40%) 
HRMS (ES):  calcd for C21H24BrN2O3 ([M+H]
+):  431.0965 found 431.0957  146 
1 (2 Bromo 3 methoxy 3 phenyl propionyl) 3,4 dimethyl 5 phenyl 
imidazolidin 2 one (2S,3R 241) 
N N
O
Ph
O
Ph
Br
OMe
 
Epimer of 241 minor – tentative assignment 
241 minor (0.5 mmol) and tetra butyl ammonium bromide (2.5 mmol) in NMP (5 
mL) were heated in the microwave for 90 min at 120 °C. The reaction mixture was 
portioned between Et2O (20 mL) and 10% lithium chloride solution (10 mL). The 
aqueous layer was extracted with with Et2O (2 x 10 mL). The combined organic 
extracts were washed with water (1 x 10 mL), dried (Na2SO4) and concentrated in 
vacuo. The product was isolated by column chromatography (petroleum ether/diethyl 
ether) as a white foam (12 mg, 0.028 mmol, 22%). 
 [α]
20
D                15.98 º (c = 0.1, CHCl3)
 
1H NMR   (600  MHz,  CDCl3)  δ  7.32 7.10  (m,  6H,  ArH),  7.08 7.05  (m,  2H, 
ArH), 6.52 (d, J = 9.48Hz, 1H, CHBr), 6.49 (br.s, 2H, ArH), 5.20 (d, J 
= 8.64 Hz, 1H, CHPh), 4.58 (d, J = 9.46 Hz, 1H, OCH3), 3.86 (dq, J = 
6.58, 8.56 Hz, 1H, CHCH3), 3.22 (s, 3H, CH3N), 2.79 (s, 3H), 0.68 (d, 
J = 6.65 Hz, 3H, CH3CH) 
13C NMR  (151 MHz, CDCl3) δ 166.49 (s), 154.41 (s), 136.80 (s), 135.35 (s), 
128.58 (d), 128.51 (d), 128.45 (d), 128.28 (s), 127.47 (d), 126.24 (d), 
83.34 (d), 59.33 (d), 56.92 (d), 53.48 (d), 45.49 (q), 28.29 (q), 14.89 
(q) 
IR (thin film)  νmax 2933, 1726, 1684, 1378, 1195, 1109 cm
 1   
LRMS   433 (100%), 431 (100%, [M+H]
+), 401 (40%), 399 (40%)   
HRMS (ES):  calcd for C21H24BrN2O3 ([M+H]
+):  431.0965 found 431.0961 147 
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